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ABSTRACT 
Enterovirus A71 (EV-A71), a single, positive-stranded RNA virus, belongs to the 
Picornaviridae family within the Enterovirus genus. Rarely, EV-A71 could lead to 
severe neurological complications such as aseptic meningitis, encephalitis and 
poliomyelitis-like acute flaccid paralysis. Patients with fatal brainstem encephalitis 
usually die within a few hours after hospital admission due to sudden cardiopulmonary 
arrest. The objectives of this project were to investigate various aspects of viral 
transmission, neuropathogenesis and effectiveness of therapeutic antibodies in a murine 
model of EV-A71 encephalomyelitis.  
EV-A71 retrograde axonal transport up peripheral spinal nerves has been 
previously reported. However, whether EV-A71 could use retrograde axonal transport 
up cranial nerves to enter the brainstem remains unknown. To investigate this, mouse-
adapted-virus-strain (MAVS) was injected into unilateral jaw/facial muscles of groups 
of mice. Infected mice were sacrificed at several time points for pathological (H&E, 
immunohistochemistry and in situ hybridisation) and viral titration analysis. Viral 
antigens/RNA were visualised within the cranial nerves and brainstem (motor-related 
region), ipsilateral to the injection site. Brainstem viral titres were also significantly 
higher than spinal cord titres at early time point. 
The distribution of neuronal infection in human or mouse brain was distinct and 
rather stereotyped. This could be due to the variable susceptibility of different neurons 
to EV-A71 infection, or related to virus entry routes into the CNS. To study this, 2 
groups of mice were intra-cerebrally (thalamus/hypothalamus or pons/medulla) 
inoculated with MAVS. Infected mice were sacrificed at various time points for 
pathological and viral titration analysis. In addition, a primary motor neuron cell was 
also prepared from E14 mouse spinal cord to study the permissiveness of mouse motor 
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neuron to MAVS infection. Based on the results, MAVS was not found to be replicating 
extensively in the brain or primary motor neuron cells.  
Skeletal muscle injury has been shown to facilitate poliovirus retrograde axonal 
transport and subsequently enhances viral invasion into the CNS. To study the 
possibility of involvement of this important paralytic risk factor in EV-A71 infection, 
groups of mice with muscle-traumatised or non-traumatised hindlimb were 
intraperitoneally-infected with MAVS. Both groups of mice did not show significant 
differences in viral antigens/RNA and viral titres in hindlimb muscles and spinal cords.   
To date, neither licenced vaccines nor therapeutic drugs were available to 
prevent or treat EV-A71 patients with CNS manifestations. A mouse IgM MAb was 
previously developed and showed cross-neutralisation of EV-A71 strains with 
genotypes B3-B5, and C1-C5. With an optimum dose of MAb given after MAVS CNS 
infection, a reduction of disease severity (reduced viral antigens/RNA and viral titres in 
the CNS) and mortality were observed in treated mice.  
In conclusion, MAVS could utilise cranial nerves to achieve brainstem infection 
via retrograde axonal transport. The stereotype distribution of neuronal infection was 
more likely due to viral entry routes but not due to differences in neuron susceptibility. 
Skeletal muscle injury did not enhance the retrograde axonal transport of MAVS. 
Mouse monoclonal antibody was useful in preventing and ameliorating CNS infection. 
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ABSTRAK 
 
Enterovirus A71 (EV-A71), adalah virus RNA berbenang tunggal yang tergolong dalam 
keluarga Pikornaviridae dalam genus enterovirus. Kadang-kala, EV-A71 boleh 
mengakibatkan komplikasi neurologikal yang serius seperti meningitis aseptik, 
ensefalitis dan kekakuan dan kelumpuhan flasid. Biasanya, pesakit dengan ensefalitis 
mati akibat kegagalan jantung atau system pernafasan secara tiba-tiba, selepas beberapa 
jam diwadkan. Tujuan utama pengajian ini adalah untuk mengaji tentang penyebaran, 
neuropatogenesis dan kesan antibodi terapeutik dalam model tetikus jangkitan 
Enterovirus 71. EV-A71 yang disesuaikan dalam tetikus (MAVS) dan tikus ICR yang 
berumur 2 minggu digunakan dalam sepanjang kajian ini. 
            Sebelum ini, ramai telah melaporkan bahawa, EV-A71 boleh memasuki saraf 
pusat melalui hujung saraf otot, akan tetapi, pengajian atas saraf kranial masih tidak 
diketahui. Oleh itu, MAVS telah disuntik ke dalam otot muka/rahang kanan tikus. Tikus 
kemudian dikorbankan pada titk masa tertentu untuk patologi (H&E, immunohistokimia 
dan hibridisasi in situ) dan virus kuantifikasi analisasi. Antigen/RNA virus telah 
diperhatikan dalam saraf kranial dan batang otak (kawasan neuron motorik), pada sisi 
suntikan yang sama. Virus dalam batang otak juga jauh lebih tinggi daripada saraf 
tulang belakang pada masa awal. 
            Lokasi virus dalam otak manusia atau tetikus adalah unik dan stereotipe. Ini 
mungkin disebabkan oleh kecenderungan infeksi yang berbeza oleh EV-A71 dalam sel 
neuron yang berbeza, atau berkait dengan laluan kemasukan virus ke dalam saraf pusat. 
Dengan ini, MAVS disuntikan ke thalamus/hipotalamus atau pons/medulla dalam 2 
kumpulan tikus yang berbeza. Tikus yang terlibat dikorbankan pada titik masa tertentu 
untuk patologi dan kuantifikasi virus analisasi. Di samping itu, sel neuron motorik 
dalam tulang belakang juaga diasingkan dari E14 tikus untuk mengaji permisif sel 
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neuron motorik kepada jangkitan MAVS. Berdasarkan kajian ini, MAVS tidak dapat 
berkembang biak secara cekap dalam sel-sel otak atau neuron motorik tulang belakang. 
            Dalam jangkitan poliovirus, kecederaan otot telah dibuktikan akan 
meningkatkan jangkitan saraf pusat melalui penyebaran hujung saraf otot. Untuk 
mengaji faktor risiko lumpuh yang penting ini dalam jangkitan EV-A71, 2 kumpulan 
tikus dengan trauma otot kaki belakang atau tidak, dijangkiti dengan MAVS secara 
intraperitoneum. Kedua-dua kumpulan tikus tersebut tidak menunjukkan sebarang 
perbezaan yang signifikasi dalam antigen/RNA virus dan titer virus dalam otot kaki 
belakang dan tulang belakang. 
            Setakat ini, tiada vaksin ataupun ubat terapeutik yang berlesen untuk mencegah 
atau merawat pesakit EV-A71 dengan jangkitan saraf pusat. Satu antibody IgM tetikus 
(MAb) yang disediakan sebelum ini menunjukkan peneutralan kepada genotipe B3-B5, 
dan C1-C5 EV-A71. MAb dalam kuantiti yang optimum diberikan selepas jangkitan 
saraf pusat oleh MAVS, boleh melegakan penyakit teruk (dengan mengurangkan 
antigen/RNA virus dan titer virus dalam saraf pusat) dan menurunkan kadar kematian 
dalam tikus yang dirawati. 
Kesimpulannya, MAVS boleh menggunakan saraf kranial untuk jangkitan 
batang otak melalui penyebaran hujung saraf otot. Lokasi virus yang unik dalam 
jangkitan saraf pusat adalah lebih mungkin disebabkan oleh laluan kemasukan virus dan 
bukannya disebabkan oleh kecenderungan infeksi yang berbeza dalam sel neuron yang 
berbeza. Kecederaan otot tidak meningkatkan jangkitan saraf pusat oleh MAVS. 
Antibodi monoklonal tetikus adalah berguna dalam mencegah dan melegakan jangkitan 
saraf pusat. 
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1.0 Introduction 
Human Enterovirus A71 (EV-A71) belongs to the Picornaviridae family and genus of 
Enterovirus (Fields, Knipe, & Howley, 2013). EV-A71 is one of the major causative 
agents for hand-foot-mouth disease (HFMD), affecting mainly children below 5 years 
old. In some cases, it may progress to central nervous system (CNS) causing aseptic 
meningitis, encephalomyelitis and acute flaccid paralysis (AFP). Severe 
encephalomyelitis can be fatal, especially in younger patients (Ong & Wong, 2015; 
Solomon et al., 2010). 
EV-A71 was first isolated in 1969, from a CNS-infected patient in California, 
USA, and reported by Schmidt, Lennette, and Ho (1974). Since then, there have been 
many more reports of EV-A71 outbreaks periodically in many parts of the world – USA, 
Europe, Asia, Australia, and Africa (World Health Organization, 2011). Recently, large 
outbreaks of HFMD mainly due to EV-A71 infection, appeared across the Asia Pacific 
regions, causing fatal neurologic complications. During the outbreak in mainland China 
in 2009, 1,155,525 cases with 13,810 severe cases and 353 deaths were reported (World 
Health Organization, 2011). Typically, after a few days of nonspecific fever, cough, 
with or without skin lesions, children with severe EV-A71 encephalomyelitis usually 
die from sudden cardiorespiratory collapse and pulmonary oedema within hours of 
hospital admission (Ong & Wong, 2015; K. T. Wong et al., 2008). Based on autopsy 
studies, fatal EV-A71 cases showed severe inflammation within the spinal cord, 
brainstem, hypothalamus, and cerebellar dentate nucleus (Lu et al., 2009; Wei, Li, & 
Chen, 2010; K. T. Wong et al., 2008; Yang et al., 2009). This distinct and stereotyped 
distribution of inflammation suggested the possibility that EV-A71 could utilise 
retrograde axonal transport via peripheral nerves to reach the CNS.  
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Several animal experiments support the hypothesis of retrograde axonal 
transport from peripheral nerves (Ong et al., 2008; Y. F. Wang & Yu, 2014). We 
hypothesised that EV-A71 can utilise cranial nerves to directly infect the brainstem, 
resulting in a sudden cardiopulmonary collapse in fatal encephalomyelitis. Very little is 
known about transmission and spread of EV-A71 within the CNS after viral entry via 
peripheral nerves. After entry into the CNS, following neuronal infection, viral cytolysis 
occurs but immune mediated or bystander effects might also play an important role in 
tissue injury. In support of viral cytolysis, EV-A71 antigens/RNA were visualised 
within the neuronal bodies and processes in human autopsy reports and animal models 
(Ong & Wong, 2015).  
Among the various possible viral entry receptors for EV-A71, Scavenger 
Receptor Class B, Member 2 (SCARB2) appears to be the most promising so far. The 
essential role of SCARB2 in the development of EV-A71 neurological disease in vivo 
was shown in a recent transgenic (Tg) mouse model (Yamayoshi, Fujii, & Koike, 2014). 
The association of SCARB2 receptors and viral tissue tropism was also suggested in 
human and other mouse studies but the results have yet to be confirmed (Fujii et al., 
2013; Y. He et al., 2014; Jiao, Guo, Huang, Chang, & Qiu, 2014; Yu et al., 2014). 
 “Provocation poliomyelitis” defined as muscle weakness (or paralysis) caused 
by poliovirus infection in motor neurons within spinal cord has been known for a long 
time. It is believed to be due to injured muscle tissues from the trauma of injection that 
aids the poliovirus infection of the spinal cord (Gromeier & Wimmer, 1998; John & 
Vashishtha, 2013). Since EV-A71 belongs to the same Enterovirus genus as poliovirus, 
and could cause similar AFP, it is possible that EV-A71 infection may be associated 
with the same “provocation poliomyelitis” phenomenon (Gorson & Ropper, 2001). EV-
A71 provocation AFP was studied by comparing the viral localisation and quantitation 
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in the CNS in a muscle-traumatised and non-traumatised mouse model of EV-A71 
encephalomyelitis.  
 Although several vaccines are actively being studied and clinical trials are 
progressing well, there are still no vaccines and therapeutic drugs licenced for EV-A71 
infection (Ng, He, & Kwang, 2015). Intravenous immunoglobulin (IVIG) at high 
neutralising titres, have been recommended as possible therapeutic treatments against 
severe EV-A71 infection in Taiwan and China (R. Cao, Han, Qin, & Qin, 2011; C. C. 
Huang, 2001). However, the effectiveness of IVIG varies according to different 
manufacturers and times of collection causing batch to batch variations in the pooled 
sera (Ng et al., 2015). Several monoclonal antibodies (MAbs) as an alternative options 
to IVIG had been proven to have good prophylactic effect in animal models. 
Nevertheless, to date, most MAbs have been tested on animal models of EV-A71 
infection, that display both myositis and CNS infection. Since, myositis and/or CNS 
infection could lead to limb paralysis or death, improvements in survival or 
amelioration/prevention of paralysis, without histopathological analysis is not sufficient 
to show if MAb is effective after CNS infection has occurred. This is particularly 
important since in human infections, CNS involvement is a major cause of death.   
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The objectives of this study are as follows: 
1. To determine the role of cranial nerves in direct brainstem infection. 
2. To investigate neuronal susceptibility to EV-A71 transmission within the brain, 
and its association with SCARB2 receptors. 
3. To investigate the phenomenon of “provocation poliomyelitis” in EV-A71 
infection. 
4. To investigate the effectiveness of a MAb after established CNS infection. 
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2.0 Literature review 
2.1 Enterovirus 71 
2.1.1 Classification 
Enterovirus 71 (EV-A71) belongs to the Enterovirus genus of the Picornaviridae family. 
The name “Picornavirus” is derived from the prefix pica (meaning very small) + RNA + 
virus. Picornaviruses are non-enveloped viruses, each with a single positive strand of 
RNA (Fields et al., 2013). The genus Enterovirus consists of 12 species: Enterovirus A-
H, Enterovirus J and Rhinovirus A-C, based on molecular and biological properties of 
the viruses. Serotypes EV-A71 and coxsackieviruses A2-A8, A10, A12, A14, A16 and 
enteroviruses A76, A89-92, A114, A119-121 and the simian enteroviruses SV19, SV43, 
SV46 and baboon enterovirus A13 are all belong to the species Enterovirus A (Adams, 
King, & Carstens, 2013). EV-A71 can be further classified into three genogroups (A, B 
and C) based on the complete VP1 sequence. Genogroup A consists of a single member, 
strain BrCr-CA-70. Genogroups B and C, each can be divided into five distinct 
subgenogroups (B1 to B5, and C1 to C5) (Brown, Oberste, Alexander, Kennett, & 
Pallansch, 1999).  
 Like other enteroviruses, EV-A71 has a diameter of approximately 30 nm, a 
non-enveloped, pentameric icosahedral capsid, which comprises 60 identical protomers. 
Each protomer consists of 4 structural viral proteins (VP1 to VP4) (Figure 2.1). The 
VP1, VP2 and VP3 proteins are located on the external surface of the capsid whereas 
VP4 is located on the inside (Fields et al., 2013; Plevka, Perera, Cardosa, Kuhn, & 
Rossmann, 2012). Within the viral capsid is the RNA genome, which is about 7.4 kb. 
The viral protein (VPg) is covalently anchored at the 5’ terminal and acts as a protein 
primer to initiate RNA synthesis during the viral replication (Figure 2.1). The coding 
region is flanked by 5’ and 3’ untranslated regions (UTR) at both ends, respectively, 
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followed by a variable length of poly-A tract located at the terminal of the 3’ UTR 
(Bedard & Semler, 2004). The protein coding region encodes a 2194 amino acid 
polyprotein that can be divided into three primary precursor molecules: P1 region 
encodes for structural proteins VP4, VP2, VP3, and VP1; P2 and P3 for the non-
structural proteins 2A to 2C and 3A to 3D, respectively (P. C. McMinn, 2002). Non-
structural proteins are essential for genome replication and protein processing (Fields et 
al., 2013).  
 
 
Figure 2.1: Structure of EV71 virion. The icosahedral capsid is formed by 60 
protomers, each comprising 4 structural proteins VP1, VP2, VP3 and VP4. VP1-VP3 is 
located on the surface of the capsid while VP4 is located on its internal side. A 7.5 kb 
RNA genome forms the core of the capsid and anchors itself to the capsid via VP4. It 
has a viral protein (VPg) at its 5’ end instead of a methylated nucleotide cap structure. 
(Adapted from Solomon et al., 2010) 
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2.1.2 Physical and chemical properties 
EV-A71 as a non-enveloped virus, is relatively stable to acid (up to pH 3.0) and 
common laboratory disinfectants such as ether, chloroform, detergent, 70% ethanol, 
isopropanol, dilute Lysol and quaternary ammonium compounds. However, EV-A71 is 
oxidant sensitive and is rapidly inactivated by 1% of potassium permanganate, 1% of 
hydrogen peroxidase, 0.3% of formaldehyde, 0.1N of hydrogen chloride and chlorine. 
Similar to other infectious agents, EV-A71 can also be inactivated by ultra-violet light, 
particularly on surfaces but its antigenicity is retained (Fields et al., 2013). EV-A71 is 
also relatively sensitive to temperature and can be instantly inactivated by boiling water 
at 65°C for 2.5 minutes (min) and 56°C for 30 min. The high temperature alters the 
virions and causes RNA release which is irreversible. Drying can also rapidly inactivate 
the virus but slightly less efficiently in the presence of organic material (Fields et al., 
2013). 
 
2.1.3 EV-A71 infection and clinical manifestations 
Enterovirus 71 infection is usually asymptomatic especially in adult patients. The most 
common clinical manifestation of EV-A71 infection is HFMD, seen mainly in children. 
HFMD patients have fever, sore throat, rash (flat or raised spots) or small blisters on the 
palms of hands, soles of feet, and/or buttocks, and mouth ulcers in the oral cavity or 
sides of the tongue (Figure 2.2) (Solomon et al., 2010).  
 However, the infection can be serious and fatal in young children notably those 
who are less than five years old because of CNS complications. The trend of EV-A71 
infection or clinical manifestations appear to vary at different locations and times. For 
example, in 1970s, clinical manifestations of an EV-A71 outbreak in Europe were 
mainly encephalitis and polio-like paralysis with few cases of HFMD. Whereas, an EV-
A71 outbreak in Japan at about the same period of time, mainly manifested as self-
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limiting HFMD with only a minority of cases with CNS involvement (Ho, 2000; S. S. 
Wong, Yip, Lau, & Yuen, 2010). In 1998, an EV-A71 outbreak in Taiwan appeared to 
have caused the largest number of severe cases (405 cases) and deaths (78 cases) at that 
time (T. Y. Lin, Chang, Hsia, et al., 2002; S. M. Wang et al., 1999). However, only 7% 
of patients were reported to have CNS complications in Australia at the same period (P. 
McMinn, Stratov, Nagarajan, & Davis, 2001).  
 
 
Figure 2.2: Mucocutaneous lesions in hand, foot, and mouth disease. Ulcers on 
tongue (A) and inside the lip (B); Maculopapular and vesicular lesions on the wrists (C) 
and the soles (D) of children infected with EV71. (Adapted from Ooi et al., 2010) 
 
Among the neurological diseases are aseptic meningitis (mononuclear 
inﬁltration in the meninges), poliomyelitis-like paralysis (or AFP, causing limb 
weakness), brainstem encephalitis (or rhombencephalitis, brainstem inflammation) and 
encephalomyelitis (inflammation of the brain and spinal cord) (Weng, Chen, Huang, & 
Shih, 2010). Patients with brainstem encephalitis or encephalomyelitis have the worst 
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prognoses and are usually associated with pulmonary oedema and myocardial 
dysfunction (Lum, Wong, Lam, Chua, & Goh, 1998; Weng et al., 2010). C. C. Huang et 
al. (1999) had analysed 44 cases of EV-A71 CNS involvement during the 1998 Taiwan 
outbreak and divided the brainstem encephalitis / encephalomyelitis into 3 stages based 
on degree of CNS infection. The first stage is defined by muscle tremors and ataxia 
from which 5% of the children develop permanent neurological sequelae. The second 
stage is muscle tremors and cranial nerve involvement which is associated with 
permanent neurological sequelae in 20% of the children. The last stage is defined by 
rapid cardiopulmonary failure and fatality in 80% of the children. Survivors are often 
left with serious sequelae (C. C. Huang et al., 1999).  
The locations of lesions identified by MRI examination were mainly on the 
dorsal pons, medulla oblongata (Figure 2.3) and spinal cord (F. Chen, Li, Liu, Wen, & 
Xiang, 2013; Zeng, Wen, Gan, & Huang, 2012). With increasing disease severity, the 
lesions also extend to the upper or lower areas or involve other regions such as the 
midbrain, hypothalamus, and cerebellum. Involvement of the dorsal pons affect the 
cranial nerve VI and VII nuclei. When the midbrain is involved, the red nucleus, 
substantia nigra and cranial nerve III and IV nuclei were affected as well. Involvement 
of the dorsal medulla could affect the dorsal nucleus of the vagus nerve, fasciculus 
longitudinalis medialis, and reticulate body and lead to respiratory and circulatory 
dysfunction (Zeng et al., 2012). Patients with flaccid paralysis could show a diffuse 
lesion from lower medulla throughout the spinal cord, particularly in ventral root and 
anterior horn (Figure 2.4) (F. Chen et al., 2013; P. McMinn et al., 2001; Zeng et al., 
2012). These reports support the hypothesis that EV-A71 damages the medulla leading 
to very high levels of norepinephrine and epinephrine that may cause cardiac damage 
and arrhythmia, and pulmonary oedema via raised pulmonary vascular pressures 
(neurogenic pulmonary oedema). 
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Figure 2.3: MRI characteristics of EV-A71 encephalomyelitis. Sagittal T2 weighted 
image showed slightly patchy signal (black arrow) at the junction of the pons and 
medulla oblongata (A) and an enhanced sagittal T1 weighted image showed mild 
enhancement (white arrow) in a 3 years old boy with HFMD at day 8 (adapted from 
Zeng et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: MRI characteristics of EV-A71 related AFP. Long strip high signal on 
T2 weight image in cervical spinal cord (A) and low signal on T1 weight image in 
anterior horn (B). With Contrast gadolinium-DTPA, there were obvious enhancement in 
ventral root (C) (adapted from F. Chen et al., 2013). 
11 
 
2.1.4 Pathogenesis 
EV-A71 pathogenesis is still not fully understood and is being actively studied at the 
moment. It is widely accepted that EV-A71 is transmitted via faecal-oral route 
(Solomon et al., 2010). However, it may also spread through contact with virus-
contaminated oral secretions, vesicular fluids, surfaces and respiratory droplets (Ong & 
Wong, 2015). Similar to what is believed to be happening in poliovirus infection, EV-
A71 may start its initial replication in lymphoid tissues of the oropharyngeal cavity 
(tonsils) and the (Peyer’s patches) small bowels. Previous reports had shown that viral 
titres from throat swabs were significantly higher than viral titres from rectal swabs or 
faeces (M. H. Ooi et al., 2009; M. H. Ooi, Wong, et al., 2007). Furthermore, viral 
antigens and RNA were detected in squamous epithelium lining of tonsillar crypts via 
immunohistochemistry (IHC) and in situ hybridisation (ISH) staining, respectively, 
suggesting that the palatine tonsil and other parts of the oral mucosa could be the 
primary replication sites for EV-A71 (Y. He et al., 2014). On the other hand, so far 
gastrointestinal tract has not been found to be infected in any of the infected human 
cases, but various animal models suggested that the viruses may be able to replicate in 
gastrointestinal epithelium (Y. C. Chen et al., 2004; Phyu, Ong, & Wong, 2016). In in 
vitro studies, EV-A71 had been shown to infect, replicate and induce apoptosis in 
endothelial cells (C. C. Liang et al., 2004). Following primary replication, viruses could 
enter the tonsil and/or oropharyngeal mucosa to further spread into regional lymph 
nodes and leading to mild viraemia. However, lymph node infection/replication has not 
been demonstrated so far.  
Based on poliovirus CNS infection as a model, EV-A71 could theoretically 
invade the CNS via two routes, either by a haematogenous route and a retrograde 
peripheral nerve axonal transport route. EV-A71 could penetrate the blood-brain-barrier 
(BBB) following viraemia (C. S. Chen et al., 2007) with or without infection of 
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leucocytes (as with measles and mumps virus). The infected leucocytes may then 
migrate across the BBB due to upregulation of cellular adhesion molecules (Jackson, 
2013; Tyler, 2009). Alternatively, alteration of the BBB’s permeability as a result of 
pro-inflammatory cytokines such as tumour necrosis factor, interleukin 1β (IL-1β) and 
IL-6, caused by infection in other organs could permit the virus entry or virus may be 
taken up by receptors. Pinocytotic vesicles on endothelial cells that contain virus may 
be actively transported into the CNS as in Semliki Forest virus infection (Jackson, 2013; 
Tyler, 2009). EV A71 may also enter the CNS by retrograde axonal transport via the 
peripheral motor nerves (C. S. Chen et al., 2007; Ong et al., 2008). Various in vivo 
models and autopsy reports had suggested the possibility of retrograde axonal transport 
based on tissue tropism and CNS distribution of inflammation and virus (C. S. Chen et 
al., 2007; Lu et al., 2009; Ong et al., 2008; Y. F. Wang et al., 2004; Y. F. Wang & Yu, 
2014; Wei et al., 2010; K. T. Wong et al., 2008; Yang et al., 2009). Furthermore, Ohka, 
Yang, Terada, Iwasaki, and Nomoto (1998) had shown retrograde transport of intact 
poliovirus through the axon via the fast transport system in a transgenic mouse model. 
 
2.1.5 “Provocation Poliomyelitis”  
“Provocation poliomyelitis” is defined as a phenomenon in which skeletal muscle injury 
predisposes the patient who has concurrent poliovirus infection to neurological 
complications such as muscle weakness (or paralysis). The history of “provocation 
poliomyelitis” can be traced to the 1940s in the USA when vaccines were not yet 
available. Initially, “provocation poliomyelitis” among unvaccinated children in 
endemic countries was believed to be due to poor hygiene or immigrant populations. 
After poliovirus was found to involve spinal cords, the causes of “provocation 
poliomyelitis was expanded to include the effects of diet, fatigue and hygiene 
(Mawdsley, 2014). In 1940s, based on 2000 case studies, the Harvard Infantile Paralysis 
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Commission suggested that tonsillectomies could lead to respiratory paralysis due to 
bulbar polio (Mawdsley, 2014). On the other hand, German doctors suggested that 
paediatric injections could provoke poliomyelitis. Although these observations were 
supported by doctors in France and Italy, it did not gain much attention until the end of 
World War 2. Several studies from United Kingdom, Australia and USA, reported that 
diphtheria, tetanus, and pertussis vaccines could provoke poliomyelitis suggesting to 
some that injured tissues at the injection site could somehow aggravate poliovirus 
infection. Others believed that the injections delivered poliovirus on the surface of skin 
into deeper tissues.  
 In 1955, Salk’s polio vaccine, made by inactivating poliovirus with 
formaldehyde, had been approved by authorities in the USA. Five pharmaceutical 
companies, Eli Lilly, Parke-Davis, Wyeth, Pitman-Moore, and Cutter were licensed for 
vaccine production. Two weeks after the release of the vaccine, Cutter’s vaccine was 
immediately recalled, but 380,000 doses had already been administered. Two 
production pools made by Cutter Laboratories (accounting for 120,000 doses) contained 
live poliovirus. Among the children who had received the vaccine from these pools, 
abortive polio (characterised by headache, stiff neck, fever, and muscle weakness) 
developed in 40,000 children; 51 were permanently paralysed; and 5 died. Cutter’s 
vaccine also started a polio epidemic in which 113 people in the affected children’s 
families or communities were paralysed, and 5 died. Subsequent studies found that cell 
debris contained in Cutter’s vaccine had prevented adequate exposure of virus particles 
to formaldehyde. Later, safer inactivated polio vaccines successfully decreased the 
incidence of poliomyelitis (Nathanson & Langmuir, 1995; Offit, 2005). 
 “Provocation poliomyelitis” in 1980s again became an important issue when 
WHO introduced vaccines into third world countries where poliovirus epidemics were 
occurring and children were reported to develop paralysis after vaccination. Studies 
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proposed that injections within 30 days of onset were a risk factor for paralysis. 
Although some refused the findings, injections were done more carefully in epidemic 
regions (Mawdsley, 2014; Strebel, Ion-Nedelcu, Baughman, Sutter, & Cochi, 1995).  
 The most likely mechanism for “poliovirus provocation” was first published in 
1998 by State University of New York. Injured tissues from the physical act of injection 
induces retrograde axonal transport of poliovirus and thereby facilitates viral invasion of 
the central nervous system and the progression of spinal cord damage. It was also 
proposed that other enteroviruses may cause “provocation poliomyelitis” (Gromeier & 
Wimmer, 1998). As far as we are aware, there have been no report of EV-A71 causing a 
“provocation poliomyelitis”-like phenomenon.  
 
2.1.6 Autopsy findings in EV-A71 CNS infection 
Upon gross assessment of the brain, flattened cerebral gyri, shallowed intervening sulci 
and cerebral oedema may be observed (Yang et al., 2009). Under light microscopy, 
inflammation was found in different regions of CNS including all levels of the spinal 
cord, brainstem and cerebrum (especially hypothalamus and cerebellar dentate nucleus) 
(Ong & Wong, 2015). Typical viral encephalitic features such as widespread 
perivascular cuffing, mild mononuclear meningitis, multifocal necrosis, microglial 
nodules and neuronophagia were observed. However, no viral inclusions were found. 
These neuropathological changes were mostly found in the medulla, pons, midbrain 
posterior to the corticospinal tracts (crus cerebri), hypothalamus, subthalamic nucleus 
and grey matter of anterior and posterior horns of spinal cord. Inflammation in the 
cerebral cortex was less intense and mostly in the motor cortex (Ong & Wong, 2015; 
Yang et al., 2009).  
EV-A71 antigens and RNA can be found in inflamed regions, although the viral 
antigens/RNA may be very focal even in severely inflamed areas. EV-A71 
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antigens/RNA had been shown in the cytoplasm of neuronal cell bodies, processes and 
inflammatory cells (Ong & Wong, 2015). The inflammatory cells were predominantly 
CD68+ macrophages/microglias, followed by CD15+ neutrophils, CD4+ lymphocytes, 
CD8+ lymphocytes and a small percentage of CD20+ B cells. CD68+ macrophages 
were mostly found in the brainstem, meninges, perivascular areas and in microglia 
nodules. Whereas, CD15+ neutrophils, lymphocytes and B cells were mainly found as 
perivascular cuffing and in meninges (Ong & Wong, 2015; Yang et al., 2009).  
Some cases showed pulmonary oedema with or without inflammation. However, 
EV-A71 was never isolated from any lung samples nor antigens/RNA localised within 
the lung. Whereas, viruses had been isolated from myocardium although the 
antigens/RNA staining were negative so far. Other organs positive for viral isolation 
were tonsils, intestine and pancreas (Ong & Wong, 2015).  
In conclusion, autopsy studies of EV-A71 patients suggest that EV-A71 could 
reach the CNS via peripheral motor nerves via retrograde axonal transport, and both 
severe brainstem encephalomyelitis and neurogenic pulmonary oedema were the major 
cause of death. 
 
2.1.7 Neuropathogenesis  
Neuropathogenesis of EV-A71 infection is actively being studied at the moment. At 
least two possible mechanisms may be involved in direct neuronal damage by 
apoptosis/necrosis and immune mediated neuronal damage (Weng et al., 2010). EV-
A71 antigens and RNA were often detected in degenerated neurons and in neurons 
being phagocytosed (neuronophagia) in human autopsy cases and several animal 
models, suggesting viral cytolysis as a pathogenic mechanism (Ong & Wong, 2015). 
However, several in vitro experiments have suggested that EV-A71 induced apoptosis 
can occur. Phosphatidylserine had been detected on the outer plasma membranes 
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indicating an early apoptosis event in EV-A71 infected neuronal cells (S. C. Chang, Lin, 
Lo, Li, & Shih, 2004). In addition, S. C. Chang et al. (2004) had shown that efflux of 
cytochrome c from the mitochondria to cytoplasm, and cleaved activated caspase 9 
which could lead to apoptosis. In another study, EV-A71 infection triggered Abl and 
thus activated the cyclin-dependent kinase 5 kinase activity which led to neuronal 
apoptosis (S. C. Chang et al., 2004). In addition, Li et al. (2002) had shown that EV-
A71 3C protease is a key factor in apoptosis. Transient expression of EV-A71 3C 
protease in SF268 cells (human glioblastoma cell line) caused DNA fragmentation by 
the caspase 3 pathway. In another study, host cell mRNA polyadenylation could be 
impaired by cleavage of EV-A71 3C protease protein leading to apoptosis (Weng, Li, 
Hung, & Shih, 2009). 
 Another mechanism of tissue injury induced by inflammation in adjacent CNS 
regions (bystander effect) cannot be excluded. In autopsy studies, the extensive areas of 
inflammation within the CNS could be due to immune dysregulation by inappropriate 
activation of pro-inflammatory cytokines, whose actions lead to pathological 
consequences/ neuronal damage of non-infected cells (Ong & Wong, 2015). Infected 
inflammatory cells are believed to trigger the pro-inflammatory cytokines production in 
patients with severe EV-A71 infection. Infected human T cell lines (Jurkat), 
macrophage cell lines (THP-1) and human peripheral blood mononuclear cells were 
found to be infected in vitro to produce Tumor Necrosis Factor-α (TNF-α) and 
“macrophage migration inhibitory factor” (MIF) (Gong et al., 2012). Whereas, infected 
human dendritic cells via the “Dendritic Cell-Specific Intercellular adhesion molecule-
3-Grabbing Non-integrin” (DC-SIGN) receptor could trigger the production of IL-6, IL-
12 and TNF-α (Y. W. Lin, Wang, Tung, & Chen, 2009). EV-A71 infection could also 
activate the “nuclear factor kappa-light-chain-enhancer of activated B cells” (NF-κB) 
pathway which leads to production of Interferon-β (IFN-β) and TNF-α (Chu et al., 1999) 
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and could increase the expression of “vascular cell adhesion molecule 1” (VCAM-1) 
which facilitates the binding of neutrophils and leukocytes to “vascular smooth muscle 
cells” (VSMC) (Tung et al., 2007). Expression of “cyclooxygenase-2” (COX-2), a 
neurotoxic mediator, increase with EV-A71 infection in SK-N-SH cells. The metabolite 
of COX-2, “Prostaglandin E2” PGE2, had been shown to accelerate EV-A71 infection 
in cells (N. Chen & Reis, 2002; Hinson & Tyor, 2001). Lastly, the immune mediated 
auto-antigen effect cannot be excluded. Fan et al. (2015) suggested that the common 
epitope between VP1 of EV-A71 and “human mediator complex subunit 25” could lead 
to autoantigen effect. 
 
2.2 Immune response 
Innate immunity, the non-antigen-specific immunity, is the early phase defence against 
viral infection. It reacts immediately to kill pathogens, by activating the adaptive 
immunity as well (Elgert, 2009; Levinson & Jawetz, 1992). Immune cells, such as 
macrophages, and non-immune cells, such as epithelial cells, have “pattern-recognition 
receptors” (PPRs) located on the surface of cell membranes, within the cytoplasm or in 
the endosome (Elgert, 2009; Levinson & Jawetz, 1992). PPRs can be triggered by two 
classes of molecules: “Pathogen-Associated Molecular Pattern” (which included viral 
DNA/RNA and bacterial lipopolysaccharide), and “Danger Associated Molecular 
Pattern” (endogenous molecules released from stressed or dying cells such as heat 
shock protein, high-mobility group box1, cytosolic RNAs, cytosolic DNAs and 
mitochondria DNAs). All these signals activate innate immunity and pro-inflammatory 
responses (Pathinayake, Hsu, & Wark, 2015). 
 There are three major types of PPRs; namely “toll-like receptors” (TLRs), 
“retinoic acid-inducible gene I like receptors” (RLRs) and “nucleotide oligomerisation 
domain like receptors” (Pathinayake et al., 2015). Picornaviruses are mainly recognised 
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by “melanoma-differentiation-associated” (MDA5), RLRs. Binding of viral RNA leads 
to conformation changes on MDA5, and activation of a series of cascade effects 
downstream (Gitlin et al., 2006). Briefly, MDA5 activates the mitochondrial antiviral 
signalling to phosphorylate “interferon regulatory factor 3” (IRF-3) and IRF-7, thereby 
resulting in the expression of the type I IFN gene (Gitlin et al., 2006; Kato et al., 2006). 
NF-κB is also activated by mitochondrial antiviral signalling, and in turn activates pro-
inflammatory cytokines, adhesion molecules, chemokines, acute phase proteins and 
inducible enzymes (Takeuchi & Akira, 2008). In addition, TLR3, a member of TLRs, 
can be activated by RNA of picornaviruses, to activate the NF-κB (Oshiumi et al., 2011). 
Several studies show that 3C and 2A protease of EV-A71 are the main antagonists of 
innate immunity by cleaving and binding to different antiviral signalling molecules 
(such as MDA5, IRF3, IRF7, cellular micro RNAs, mitochondrial antiviral signalling 
and NF-κB.) (Pathinayake et al., 2015). 
 Natural killer (NK) cells are also important in innate immunity. Type 1 IFN can 
increase NK cells cytotoxicity through perforin to cause death of infected cells. Besides, 
“killer immunoglobulin-like receptors” on NK cells can recognise downregulation of 
“major histocompatibility complex” (MHC) class I molecules, as transformation or 
virus infection are known to downregulate its expression. In addition, NK cells can 
activate both dendritic cells and T cells which are involved in adaptive immunity (Paust, 
Senman, & von Andrian, 2010; Warren & Smyth, 1999). 
Adaptive immunity is involved in a later phase of infection and is important for 
immunological memory. It is highly antigen-specific and can be divided into cell-
mediated and humoral immunity (Elgert, 2009; Pathinayake et al., 2015). Little is 
known about cell-mediated immunity response to EV-A71 infection, even for other 
picornaviruses such as poliovirus and coxsackievirus (Dotzauer & Kraemer, 2012; Paust 
et al., 2010). Dendritic cells and macrophages had been shown to be important antigen 
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presenting cells via MHC class II molecules in poliovirus and coxsackievirus infection 
(Dotzauer & Kraemer, 2012). EV-A71 specific CD4+ T cells (T helper cells) were 
induced in vaccinated children in a few vaccine trial studies (Collins, 1974; L. Liu et al., 
2015; Ng et al., 2015; F. C. Zhu et al., 2013). In general, activated T helper 1 cells 
produce the cytokines IFN-γ and IL-2. IFN- γ secreting T cells had been shown in 
vaccinated EV-A71 patients, which theoretically can lyse the infected cells via 
activation of NK cells. Activated T helper 2 cells produce IL-4, IL-5 and IL-10 which 
are important to regulate antibody and allergic responses (Seder & Hill, 2000). In 
addition, virus-specific cytotoxic T lymphocytes (CD8+) are believed to be important in 
preventing viral multiplication. These cells had been shown to help in viral elimination 
in poliovirus infection via MHC class I pathway (Dotzauer & Kraemer, 2012). However, 
coxsackieviruses had been reported to strongly inhibit antigen presentation via MHC 
class I pathway and thus evade CD8+ T cell immunity (Kemball, Alirezaei, & Whitton, 
2010).  
Humoral immunity is activated when B cell receptors are activated by specific 
antigens via T cell independent (TI) or dependent (TD) pathways. TI response is faster 
but is short-lived compared to the TD response. After exposure to viral particles or 
RNA, the TI response leads to secretion of Immunoglobulin M (IgM) antibodies. TD 
response is activated when naïve T helper cells or T helper cells recognise the presented 
viral particle on the MHC class II molecule, resulting in cytokine production which is 
important in B cell proliferation and antibody production (mainly IgG). IgG antibodies 
are important for long-term memory (Elgert, 2009). All these neutralising antibodies are 
important in controlling viraemia and hence could help with the infection (Dotzauer & 
Kraemer, 2012; Kemball et al., 2010). In addition, certain antibodies could activate the 
complement system to eliminate infected cells (Elgert, 2009).  
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Neutralising antibodies could be present in adults, especially in regions with 
EV-A71 epidemics. Luo et al. (2009) had shown that about 50-60% of pregnant women 
had serum EV-A71 antibodies which helped in protection against EV-A71 infection 
immediately after birth. However, the maternal antibodies decline and are almost 
undetectable in 99% of infants by 6 months (Kim et al., 2015; Luo et al., 2009; E. E. 
Ooi, Phoon, Ishak, & Chan, 2002). Pre-existing maternal neutralising antibodies could 
interfere with the production of neutralising antibody secreting cells following active 
immunisation (Kim et al., 2015). Consequently, EV-A71 vaccines were suggested to 
target infants > 6 months of age. 
 
2.3 Animal models 
The only natural host for EV-A71 infection is human beings. Severe outbreaks in 1990s 
in the Asia Pacific region, drove researchers to develop several animal models for EV-
A71 studies as summarised by Y. F. Wang and Yu (2014) in Table 2.1.  
Up to date, none of the models are perfect. Different monkey models 
(Cynomolgus monkey, adult and neonatal rhesus monkeys) present different tissue 
tropism, primary viral replication sites and disease manifestations. However, 
observations in monkey studies had advanced our understanding on viral transmission, 
clinical manifestations, pathogenesis, viral distribution and immune responses of EV-
A71 infection (Y. F. Wang & Yu, 2014). Infected cynomolgus monkeys display both 
pyramidal tract signs (flaccid paralysis) and extrapyramidal tract signs (including tremor 
and ataxia) with a broad viral antigen distribution that involves the spinal cord, 
brainstem, cerebellar cortex, dentate nuclei and cerebrum which was similar to humans 
(Table 2.1). However, the monkeys do not manifest cutaneous lesions or develop 
pulmonary oedema (Arita et al., 2007; Arita et al., 2005). Neonatal rhesus monkeys did 
demonstrate HFMD-like papules and vesicles on the limbs and in the mouths. Although 
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both medulla oblongata and thalamus contain very high virus titres and display 
neuropathological lesions, the neonatal rhesus monkeys did not display the typical 
neurological complications such as flaccid paralysis and ataxia (H. Chen et al., 2012). 
So far, mouse models are more frequently used in EV-A71 research. Several 
infected mouse models demonstrated strong neuronotropism in the CNS which shared 
many features with the human encephalomyelitis. These models strengthened the 
hypothesis that virus enters the CNS via peripheral motor nerves (Table 2.1). However, 
these animal models showed age-dependent susceptibility toward EV-A71 infection and 
demonstrated strong myotropism. In addition, pulmonary oedema was not demonstrated 
in any of the models. Virus strains produced by passaging to adapt virus to mouse 
models have been attempted but full infectivity in adult mice has not been achieved 
(Table 2.1). In 2013, a SCARB2 Tg mice model became available. These hSCARB2-
expressing mice exhibited ataxia, paralysis, and death after infection. The pathological 
features in these mice were generally similar to those of EV-A71 encephalomyelitis in 
humans and experimentally infected monkeys. Although the Tg mice showed some 
level of muscle infection, it should be useful to replace the monkey and other mice 
models (Y. F. Wang & Yu, 2014). Recently, an orally-infected hamster model for EV-
A71 encephalomyelitis which demonstrated squamous lesions in the paws, skin and oral 
cavity reminiscent of HFMD was described by Phyu et al. (2016). This hamster model 
which was consistently infected via the natural oral route should be useful to study 
squamous epitheliotropism, neuropathogenesis, oral/faecal shedding in EV-A71 
infection, person-to-person transmission, and to test anti-viral drugs and vaccines. 
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Table 2.1 Enterovirus 71 animal models for pathogenesis studies (adapted from Y. F. Wang & Yu, 2014) 
Animal Virus strain 
Infection 
route/dose 
Clinical manifestations, viral replication and other remarks Ref 
Non-human primate     
Cynomolgus monkey Clinical 
isolates and 
prototype BrCr 
IS/106 
CCID50 
IV/105.5 to 
107 TCID50 
Neurological manifestations including pyramidal and extrapyramidal tract signs, 
such as flaccid paralysis, tremor and ataxia. The virus replicated in the spinal cord, 
brainstem, cerebellum and cerebrum. EV-A71 had a wider neurotropism than that 
of polioviruses. 
(Arita et al., 2007; 
Arita et al., 2005) 
Rhesus monkey, adult  Clinical isolate 
(FY-23, C4 
genotype) 
IC, IV/106.5 
CCID50 
Monkeys developed CNS infection and neuronal impairment with extra-neuronal 
pathological changes confined to the lung tissues but not in the pancreas and 
spleen, where high viral loads were detected. Infiltration of inflammatory cells in 
the caudate nucleus, pontine nucleus and substantia nigra; neurons retrogression; 
and pronounced perivascular cuffing 
(Zhang et al., 
2011) 
Rhesus monkey, 
neonate 
Clinical isolate 
(FY-23, C4 
genotype) 
IT/104.5 
CCID50 
Oral/106.5 
CCID50 twice 
HFMD-liked papules and vesicles were found on the limbs and in the mouth after 
intra-tracheal infection. However, neurological complications were not observed. 
High viral titres were transiently detected in the brown adipose tissue, skeletal 
muscle and CNS (thalamus, pons and spinal cord).  
(H. Chen et al., 
2012) 
Rodents 
(immunocompetent) 
    
ICR, 1 to 14-day-old 
mouse 
Mouse-adapted 
EV-A71 strain  
(MP4, C2 
genotype) 
Oral/5 x 106 
pfu 
IM/5 x 103 
pfu 
IC/5 x 104 
pfu 
Mice developed rear limb paralysis with massive and widespread necrotising 
myositis, and neuronal loss and apoptosis in the spinal cord and brainstem before 
death. The spinal cord, brain and muscle were the major organs for virus 
replication in the late phase of infection. Retrograde axonal transport in peripheral 
nerves might represent the major transmission route of EV-A71 in mice.  
(Y. F. Wang et al., 
2004) 
BALB/c, 1 to 7-day-
old mouse 
 
 
Mouse-adapted 
strain  
(MP-26 M) 
IC/3.4 x 104 
TCID50 
IM/3.4 x 103 
TCID50 
IP/3.4 x 104 
TCID50 
Mice developed limb paralysis followed by death. Skeletal muscle displayed 
severe necrotising myositis and contained a high viral load. Virus was also isolated 
from the blood, heart, liver, spleen and brain. The VP1 mutation (G145E) alone 
was sufficient to increase virulence in mice. 
(B. H. Chua, 
Phuektes, Sanders, 
Nicholls, & 
McMinn, 2008) 
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Table 2.1, continued 
Animal Virus strain 
Infection 
route/dose 
Clinical manifestations, viral replication and other remarks Ref 
ICR, 2-week-old 
mouse 
Mouse-adapted strain 
(MAVs, B3 
genotype) 
IC, IP, SC, 
oral/105 
CCID50 
IM/3 x 105 
CCID50 
Mice developed paralysis followed by death after IC, IP, SC and IM infection 
but not after oral administration of the virus. The highest viral titres were 
detected in the skeletal muscle, spleen and spinal cord. The virus might enter 
the CNS via peripheral motor nerves after skeletal muscle infection.  
(Ong et al., 
2008) 
 Mouse muscle-
adapted strain 
(Fuyang-0805a, C4 
genotype) 
IP/105 
TCID50 
Mice showed strong myotropism manifesting as severe necrotising myositis in 
both skeletal and cardiac muscles. Virus was detected in the muscle, heart and 
intestines. 
(W. Wang et al., 
2011) 
Syrian 
golden hamsters,  
2-week-old 
Mouse-adapted strain 
(MAVs, B3 
genotype) 
Oral/104 
CCID50 
Mice demonstrated macroscopic cutaneous lesions around the oral cavity and 
paws. Viral antigens/inflammation were found in squamous epithelium (lip, 
oral cavity, paw, skin, and oesophagus), neurons (brainstem, spinal cord, 
sensory ganglia), acinar cells (salivary gland, lacrimal gland), lymphoid cells, 
and muscle fibres, liver and gastric epithelium. In addition, virus could be 
isolated from oral washes and faeces. 
(Phyu et al., 
2016) 
Rodents 
(immunodeficiency) 
    
NOD/SCID, 
3- to 4-week old 
mouse 
NOD/SCID mouse-
adapted strain 
(EV-
A71(NOD/SCID), B1 
genotype) 
IC/106 
CCID50 
Infected mice showed hindlimb paralysis. Viral RNA was first detected in the 
CNS and serum, followed by high copy numbers in the heart, skeletal muscle 
and spinal cord. 
(Arita, Ami, 
Wakita, & 
Shimizu, 2008) 
AG129, 10-week-old 
mouse 
A129 and AG129 
mouse-adapted strain 
(B2 genotype) 
IP/5.2 x 104 
TCID50 
Infected AG129 mice, but not A129 mice, developed limb paralysis, eye 
irritation, loss of balance and movement control, and exhibited high mortality. 
(Caine, Partidos, 
Santangelo, & 
Osorio, 2013) 
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Table 2.1, continued 
Animal Virus strain 
Infection 
route/dose 
Clinical manifestations, viral replication and other remarks Ref 
AG129, 2-
week-old 
mouse 
Clinical isolate 
(5865/SIN/00009, B4 
genotype) 
IP/106 pfu 
Oral/107 pfu 
Infected mice displayed progressive limb paralysis before death. Virus replication 
resulted in massive damage in the limb muscles, brainstem and anterior horn of the 
spinal cord. Low viral particles in the limbs after oral inoculation indicated that the 
paralysis was a consequence of EV-A71 neuroinvasion rather than myositis.  
(Khong et 
al., 2012) 
Gerbils, 21-
day-old 
Clinical isolate 
(EV-A71/58301, C4 
genotype) 
IP/105 TCID50 Infected animals developed hindlimb paralysis, slowness and ataxia before death. 
Significantly high viral titres were detected in the spinal cord, brainstem and skeletal 
muscle. 
(Yao et 
al., 2012) 
Transgenic 
mice 
    
PSGL-1, 10-
day-old 
Clinical isolates C4 
genotype and Mouse 
muscle-adapted strain 
(Fuyang-0805a, C4 
genotype) 
IP/108 TCID50 Susceptible to a mouse muscle-adapted EV-A71 strain and not the clinical isolates, 
exhibiting severe infection that was comparable to those of the wild-type mice upon 
EV-A71 infection. High viral titres were detected in the muscle, spinal cord and brain 
after mouse-adapted virus infection. This study concluded that human PSGL-1 alone 
was not sufficient to facilitate EV-A71 infectivity in mice. 
(J. Liu et 
al., 2012) 
SCARB2, 1- 
to 14-day-old 
Clinical isolates, C2, C4, 
B4 and B5 genotypes and 
CA16 
SC/3 x 104 to 
106 pfu 
EV-A71 B genotypes were capable of inducing HFMD-like lesions and neurological 
disease with limb paralysis in 1-day-old but not Tg mice older than 2 weeks. In 
contrast, 7- and 14-day-old but not 21-day-old Tg mice were more susceptible to the 
EV-A71 C genotypes and coxsackievirus A16, exhibiting more severe CNS disease, 
limb paralysis and death than non-Tg mice. 
(Y. W. 
Lin et al., 
2013) 
SCARB2, 3-
week-old 
Clinical isolates 
(Isehara/Japan/99, C 
genotype) 
SC, IV, IP, 
oral/104 to 106 
TCID50 
Mice displayed ataxia, paralysis and death. The CNS, including the spinal cord, 
brainstem, cerebellum, cerebrum, hypothalamus and thalamus, was the major 
replication site for the virus, which is similar to the human. Nonetheless, Tg mice 
were less susceptible to oral infection and pulmonary oedema was not observed. 
Adult Tg mice did not display the typical cutaneous lesions found in human HFMD.  
(Fujii et 
al., 2013) 
IS:intra-spinal; IV:intra-venous; IC:intra-cranial/intra-cerebral; IT:intra-tracheally; IP:intra-peritoneal; IM:intra-muscular; SC: subcutaneous 
HFMD: Hand foot mouth disease; PSGL-1: P-selectin glycoprotein ligand-1; SCARB2: scavenger receptor class B member 2 
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In this laboratory, an EV-A71 encephalomyelitis mouse model that shared many 
features with human CNS disease was developed, using a “mouse-adapted virus strain” 
(MAVS). This model, generally demonstrated similar tissue tropism, including 
neurotropism by most routes of infection (IP, IM, SC and oral). Despite the presence of 
only sparse inﬂammation, the distribution of CNS viral RNA and antigens seems to 
parallel the distribution of inﬂammation and virus in human EV-A71 encephalomyelitis. 
Anterior horn of spinal cord, medulla, pons (sparing the pontine nuclei), midbrain, and 
lateral cerebellar nucleus were often severely infected (Ong et al., 2008). These were 
also the areas in which inﬂammation was found to be severe in human cases. In addition, 
the rarity and absence of virus in the murine motor cortex and cerebellar hemisphere, 
respectively, also seem to resemble the human infection. Although peripheral nerve 
viral transmission was first reported using another mouse model (C. S. Chen et al., 
2007), based on findings in this model, peripheral spinal motor nerves were postulated 
to be responsible for viral entry into the CNS, most likely by retrograde axonal transport 
after skeletal muscle infection.  
 
2.4 Anti-viral therapeutics and vaccines 
2.4.1 Inactivated vaccines 
Various types of inactivated EV-A71 vaccines have been reported. However, the 3 
leading and best developed and/or tested vaccines are all formalin-inactivated EV-A71, 
subgenotype C4, vaccines (Z. Liang & Wang, 2014). All three vaccines had completed 
phase III clinical trials and one of them, had just been approved by the China Food and 
Drug Administration in December 2015 (Mao, Wang, Bian, Xu, & Liang, 2016). From 
the clinical reports, these vaccines were able to induce high “Geometric Mean Titres”, 
and thus could potentially prevent 80% of EV-A71 associated diseases (F. C. Zhu et al., 
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2013; F. Zhu et al., 2014). Unfortunately, these vaccines were all prepared from a single 
subgenotype C4 strain, and thus showed limited cross-immunity and cross-
neutralisation of other genotypes (Z. Liang & Wang, 2014; Ng et al., 2015). This may 
be challenging if the vaccines are deployed worldwide, as different EV-A71 genotypes 
circulate in different regions at different times. For example, subgenotype B3 was 
circulating during the 1997 outbreak in Sarawak, Malaysia (Cardosa et al., 2003), while 
subgenotypes B4 and C1 dominated in the 2000 outbreak. Subgenotype B5 and C1 was 
circulating during the 2005 outbreak in Peninsular Malaysia (K. B. Chua et al., 2007). 
Genomic sequence variations found in different subgenotypes and the antigen 
destruction/masking by formaldehyde could be some of the reasons behind this limited 
cross-immunity of the vaccines (Wilton, Dunn, Eastwood, Minor, & Martin, 2014). It is 
possible that limited cross-immunity could trigger “antibody-dependent enhancement” 
in which antibodies against the one EV-A71 subgenotype binds to but does not 
neutralise other subgenotypes, thus enhancing viral entry into the cells (R. Y. Cao et al., 
2013; Han et al., 2011; Tirado & Yoon, 2003; S. M. Wang et al., 2010). Furthermore, 
although these vaccines were intended for use in regions where subgenotype C4 is 
predominant, there is always the possibility that other subgenotypes may shift to this 
region and this has to be taken into consideration.  
 
2.4.2 Baculovirus-expressed vaccines 
Baculovirus is a lepidopteran-specific (insect-specific) pathogen widely used in protein 
expression nowadays because of its ability to express native conformation-eukaryotic 
proteins by post-translational modification, and to produce multi-protein subunit 
complexes with tertiary structures, which cannot be done in E. coli expression systems 
(Jarvis, 2009). With the baculovirus system, several groups had successfully produced 
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EV-A71 virus-like particles (VLPs) which were similar to the native viruses without the 
viral genome. These VLPs had proven to induce high neutralising titres of up to 1:5042. 
Particles with complete viral surfaces are able to stimulate both innate and cell-mediated 
immunity (Chung et al., 2010; Ku et al., 2013; S. Y. Lin et al., 2015). Unfortunately, 
baculovirus expression systems are too low-yielding and too expensive for mass 
production of VLPs, despite efforts to increase the yield using different cells. 
 Others had tried to express the VP1 protein on the surface of the baculovirus 
envelope, also known as baculovirus surface display vaccines, to improve yield of VLPs. 
Although the sera derived from this system have neutralising titres lower than the 
conventional baculovirus system, it is still higher compared to titres with formalin 
inactivated vaccines. Currently, research groups are focusing on co-display all three 
VP1-3 on the baculovirus to induce more neutralising epitopes (Meng, Kolpe, Kiener, 
Chow, & Kwang, 2011; Premanand et al., 2012).  
 
2.4.3 Intravenous immunoglobulin (IVIG) treatment 
IVIG, a highly purified blood product containing IgG antibodies, have been actively 
used in immunocompromised or autoimmune disease patients to provide passive 
immunisation against infectious diseases such as tetanus, botulism, hepatitis B, rabies, 
and varicella. In severe cases of EV-A71 infection, it has been successfully used to 
change both pro- and anti-inflammatory cytokine levels and thus save the patient’s life. 
Moreover, neutralising antibodies against EV-A71 found therein may play a therapeutic 
as well as prophylactic role. However, IVIG products are subjected to batch-to-batch 
variations, as a result of blood pooling from a large group of healthy individuals 
contributing to different compositions and thus different degrees of effectiveness and 
consistency. Besides, use of blood-derived products could lead to spread of blood-borne 
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pathogens (R. Cao et al., 2010; Hemming, 2001; Jolles, Sewell, & Misbah, 2005; S. M. 
Wang et al., 2006).  
 
2.4.4 Monoclonal antibody (MAb) 
Specific neutralising antibodies are important in antiviral immunity for preventing and 
modulating viral infections such as infections by respiratory syncytial virus, human 
immunodeficiency virus, cytomegalovirus, hepatitis C virus and rabies (Hemming, 
2001). Many researchers have reported that anti-EV-A71 MAbs targeted against VP1, 
VP2 and VP3 are effective against EV-A71 infection (G. H. Chang et al., 2010; Deng et 
al., 2015; D. L. He et al., 2012; Kiener, Jia, Meng, Chow, & Kwang, 2014; Lee et al., 
2013; Lim et al., 2012; C. C. Liu et al., 2011; Xu et al., 2014). However, to date, only 2 
antibodies, showed cross-immunity against all EV-A71 subgenotypes, and both of them 
are IgM antibodies (Ng et al., 2015). As there are no licensed vaccines available at the 
moment, passive immunisation of antibodies may offer an effective 
prophylactic/therapeutic measure against encephalomyelitis, to reduce morbidity and 
mortality. Although a few studies described the efficacy of antibodies in early infection 
(Bek et al., 2011; G. H. Chang et al., 2010; H. W. Chang et al., 2013; Foo, Alonso, 
Chow, & Poh, 2007; Y. X. Li et al., 2014; Z. Li et al., 2014; Liou et al., 2010; Tian et al., 
2012; Xu et al., 2014), the effectiveness of antibodies after disease onset or more 
importantly after CNS involvement has not been adequately investigated (Ng et al., 
2015). Hence, the effectiveness of MAb was tested in CNS infected mice as part of our 
investigations.  
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3.0 Materials and methods 
The majority of the work was done at the University of Malaya, Malaysia while all the 
primary motor neuron studies (section 4.3.3, page 81; section 4.4, page 83) were 
performed at the Tokyo Metropolitan Institute of Medical Science, Japan.  
 
3.1 Cell lines 
African green monkey kidney (VERO) cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM; Sigma, USA) growth medium (GM), supplemented with 5% foetal 
bovine serum (FBS), 0.02 M HEPES (pH 7.4), 0.0825% sodium bicarbonate, 1 mM 
sodium pyruvate and 50 µg/mL gentamycin. Infected VERO cells were maintained in 
DMEM maintenance medium (MM) supplemented with 2% FBS, 0.02 M HEPES, 
0.19% sodium bicarbonate and 1 mM sodium pyruvate and 50 µg/mL gentamycin. 
In the Tokyo laboratory, human rhabdomyosarcoma (RD) cells transfected with 
hSCARB2 receptor gene were grown in RPMI-1640 GM, supplemented with 10% FBS 
or 6% FBS for MM. These cells were used for virus titration analysis in section 4.4.1.1 
(page 83), according to approved protocols submitted to the Animal Use and Care 
Committee, Tokyo Metropolitan Institute of Medical Science. 
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3.2 Virus preparation and concentration  
All the viruses used in this project (Table 3.1) were propagated in VERO cells or RD 
cells at a multiplicity of infection (MOI) of 0.1 until 90% of cells showed cytopathic 
effect (CPE). The infected cells were subjected to 3 freeze-thawing cycles before 
centrifugation at 4000 rpm, 4°C for 15 min to remove cell debris. The supernatant was 
then further concentrated by polyethylene glycol (PEG) precipitation as described 
previously (Yamamoto, Alberts, Benzinger, Lawhorne, & Treiber, 1970). Briefly, PEG 
6000 (Fluka, USA) and sodium chloride were added to the virus suspension to a final 
concentration of 8% (wt/vol) and 0.3 M, respectively. The mixture was stirred overnight 
at 4°C and centrifuged at 4000 x g, 4°C for 1 hour (hr). The PEG 6000-supernatant was 
discarded, and virus-containing pellet was re-suspended in a small volume of phosphate 
buffer saline (PBS, pH 7.4) and filtered through a 0.2 µM pore size filter. Small aliquots 
were stored at -80oC. Virus stock titre was determined by standard microtitration assay 
in VERO cells (section 3.6.1.2, page 37). 
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Table 3.1: Virus strains used and their characteristics  
Virus 
(Subgenogroup) 
Virus designation 
Genebank 
No 
Country 
Year 
isolated 
Clinical 
syndrome 
Used in section Page 
EV-A71 (C1) 9522 AY258300 Malaysia 2003 HFMD* 4.6.2 100 
EV-A71 (C2) 8M/6/99 AY126012 Australia 1999 Myelitis 4.6.2 100 
EV-A71 (C3) 001-KOR-00 AY125966 Korea 2000 HFMD* 4.6.2 100 
EV-A71 (C4) VN5559 AM490152 Vietnam 2005 HFMD* 4.6.2 100 
EV-A71 (C5) VN5784 AM490158 Vietnam 2005 HFMD* 4.6.2 100 
EV-A71 (B3) 13903# AY207648 Malaysia 1997 Encephalomyelits 4.6.2 100 
EV-A71 (B3) MAVS# - - - - 4.2, 4.3.1, 4.3.2, 4.5 and 
4.6 
51, 68, 74, 87, 
94 
EV-A71 (B4) A10/4 AF376067 Malaysia 2000 HFMD* 4.6.2 100 
EV-A71 (B5) 18431 NA$ Malaysia 2006 Encephalomyelitis 4.6.2 100 
CV-A16 North  NA$ Malaysia 2006? HFMD* 4.6.2 100 
EV-A71 (B3)** MAVS# - - - - 4.3.3 81 
EV-A71 (B3)** SK-
EV006/Malaysia/97 
AB051331 Malaysia 1997 Encephalomyelits 4.4 83 
*HFMD = Hand, foot and mouth disease 
#MAVS is a mouse adapted virus from the EV71 parental, clinically-isolated 13903 strain  
$NA = not available  
**These viruses were propagated in RD cells, while the rest of the viruses were propagated in VERO cells.
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3.2.1 Preparation of fluorescence-labelled EV-A71 
EV-A71 (SK-EV006/Malaysia/97 virus) was fluorescence-labelled according to the 
manufacturer’s protocol (Molecular Probes, USA). Briefly, purified EV-A71 in 0.1 M 
sodium bicarbonate solution was prepared by dialysis. The total protein concentration of 
the virus was measured using Pierce BCA Protein Assay Kit (Thermo Fisher, USA) 
according to manufacturer’s protocol. Then 50 µL of 1.0 M bicarbonate (pH 8.3) was 
added to 0.5 mL of 2 mg/mL virus followed by a vial of reactive dye. After stirring at 
room temperature (RT) for an hour in the dark, excess dye was removed by a NAP5 
resin column. The fraction containing the labelled virus was determined by absorbance 
measurements at 280 nm and 555 nm. The degree of labelling was calculated using the 
manufacturer’s formula. Virus titre was determined by a standard microtitration assay 
using RD hSCARB2 cells (section 3.6.1.2, page 37). 
 
3.2.2 Preparation of light-sensitive MAVS 
MAVS was propagated in VERO cells at an MOI of 0.1 for an hour at 36°C. Then, MM 
supplemented with 10 μg/ml of neutral red was added and incubated in the dark until 
90% of cells showed CPE (about ~ 6 days). Viruses were harvested as usual (section 3.2, 
page 30) via freeze-thaw cycles but the whole process was performed in the dark.   
 
3.3 Preparation of hyperimmune sera against MAVS 
All animal experiments were approved and performed in Malaysia, according to the 
University of Malaya’s Animal Welfare and Use Committee guidelines (2014-02-
14/PATHO/R/WKT). Hyperimmune sera with neutralising antibodies against MAVS 
were prepared by inoculating 16 µg of formaldehyde-inactivated MAVS virus, 
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containing 0.5 mg/mL aluminium hydroxide as adjuvant, into a group of 6-8 week-old 
ICR mice (n= 40), followed by 2 boosters given 2 weeks apart via the intra-peritoneal 
(IP) route. Mock-immunised mice received the same concentration of formaldehyde-
fixed VERO cell lysates. All mice were sacrificed 6-week post-immunisation or 3 days 
after the second booster. Blood was harvested by cardiac puncture at the time of 
euthanasia, and sera separated, pooled and heat-inactivated at 56°C for 30 min. Sera 
were tested for neutralising antibodies against EV-A71 by the microneutralisation test 
using VERO cells (section 3.5, page 34) as described previously (Ong, Devi, Cardosa, 
& Wong, 2010).  
 
3.4 Preparation of specific monoclonal antibody against MAVS 
BALB/c mice were immunised with MAVS by IP inoculation of approximately 105 
CCID50 (50% cell culture infective dose) virus emulsified in complete or incomplete 
Freund adjuvant (Sigma-Aldrich, USA), in a total of 3 inoculations given 3 weeks apart. 
Three days after the last booster (without adjuvant), the spleen cells were harvested, and 
fused with SP2/0 mouse myeloma cells at a ratio of 10:1 as described previously (Lim 
et al., 2012). The fused cells were suspended in hypoxanthine-aminopterin-thymidine 
medium. After 10 to 14 days, the supernatant from wells with hybridoma cells were 
screened by a microneutralising assay as described previously (section 3.5, page 34) 
(Ong et al., 2010). Hybridoma cells secreting neutralising antibodies were subcloned by 
limiting dilution and cultured as described previously (Lim et al., 2012). A monoclonal 
antibody (MAb) designated as MAb 3D1 was selected out of 48 clones for further 
experiments because it demonstrated complete neutralisation against EV-A71 in the 
neutralising assay. 
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3.4.1 MAb characterisation 
MAb isotype was determined using the commercially-available IsoStrip Mouse 
Monoclonal Antibody Isotyping Kit (Roche, German), by dipping the strip into the 
MAb solution. The Pierce™ BCA Protein Assay Kit (USA) was used for measurement 
of the protein concentration. Briefly, 25 µL of samples were mixed well with 200 µL of 
working solution in a 96 well plate. After incubation at 37°C for 30 min, the plate was 
allowed to cool before absorbance reading at 540 nm. 
 
3.5 Microneutralising assay 
Two-fold dilutions of heat inactivated sera or MAb (1:2 to 1:1024) in MM were 
prepared. Diluted sera or MAb was mixed with equal volumes of 100 CCID50 EV-A71 
(Table 3.1, page 31) at 37°C for 2 hr and then transferred to duplicate wells containing 
90%-confluent VERO cells and incubated at 36°C for 7 days. In this way, neutralising 
titres defined as the highest dilution of serum that completely inhibited CPE for EV-
A71 (C1 – C5 and B3 – B5, Table 3.1, page 31) were determined. Negative control 
wells contained cells incubated with MM only while positive control wells contained 
cells incubated with a mixture of MM and virus without any antibodies. 
 
3.6 Mouse infection experiments 
All animal experiments were approved and performed in Malaysia, according to the 
University of Malaya’s Animal Welfare and Use Committee guidelines (2014-02-
14/PATHO/R/WKT). Hence all mice were sacrificed with lethal dose of isoflurane at 
the end of experiment or at the moribund stage. Table 3.2 summarises all the animal 
experiments done in this study. 
35 
 
Table 3.2: Summary of mouse infection experiments 
Section Objective Page 
3.6.1 To investigate cranial nerve involvement in direct brainstem infection. 35 
3.6.2 To optimise passive immunisation in unilateral jaw/facial muscles 
infected mice to obligate viraemia. 
38 
3.6.3 To confirm unilateral retrograde axonal transport in peripheral nerves, 
and to show that viraemia spreads virus to contralateral side and 
contributes to bilateral CNS involvement. 
40 
3.6.4 To investigate the susceptibility of neurons to MAVS infection, and 
the association of viral antigens and SCARB2 in the brain.  
41 
3.6.5 To investigate the “provocation poliomyelitis” phenomenon in MAVS 
infection following trauma to gastrocnemius muscles.  
42 
3.6.6 To investigate the link between muscle infection and retrograde axonal 
transport in spinal cord infection. 
44 
3.6.7 To investigate the potential of neutralising antibodies as a prophylactic 
and/or therapeutic against EV-A71 encephalomyelitis. 
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3.6.1 MAVS infection via unilateral jaw/facial muscle inoculation  
Cranial nerve involvement in retrograde axonal transport of EV-A71 into the brainstem 
was investigated using groups of 2-week old ICR mice. A dose of 6.3 x 105 CCID50 
MAVS in 10 µL was delivered via an intra-muscular (IM) route by injecting into the 
unilateral jaw/facial muscles of the mouse using a 31-G needle. Groups of mice were 
monitored daily for signs of infection and sacrificed at 12 hours post-infection (hpi) (n= 
7), 24 hpi (n= 8), 36 hpi (n= 7), 48 hpi (n =8), 60 hpi (n= 7) and 72 hpi (n= 8). Tissues 
were harvested from 3 animals from 12, 36 and 60 hpi, and 4 animals from 24, 48 and 
72 hpi for histopathological analysis, and the remaining 4 animals from each timepoint 
for virus titration studies. Mock-infected mice (n= 8) were injected with PBS and 
sacrificed at 72 hpi and tissues harvested for analysis as described. 
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3.6.1.1 Histopathological analysis  
Tissue fixation and processing were carried out as previously described (Tan, Ong, & 
Wong, 2014). In brief, the whole animal carcass was fixed in 10 % neutral buffered 
formalin and then transversely cut into seven standard cross-sectional tissue blocks 
which include all of the main organs. After overnight decalcification in 5% formic acid 
and routine processing, 4 µm thick sections were prepared from paraffinised tissue 
blocks and stained with haematoxylin and eosin (H&E) for light microscopy, 
immunohistochemistry (IHC) to detect viral antigens and in situ hybridisation (ISH) to 
detect viral RNA. 
 
3.6.1.1 (a) IHC to detect viral antigens  
IHC was performed as described previously (Tan et al., 2014). Briefly, slides containing 
tissues were dewaxed and rehydrated with serial xylene and graded alcohols, 
respectively. After antigen retrieval with citrate buffer (pH 6) at 99⁰C for 20 min, tissue 
slides were allowed to cool for 10 min. This was followed by peroxidase blocking with 
3% hydrogen peroxidase in methanol. Background blocking was done with 5% of 
normal goat serum in Tris-buffer saline (TBS). Primary polyclonal rabbit anti EV-A71 
antibody (A gift from Dr Shimizu, National Institute of Infectious Diseases, Japan) 
diluted in PBS at 1:3000, was applied for 2 hr at RT. After TBS washing twice, goat 
anti-mouse secondary antibody polymer complexes (EnVision + System - peroxidase; 
Dako, Denmark) were added in the dark for 30 min, followed by TBS washing twice. 
The 3,3'-Diaminobenzidine (DAB) substrate was added and incubated for 5 min. After 
counterstaining with Harris hematoxylin, tissue sections were mounted with DPX 
mounting medium. Tissues from a previously known EV-A71 infected mouse served as 
positive controls whereas normal healthy mouse tissues served as negative controls. 
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3.6.1.1 (b) ISH to detect viral RNA 
ISH was performed as described previously (Tan et al., 2014). Tissue sections were 
dewaxed and rehydrated as for IHC (section 3.6.1.1 (a), page 36). After treatment with 
hydrochloric acid and proteinase K at 37⁰C for 20 min, approximately 1 ng of 
digoxigenin-labeled DNA probe (obtained from Ong et al. (2008)) in hybridisation 
buffer was applied on the tissue sections and heated at 110⁰C for 12 min followed by 
the probe hybridisation step at 42⁰C for 16 hr. Hybridised probes were visualised with 
an anti-digoxigenin antibody conjugated to alkaline phosphatase (Roche, Mannheim, 
Germany) in the dark for 16 hr and followed by nitrobluetetrazolium/5-bromo-4-chloro-
3-indolyl phosphate (NBT/BCIP) substrate development. After counterstaining with 
Mayer haematoxylin, tissue sections were mounted with Faramount mounting medium 
(Dako, Denmark). Similar positive and negative tissue controls described in section 
3.6.1.1 (a) (page 36) were used. 
 
3.6.1.2 Virus titration analysis 
Mouse tissues, sera, hindlimb and forelimb muscles, whole brainstems, upper half and 
lower half of spinal cords were harvested for viral titration. Different dissection sets and 
careful handling of harvested tissues were observed to prevent cross contamination 
between tissue types and between animals. The medium DMEM MM was added to each 
tissue homogenate to a final 10% (wt/vol) concentration. Serial 10-fold dilutions of 
homogenates in 50 µl were added to quadruplicate wells each containing 90% confluent 
VERO cells and incubated at 36°C for 1 hr before topping up with 100 µL of MM per 
well. Further incubation at 36°C for 7 days was followed by viral titre determination 
using CCID50 by CPE observation and calculated using the Karber method as described 
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previously (Tan et al., 2014). Viral titre from each organ/tissue were pooled and 
calculated as a mean titre with standard error of the mean. 
 
3.6.2 Optimisation of passive immunisation in mice infected via unilateral 
jaw/facial muscle  
The optimum volume and inoculation times of IP-delivered hyperimmune serum that 
could prevent viraemia and subsequent infection of non-injected muscle groups after 
unilateral jaw/facial muscles infection was determined following the schedule in table 
3.3. The MAVS challenge was as described in section 3.6.1 (page 35).  
 
Table 3.3: Schedule of various doses and inoculation times of hyperimmune sera 
given before MAVS challenge, number of mice studied and types of analysis 
Volume of 
hyperimmune 
serum (µL) 
Hours before 
MAVS 
challenge  
 
Hours 
post-
infection at 
sacrifice 
Harvested tissues 
analysed by 
Number of 
mice 
sacrificed 
per 
timepoint 
25 2 24, 48, 72, 
96 
Histopathology*  2 
50 2 24, 48, 72, 
96 
Histopathology*  2 
100 2 48, 72 Histopathology*  2 
200 2 48, 72 Histopathology*  2 
100 and 50 4 and 2 24, 48, 72, 
96 
Histopathology*  5 
100 and 50 4 and 2 24, 48 
 
Virus titration 3 
100 4 24, 48, 72 Histopathology*  3 
100 
 
4 24, 48, 72 Virus titration 3 
100 4 24, 48, 72, 
96 
RT-PCR 
 
4 
*Histopathology = H&E and IHC staining for viral antigens. 
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3.6.2.1 Histopathological analysis and IHC  
Histopathological analysis and IHC of harvested tissues were performed as before 
(section 3.6.1.1 (page 36) and section 3.6.1.1 (a) (page 36), respectively). 
 
3.6.2.2 Virus titration analysis 
Viral titration assay was performed as before (section 3.6.1.2, page 37). 
 
3.6.2.3 Viral RNA extraction, RT-PCR and qPCR  
Tissues, sera, hindlimb and forelimb muscles, whole brainstems, upper half and lower 
half of spinal cords were harvested as in section 3.6.1.2 for total viral RNA extraction 
using a commercial kit (Hybrid-R, GeneAll, Korea) following the manufacturer’s 
protocol. Extracted RNA diluted to 1 mg for cDNA generation by reverse transcription 
(Transcriptor First Strand cDNA Synthesis Kit, Roche, German) was added to the 
Random Hexamer Primer and denatured for 10 min at 65°C with a heated lid, followed 
by immediate ice treatment. Buffer, RNase inhibitor, dNTPs and transcriptor reverse 
transcriptase was added and incubated at 25°C for 10 min, followed by 55°C for 30 min 
for the reverse transcription step, and heat inactivation at 85°C for 5 min. The first 
strand cDNA product was then used for PCR and qPCR. 
The PCR mixture consisted of 1 µL of cDNA template, 1.5 units of recombinant 
Taq DNA polymerase (Fermentas, USA), 1X Taq Buffer with ammonium sulfate, 0.5 
µM of each primer (Appendix C, page 160) and 0.2 mM dNTP mix. The conditions 
were: 94°C for 3 min, 35 cycles of thermal cycling (15 seconds (sec) at 94°C, 30 sec at 
60°C and 30 sec at 72°C) and final extension at 72°C, 5 min. The PCR products were 
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analysed by electrophoresis in 15% (wt/vol) Tris-borate-EDTA agarose gel containing 
0.5 µg/mL ethidium bromide. 
 
3.6.3 Mice infected via unilateral jaw/facial muscle and treated with optimised 
passive immunisation 
Based on results obtained from Section 3.6.2 (page 38), the optimum dose of 100 µL of 
hyperimmune sera was IP-inoculated at 4 hr before MAVS infection in a group of mice 
(n= 18) as described in section 3.6.1 (page 35). Animals were sacrificed at 12 hpi (n= 3), 
24 hpi (n= 4), 48 hpi (n= 4), 72 hpi (n= 4) and 96 hpi (n= 3) for histopathological 
analysis, IHC and ISH. An additional 4 animals were sacrificed at each timepoint, and 
tissues harvested for virus titration. Mock-immunised mice (n= 8) which received 
formaldehyde-fixed VERO cell lysates at the same time of MAVS infection, were 
sacrificed at 72 hpi. 
 
3.6.3.1 Histopathological analysis, IHC and ISH 
Histopathological analysis, IHC and ISH staining were performed as before (section 
3.6.1.1 (page 36), section 3.6.1.1 (a) (page 36) and section 3.6.1.1 (b) (page 37), 
respectively).  
 
3.6.3.2 Viral titration analysis 
Viral titration assay was performed as before (section 3.6.1.2, page 37). 
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3.6.4 MAVS infection via intra-cerebral (thalamus/hypothalamus and 
pons/medulla) inoculation 
The susceptibility of neurons to MAVS infection by the intra-cerebral (IC) route, and 
the association of viral antigens and mSCARB2 in the brain was investigated in 2 
animal experiments. In the first experiment, 6.3 x 105 CCID50 of MAVS in 10 µL was 
IC-inoculated into the thalamus/hypothalamus region of a 2-week old ICR mouse using 
31-G needles. Neurons in this region are known to have a high expression of 
mSCARB2 (Lein et al., 2007). Tissues were harvested as before from 5 inoculated 
animals, at 24, 48 and 72 hpi timepoints for histopathological analysis, and 4 additional 
animals per timepoint for virus titration studies.  
In the second experiment, the same amount of MAVS was IC-inoculated into the 
pons/medulla which also expressed a similar level of mSCARB2 as the 
thalamus/hypothalamus area. Three mice each were sacrificed at 24, 48 and 72 hpi for 
histopathological analysis, IHC and ISH, and another 4 animals per timepoint for virus 
titration analysis. Control mice (n= 6 for each experiment) were mock-infected with 
sterile PBS.  
 
3.6.4.1 Histopathological analysis, IHC and ISH staining 
Generally, histopathological analysis, IHC and ISH staining were performed similar to 
section 3.6.1.1 (page 36), section 3.6.1.1 (a) (page 36) and section 3.6.1.1 (b) (page 37), 
respectively. However, in the current IHC procedure, a commercially-obtained, mouse 
monoclonal anti EV-A71 antibody (Millipore, USA) diluted 1:50, was used instead of 
the proprietary primary polyclonal rabbit anti EV-A71 antibody because the latter ran 
out. Our preliminary testing showed this new antibody to be similar to the previous one. 
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3.6.4.2 Viral titration analysis 
Viral titration assay was performed as before (section 3.6.1.2, page 37). 
 
3.6.5 Investigation of the “provocation poliomyelitis” phenomenon in MAVS 
infection 
The phenomenon of “provocation poliomyelitis” was classically described in poliovirus 
infection in which injured tissues from the act of injection (vaccination), aided 
poliovirus infection and travel into the spinal cord, causing paralysis. In this experiment, 
the possibility of a similar phenomenon occurring with EV-A71 infection was 
investigated. Two groups of 2-week old ICR mice were IP-inoculated with ~90 CCID50 
of MAVS. In the first group of mice (n= 10), bilateral gastrocnemius muscles were 
traumatised 5 times by repeatedly inserting a 28-G needle into the muscle at 0 hpi, 12 
hpi, 24 hpi, 36 hpi, 48 hpi and 60 hpi. A second group of animals (n= 10) served as a 
non-traumatised control group. At 72 hpi, tissues were harvested as usual from 5 
sacrificed animals from each group for histopathological analysis. The other 5 animals 
in the same group were sacrificed for virus titration.  
The entire experiment was repeated with a higher 1.78 x 102 CCID50 MAVS 
dose. Wheat germ agglutinin (WGA) protein, well known as a retrograde tracer (Ohka 
et al., 2009), was used to monitor the retrograde axonal transport rate in traumatised and 
non-traumatised mice. As positive controls, 10 µg of WGA protein were IM-inoculated 
into the bilateral gastrocnemius muscles of traumatised (n= 3) and non-traumatised mice 
(n= 3). Mice were sacrificed at 12 hpi for total protein extraction and WGA 
quantification.  
 
43 
 
3.6.5.1 Histopathological analysis, IHC staining 
Generally, histopathological analysis and IHC were performed as before (section 3.6.1.1 
(page 36) and section 3.6.1.1 (a) (page 36).  
 
3.6.5.2 Viral titration analysis 
Viral titration assay was performed as before (section 3.6.1.2, page 37). 
 
3.6.5.3 Total protein extraction and WGA quantification 
Tissues (hindlimb muscles, upper half and lower half of spinal cords) from sacrificed 
positive control WGA-inoculated mice were used for total protein extraction according 
to the manufacturer’s protocol (T-PER™ Tissue Protein Extraction Reagent, Thermo 
Fisher, USA). Briefly, the extraction reagent with protease inhibitor (Pierce™ Protease 
Inhibitor Tablets, EDTA-free, USA) was added to each tissue to a final concentration of 
10% (wt/vol). Homogenised tissues were incubated for 30 min at 4°C, then centrifuged 
at 10000 x g for 5 min to remove debris. 
WGA concentration in extracted protein was semi-quantified by dot blot 
analysis as previously described (Lancaster & Pfeiffer, 2010). Briefly, 5 µL of each 
sample was dropped onto a nitrocellulose membrane and air dried. Non-specific sites 
were blocked by 5% skim milk in TBS-Tween20 for 3 hr at RT. Rabbit anti-lectin 
(triticum vulgaris) primary antibody (Sigma, St Louis, USA) at 1:4000 dilution was 
added and incubated at 4°C overnight, followed by addition of goat anti-rabbit IgG AP-
conjugated (Pierce, USA) secondary antibody (1:5000 dilution, RT in dark for 1 hr) and 
1-Step™ NBT/BCIP Substrate Solution (Thermo Fisher, USA) in dark for 10 min for 
visualisation. 
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3.6.6 Investigation of the link between muscle infection and retrograde axonal 
transport in spinal cord infection. 
 The link between muscle infection and retrograde axonal transport was investigated by 
IM-inoculating 3.16 x 103 CCID50 light-sensitive MAVS into both gastrocnemius 
muscles of 2-week old ICR mice (n= 15). Tissues were harvested in the dark from 5 
animals for virus titration study at each 24, 48 and 72 hpi timepoints.  
 
3.6.6.1 Viral titration analysis 
Generally, viral titration assay was performed as before (section 3.6.1.2, page 37) with 
slight modifications. Harvested tissue samples were divided equally into light-treated 
and light-protected samples. Light-treated samples were exposed to direct white light at 
4°C for 30 min before titrated as in section 3.6.1.2 (page 37), and the whole titration 
process was done in the dark. 
 
3.6.7 Prevention and treatment of MAVS infection using neutralising antibodies 
Prevention and treatment of MAVS infection in 2-week old ICR mice using neutralising 
antibodies was investigated in 3 separate experiments. In experiment 1, 200 µL of 
hyperimmune sera containing polyclonal antibodies which could neutralise EV-A71 
was IP-inoculated into each 2-week old ICR mice 4 hr before MAVS infection, and at 
12 hr and 24 hr after MAVS infection, respectively. The mice were then challenged 
with MAVS as described in section 3.6.1 (page 36). Four animals per group were 
sacrificed at 72 hpi, and tissues harvested for histopathological analysis, and another 4 
animals were sacrificed for virus titration study, respectively. A further 4 animals in 
45 
 
each group were monitored to assess survival over a period of 21 days. Mock-treated 
infected animals (n= 12) received VERO cell lysate-derived serum at 12 hpi. 
In experiment 2, the effectiveness of MAb for treatment was investigated. Six 
groups (each group, n= 4) of 2-week old ICR mice were infected via the IP route with 
10 LD50 MAVS in 100 µL. Each group was then IP-inoculated for 2 consecutive days at 
24 and 48 hpi with 30, 60, 120 µg of MAb or PBS (mock-treated control group), 
respectively. Similar groups of mice were likewise treated for 2 consecutive days at 72 
and 96 hpi using the same MAb doses. Mice were observed daily for up to 21 days post 
infection (dpi) for signs of infection. The signs of infection were scored as follows: 0= 
healthy; 1= weight loss; 2= limb weakness; 3= hind limb paralysis; and 4= moribund 
and/or death.   
In experiment 3, MAb effectiveness before and after CNS involvement was 
evaluated. Two groups of mice (each group, n= 16) were similarly infected as in 
experiment 2. Group 1 mice were treated with an optimal 120 µg MAb for 3 
consecutive days at 24, 48 and 72 hpi. Group 2 received treatment at 72, 96, and 120 hpi. 
Group 1 was sacrificed for histopathology (n= 4), virus titration (n= 4) and quantitative 
real-time PCR (n= 4) at 96 hpi, while the same number of animals from Group 2 was 
sacrificed at 144 hpi. The remaining 4 treated mice from each group were further 
observed daily for signs of infection for 21 days. Thirty-two additional PBS-treated, 
infected mice served as mock-treated controls. From this control group, 4 mice each 
were sacrificed at 24, 72 and 96 hpi and tissues collected for histopathology and virus 
titration, respectively. Tissues from an additional 4 mice sacrificed at 96 hpi were 
obtained for quantitative real-time PCR (qPCR). The remaining 4 mock-treated mice 
were further observed for signs of infection for 21 days. A summary of the schedule for 
animal sacrifice and tissue sampling is showed in Figure 3.1. 
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Figure 3.1: Schedule of MAb 3D1 treatment, animal sacrifice and tissue sampling 
following MAVS infection, in Experiment 3. 
 
 
3.6.7.1 Histopathological analysis, IHC and ISH staining 
Histopathological analysis, IHC and ISH staining were performed as before (section 
3.6.1.1 (page 36), section 3.6.1.1 (a) (page 36) and section 3.6.1.1 (b) (page 37), 
respectively). 
 
3.6.7.2 Viral titration analysis 
Viral titration assay was performed as before (section 3.6.1.2, page 37). 
 
3.6.7.3 Viral RNA extraction, RT-PCR, qPCR 
Viral RNA extraction and cDNA transcription were performed as before (section 3.6.2.3, 
page 39). qPCR analysis was performed with the primers (section 3.6.2.3, page 39) 
according to the manufacturer’s protocol using SensiFast Probe Lo-Rox kit (Bioline, 
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UK). The qPCR mixture consisted of 2 µL of cDNA template, 1X sensifast probe mix, 
400 nM of each primer and 100 nm of probe. The conditions were: 95°C for 5 min for 
polymerase activation and 40 cycles of thermal cycling (10 sec at 95°C and 30 sec at 
60°C). Full length of MAVS was reverse transcripted and served as standard control for 
absolute quantification.  
 
3.7 Primary murine motor neuron culture 
Primary motor neuron culture (Ohka et al., 2009) was performed in Tokyo, Japan, 
following guidelines of Animal Use and Care Committee of the Tokyo Metropolitan 
Institute of Medical Science. Briefly, spinal cords of E14 mouse embryos were 
dissected in sterile PBS using a dissecting microscope. The meninges, dorsal root 
ganglia and dorsal column were removed using a fine-tip forcep. Minced spinal cords 
tissues were treated with trypsin for 10 min at 37°C with agitation every 5 min followed 
by DNase I treatment. Tissues were triturated in neurobasal medium supplemented with 
10% bovine serum albumin (BSA) in L15 medium and DNase I, to separate the motor 
neuron cells from the tissue fragments. After the tissue fragments were allowed to settle 
for 3 min, the supernatant was collected and centrifuged with a cushion of BSA/L15 
medium at 1400 rpm for 5 min. Cell pellets were resuspended in a small volume of 
freshly prepared complete GM and plated at a density of 40 000 cells /mL. 
 
3.7.1 Transfection of primary murine motor neurons  
Transfection of primary murine motor neurons was performed according to the 
manufacturer’s protocol (4D-Nucleofector™ System, Lonza, Switzerland). Briefly, 
primary motor neurons were seeded onto a 24 well plate at 1.5 x 105 cells/well. After 4 
days of incubation in a humidified 37°C/7% CO2 incubator, half of media was replaced 
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with Nb Active 4 media (BrainBits, LLC, UK). The next day, all medium was removed 
and replaced by AD1 4D-Nucleofector™ Y Kit’s solution with 17.5 µg with 
phSCARB2-FLAG-mCherry vector (courtesy of Dr. Satoshi Koike). A 24-well dipping 
electrode was placed carefully to prevent air bubble formation underneath. Transfection 
was done using the ED-158 program in the system and nucleofector solution (Lonza, 
Swiss) was then replaced by pre-warmed medium immediately. 
 
3.7.2 Double immunofluorescence staining for EV-A71 and hSCARB2 
Primary motor neurons were washed twice with growth medium before fixation with 
4% paraformaldehyde in PBS supplemented with 20% sucrose. Permeabilisation was 
done with 0.05% of saponin and 5% of BSA for 2 hr at RT after PBS washing (4 times). 
Both primary antibodies were added together as in Table 3.4 (no. 1 and 2), followed by 
secondary antibodies (Table 3.4, no. 3 and 4). Cells were mounted with “Vectashield 
Antifade Mounting Medium with DAPI” (Vector, USA). 
 
Table 3.4: Summary on primary and secondary antibodies used in double 
immuno-fluorescence staining 
No. Antigens Host Dilution 
Duration of 
Incubation 
Incubation 
Temperature 
1. EV-A71 Mouse Polyclonal 
(Produced by Dr. 
Satoshi Koike, Japan) 
1:9000 Overnight 4°C 
2. hSCARB2 Goat Polyclonal (R&D 
System, USA) 
1:1250 Overnight 4°C 
Washed four times with PBS 
3. Mouse 
IgG 
Donkey Anti-Mouse 
Alexa Fluor® 488 
(Invitrogen, USA) 
1:1000 90 minutes Room 
Temperature 
4. Goat IgG Donkey Anti-Goat 
Alexa Fluor® 647 
(Invitrogen, USA) 
1:1000 90 minutes Room 
Temperature 
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3.8 Statistic Analysis 
Statistical analyses were performed using SPSS Statistics 21. All virus titration analysis 
and viral copy numbers from qPCR results were analysed using the Kruskal-Wallis test 
to determine statistical significance in viral titres across all tissue types. The Mann-
Whitney U test was used to determine if any 2 particular tissue types were different.  
The survival and clinical score of treated and mock treated animals (section 
3.6.7, page 46) were analysed using the log-rank test. A value of P< 0.05 was 
considered signiﬁcant. 
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4.0 Results: 
4.1 Fluorescent labelled EV-A71 
After EV-A71 was fluorescent-labelled with Alexafluor-555 and purified with a NAP5 
resin column, a total of 10 fractions (200 µL/fraction) were collected. The absorbance 
values for fractions of Alexafluor-555 labelled EV-A71 virus at 280 nm and 555 nm are 
shown in Figure 4.1. Fraction number 6 with a labelling ratio of 4.05 moles of 
Alexafluor-555 dye per mole of virus was selected for the experiment (section 4.4, page 
83). Alexafluor-555 labelled EV-A71 showed similar infectivity with the clinical isolate 
EV-A71 (parental virus) based on percentage of CPE from day 1 to day 7 in RD-
hSCARB2 cells with titre of 5.6 x 106 CCID50/ml.  
 
 
Figure 4.1: NAP5 fractionation of Alexafluor-555 labelled EV-A71. A total of 10 
fractions (200 µL/fraction) were collected. Protein and fluorescent dye of each fraction 
were determined and expressed as absorbance at 280 and 555 nm, respectively.  
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4.2 Brainstem infection via retrograde axonal transport in cranial nerves 
4.2.1 MAVS infection via unilateral jaw/facial muscles  
MAVS was inoculated into right jaw/facial muscles of 2-week old ICR mice to evaluate 
cranial nerve involvement in EV-A71 CNS infection. All infected mice (n= 16) showed 
signs of infection such as back hunching, fur ruffling and obvious paralysis in both 
hindlimbs from 60 hpi onwards (Figure 4.2 A, arrows). These signs became more 
severe at 72 hpi, and all mice were moribund/dead by 96 hpi. Mock-infected mice (n= 8) 
were all active and healthy throughout the experiment. 
 
4.2.1.1 Pathological studies  
Figure 4.3 (mouse A1 – A18) shows the approximate topographic distribution of viral 
antigens/RNA in CNS tissues in each infected mouse. At 12 hpi (n= 3), the IHC and 
ISH showed no evidence of viral infection in the CNS. Viral antigens/RNA in the CNS 
were first detected at 24 hpi (Figure 4.3, mouse A1 – A4), in the motor trigeminal 
nucleus, reticular formation (medulla) and facial nucleus, ipsilateral to the injection site 
only. Moreover, some cranial nerves ipsilateral to the injection site were positive for 
viral antigens/RNA (Figure 4.2 B - F). An ipsilateral anterior horn cell in lumbar spinal 
cord was found to be infected in one mouse (Figure 4.3, mouse A2). All CNS neurons 
appeared normal by light microscopy with no obvious inflammation or other 
abnormalities observed.   
Minimal and focal viral antigens/RNA without obvious inflammation were 
detected in the injected jaw/facial muscles at 12 hpi. Later, at 24 hpi, skeletal muscles 
around the injected area showed more viral antigens/RNA and demonstrated mild 
myositis. Focal and scanty viral antigens/RNA were also detected in a few fibres in 
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contralateral jaw/facial muscles, and other skeletal muscles such as tongue and limbs 
bilaterally. All other tissues were negative. 
Bilateral CNS infection was observed in all mice starting from 36 hpi (Figure 
4.3, mouse A5 - A7). The distribution of viral antigens/RNA in brainstem neurons was 
almost similar to the findings at 24 hpi. However, in general, CNS infection on the 
ipsilateral side was more severe compared to the contralateral side (Figure 4.3, mouse 
A5 – A7). Viral antigens/RNA were found mainly in the motor trigeminal nuclei 
(Figure 4.4 A - D), reticular formation (Figure 4.4 E) and facial nuclei (Figure 4.4 F). A 
few neurons in thalamus (Figure 4.3, mouse A7; Figure 4.4 Q) and motor cortex (Figure 
4.3, mouse A5 and A6; Figure 4.4 G) were infected too. Infected neurons showed 
neuronal vacuolation and damage (Figure 4.4 A). Bilateral involvement of anterior horn 
cells in spinal cord was observed in a single mouse (Figure 4.3, mouse A7). MAVS 
inoculated jaw/facial muscles showed dense viral antigens/RNA, severe inflammation 
and necrosis. Brown adipose tissues and other systemic skeletal muscles were infected 
bilaterally but inflammation was minimal. 
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Figure 4.2: Clinical observation, and pathological findings following unilateral 
jaw/facial muscle infection. Infected mice showed back hunching (arrow), and obvious 
paralysis in both hindlimbs (arrows) and forelimbs (arrow) at 72 hpi. Viral antigens (B 
arrow, D circle, E circle and F arrow) and RNA (C arrow) were found in cranial nerves 
ipsilateral to the injection site. In the spinal cord, viral RNA (G arrows) and antigens (H 
arrows) were often detected in white matter axons adjacent to anterior horn cells that 
were positive for viral antigens or RNA (G circle). IHC with DAB chromogen and 
haematoxylin counterstain (B, D – F and H). ISH with haematoxylin counterstain (C 
and G). Original magnification: 100x objective (B); 40x objective (C, F, H and inset); 
20x objective (D and E); 10x objective (G).
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Figure 4.3: Approximation of the distribution of viral antigens/RNA in the CNS following unilateral jaw/facial muscle infection. Mice showed 
ipsilateral brainstem involvement after 24 hpi, and bilateral involvement after 36 hpi. Each red dot represents the equivalent of a positive neuron/white 
matter axon. For each mouse, cross sections of cerebral cortex, diencephalon/cortex, midbrain/cortex, caudal pons/medulla/cerebellum, 
medulla/cerebellum, cervical, thoracic, and lumbar spinal cords are displayed. 
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Figure 4.4: Pathological findings 
following unilateral jaw/facial 
muscle infection. Infected motor 
trigeminal nucleus demonstrated 
neuronal degeneration, necrosis and 
vacuolation (A arrows, inset), viral 
antigens (B circle; C arrows), and 
viral RNA (D arrows). Reticular 
formation (E circle), gigantocellular 
reticular nucleus (E arrow), facial 
nucleus (F arrows), motor cortex (G 
circle, inset), midbrain (H circle, 
inset), red nucleus (I circle, J), 
solitarius nucleus (K square, L), 
hypoglossal nucleus (M), area within 
spinal tract of trigeminal nerve (N) 
and dentate nucleus (O and P) were 
positive for viral antigens/RNA too. 
In some mice, thalamus (Q) and 
sensory cortex (R) were infected too. 
H&E stain (A). IHC with DAB 
chromogen and haematoxylin 
counterstain (B, C, E, F, G – L, N - 
R). ISH with haematoxylin 
counterstain (D and M). Original 
magnification: 40x objective (C, D, 
F, P - R and inset); 20x objective (A, 
J and L); 10x objective (B, E, G, M - 
O); 4x objective (H, I and K). 
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At 48 hpi (Figure 4.3, mouse A8 – A11), CNS infection in the mice was more 
advanced. In addition to the other areas involved at 36 hpi, in 2 mice (Figure 4.3, mouse 
A9 and A11), a few neurons in the midbrain (Figure 4.4 H) and red nucleus (Figure 4.4 
I and J) were also infected. In the spinal cord, neuronal infection mainly involved 
anterior horn cells in two of the mice (Figure 4.3, mouse A9 and A10). Infected neurons 
showed neuronal vacuolation and damage. Axons in the white matter immediately 
adjacent to infected anterior horn cells at or near the site where peripheral motor nerves 
usually exit, were positive for viral antigens/RNA. Muscle fibres at the injection site 
demonstrated extensive and dense viral antigens/RNA, severe inflammation and 
necrosis. Other skeletal muscles and brown adipose tissues showed some viral 
antigens/RNA bilaterally with minimal inflammation. 
At 60 hpi (Figure 4.3, mouse A12 – A14) and 72 hpi (Figure 4.3, mouse A15 – 
A18) there was more extensive, bilateral involvement of the CNS. The gigantocellular 
reticular nucleus (Figure 4.4 E), solitarius nucleus (Figure 4.4 K and L), hypoglossal 
nucleus (Figure 4.4 M), spinal tract of trigeminal nerve area (Figure 4.4 N), lateral 
cerebellar nucleus (dentate nucleus) (Figure 4.4 O and P) and motor and sensory cortex 
(Figure 4.4 R) were also positive for viral antigens/RNA. In the spinal cord, viral 
antigens/RNA were found in the anterior, intermediate and posterior horns bilaterally, 
although anterior horn cells showed a higher degree of infection compared to 
intermediate and posterior horn cells. Overall, no obvious CNS inflammation was 
observed.  
Brown adipose tissues and systemic skeletal muscles were more severely 
infected bilaterally at 60 and 72 hpi. Muscle degeneration and necrosis along with 
severe inflammation were observed. There was no evidence of viral infection in lung, 
heart nor evidence of pulmonary oedema, pneumonia, myocarditis or other 
abnormalities, in any of the mice examined.  
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4.2.1.2 Viral titration analysis 
Figure 4.5 shows the mean viral titres in muscle tissues (n= 4, for each time point), left 
and right forelimb and left and right hindlimb muscles, and sera. Mean sera viral titres 
remained high throughout the experiment, gradually increasing from 3.6 to 4.5 log 
CCID50. However, the mean viral titres for all muscle groups did not differ significantly 
(P< 0.05) from each other at respective time points (Figure 4.5). Nonetheless, muscle 
mean viral titres gradually increased from 12 hpi to 72 hpi with titres of around 5.3 log 
CCID50.  
The mean viral titres (n= 4, for each time point) of all CNS tissues (whole 
brainstem, upper and lower spinal cord segments), and sera are shown in Figure 4.6. 
The CNS viral titres were always lower than sera and muscle titres at respective time 
points. However, CNS mean viral titres gradually increased over time to peak at 60 hpi 
to 72 hpi with titres of around 3.5 log CCID50. Moreover, brainstem viral titres were 
significantly higher (P< 0.05), compared to upper and lower spinal cords from 12 hpi to 
48 hpi (Figure 4.6). 
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Figure 4.5: Viral titres in muscle tissues and sera following unilateral jaw/facial 
muscles infection. Sera viral titres were significantly higher (P< 0.05) than all muscles 
viral titres at 12 hpi. At 24 hpi, muscles viral titres increased drastically and finally was 
significantly higher (P< 0.05) than sera viral titres at 60 hpi onward. Mean viral titres 
are expressed as log CCID50 ± standard error of mean. 
 
 
Figure 4.6: Viral titres in CNS tissues and sera following unilateral jaw/facial 
muscles infection. Sera viral titres were significantly higher (P< 0.05) than CNS viral 
titres at all time. At 48 hpi and before, brainstem viral titres were significantly higher 
(P< 0.05) than upper and lower spinal cord viral titres. Mean viral titres are expressed as 
the log CCID50 ± standard error of mean. 
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4.2.2 Optimisation of passive immunisation in unilaterally-infected mice to 
abrogate viraemia 
Following unilateral jaw/facial muscle inoculation, bilateral CNS involvement starting 
from 36 hpi (section 4.2.1.1, page 51) was most likely due to viraemia causing 
widespread virus infection. Hence hyperimmune sera were given at various doses and 
time points before inoculation in an attempt to abrogate viraemia to confirm unilateral 
retrograde axonal transport in peripheral nerves, and to show that bilateral CNS 
involvement follows viraemia that spreads virus to the contralateral side.  
Mice (n= 8) receiving 25 µL of hyperimmune sera 2 hr before infection showed 
delayed onset of CNS infection compared to mock-treated mice. Treated mice sacrificed 
at 24 hpi (n= 2), showed viral antigens in the injected right jaw/facial muscles, part of 
shoulder muscles and forelimb muscles bilaterally as shown in Figure 4.7 A and B, 
respectively, without CNS involvement. In mice sacrificed at 48 hpi (n= 2), viral 
antigens were also found bilaterally in the brainstem reticular formation and motor 
trigeminal nucleus (Figure 4.7 C). Spinal cord anterior horn cells were involved at 72 
hpi (n= 4).  
 Mice (n= 8) receiving a higher dose (50 µL) of hyperimmune sera at 2 hr before 
infection, showed viral antigens in injected right jaw/facial muscles and part of shoulder 
muscles (Figure 4.7, D and E) at 24 hpi (n= 2). At 48 hpi (n= 2), bilateral brainstem 
reticular formation and motor trigeminal nucleus (Figure 4.7 F) and forelimb muscles 
were infected. Anterior horn cells of the spinal cord were involved from 96 hpi (n= 2). 
 Mice (n= 4) receiving 100 µL of hyperimmune sera at 2 hr before infection, 
showed similar results to mice receiving 50 µL of hyperimmune sera at early time 
points, up to 48 hpi. However, there was no evidence of infection in the forelimb 
muscles and spinal cord (Figure 4.7 G - I). In the fourth trial, mice (n= 4) receiving the 
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highest dose of 200 µL of hyperimmune sera at 2 hr before infection, only showed 
minimal infection in the injected right jaw/facial muscles throughout the experiment 
(Figure 4.7 J - L) without any CNS involvement. 
Further variations of passive immunisation in which mice (n= 20) receiving 100 
µL of hyperimmune sera at 4 hr before infection and 50 µL of hyperimmune sera at 2 hr 
before infection showed minimal infection at the injected right jaw/facial muscles 
throughout the experiment without CNS infection (Figure 4.7 M - O). Finally, mice (n= 
9) receiving 100 µL of hyperimmune sera at 4 hr before infection, showed minimal 
involvement in the injected right jaw/facial muscles only and unilateral brainstem 
involvement after 48 hpi. Sera, left and right forelimb and hindlimb muscles collected 
for viral titration (n= 9) were negative. Viral RNA were not detectable in the extracted 
samples (n= 16) by RT-PCR. Hence this passive treatment modality was used in Section 
4.2.3. 
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Figure 4.7: Viral antigens in muscles and motor trigeminal nucleus following 
unilateral jaw/facial muscles infection of pre-immunised mice. Mice pre-immunised 
with 200 µL and 100 + 50 µL of hyperimmune sera were protected from CNS infection 
completely. Whereas, lower volume of hyperimmune sera was able to delay the onset of 
disease. Original magnification: 10x objective (C, F, I, L and O); 4x objective (A, B, D, 
E, G, H, J, K, M and N). 
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4.2.3 Mice unilaterally-infected in the jaw/facial muscles and given optimised 
passive immunisation to abrogate viraemia 
None of the mice (n= 18) receiving the highest optimal dose (100 µL) of hyperimmune 
sera 4 hr before MAVS inoculation into the right jaw/facial muscles showed any signs 
of disease. Mock-immunised animals (n= 8) showed signs of disease, and death 
occurred at 96 hpi as described (section 4.2.1, page 51). 
 
4.2.3.1 Pathological studies 
Optimally-treated mice to abrogate viraemia which were sacrificed at 12 hpi (Figure 4.8, 
mouse A1 – A3) and 24 hpi (Figure 4.8, mouse A4 – A7) showed similar results under 
histopathological examination. Viral antigens/RNA were found only in the ipsilateral 
jaw/facial muscles where infected muscles showed minimal necrosis and no obvious 
inflammation.  
At 48 hpi (Figure 4.8, mouse A8 – A11), there was minimal viral antigens/RNA 
and found exclusively in the ipsilateral brainstem such as motor trigeminal nucleus 
(Figure 4.9 A - E) and reticular formation (Figure 4.9 F) but not in the facial nucleus. 
Furthermore, the density of viral antigens/RNA was much lower compared to the 
corresponding areas in non-immunised mice described in section 4.2.1.1 (page 51). 
There was no evidence of viral antigens/RNA in the spinal cord or other brain regions 
outside the brainstem. Viral antigens/RNA was detected in the injected muscle only 
focally and sparsely. All other muscles and non-CNS tissues were not infected. Similar 
findings were obtained in animals sacrificed at 72 hpi (Figure 4.8, mouse A12 – A15) 
and 96 hpi (Figure 4.8, mouse A16 – A18). Inflammation around damaged neurons was 
mild to moderate (Figure 4.9 A - C), and inflammatory cells consisted mainly of 
neutrophils and macrophages (Figure 4.9 C and F). 
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Figure 4.8: Approximation of the distribution of viral antigens/RNA/inflammation in the CNS following unilateral jaw/facial muscles infection 
in pre-infection immunised mice without presence of viraemia. Viral antigens/RNA/inflammation was only observed in the ipsilateral brainstem at 
48 hpi onward. No evidence of infection observed in other CNS regions. Each red dot represents the equivalent of a positive neuron/inflammatory 
focus. For each mouse, cross sections of cerebral cortex, diencephalon/cortex, midbrain/cortex, caudal pons/medulla/cerebellum, medulla/cerebellum, 
cervical, thoracic, and lumbar spinal cords are displayed. 
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Figure 4.9: Pathological findings in mice following unilateral jaw/facial muscle 
infection and passively immunised to abrogate viraemia. Neuronal degeneration, 
vacuolation and inflammation were observed in the motor trigeminal nucleus (A - C). 
Viral antigens (D) and RNA (E) were positive in the motor trigeminal nucleus. Viral 
antigens were seen surrounded by inflammatory cells in reticular formation (F). H&E 
stain (A - C). IHC with DAB chromogen and haematoxylin counterstain (D and F). ISH 
with haematoxylin counterstain (E). Original magnification: 40x objective (C - F and 
inset); 10x objective (B); 4x objective (A). 
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4.2.3.2 Viral titration analysis 
In the optimally-treated mice (n= 20), the mean viral titres in the brainstem at 12, 24, 48, 
72 and 96 hpi were 0.625, 1.25, 1.5, 0.625 and 0.813 log CCID50, respectively (Figure 
4.10). Viral titres did not significantly (P< 0.05) change over time. The viral titres in the 
upper and lower spinal cords, serum and pooled muscles were below detection levels 
(Figure 4.10). Overall, mean viral titres in this group of mice were all significantly lower 
(P< 0.05) than non-immunised mice (section 4.2.1.2, page 59) at all time points and for 
all tissue types. 
 
 
Figure 4.10: Viral titres in CNS tissues and sera following unilateral jaw/facial 
muscle infection and passively immunised to abrogate viraemia. Viral titres of all 
tissues except brainstem were below detection limit. Brainstem viral titres were 
significantly lower than non-immunised mice in section 4.2.1.2 (page 59). Mean viral 
titres are expressed as the log CCID50 ± standard error of mean. *ND= not detected. 
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4.3 Susceptibility of neurons to direct MAVS infection 
4.3.1 MAVS infection of neurons in IC-inoculated (thalamus/hypothalamus) mice 
MAVS was unilaterally and IC-inoculated into the thalamus/hypothalamus area to study 
neuronal and non-neuronal cell susceptibility to direct viral infection. All mice (n= 9) 
inoculated by this route developed mild paralysis in both hindlimbs at 72 hpi, while 
mock-infected mice (n= 7) remained healthy. 
 
4.3.1.1 Pathological studies 
Figure 4.11 shows the approximate topographic distribution of viral antigens in CNS 
tissues in each mouse (mouse A1 – A15). Non-specific tissue damage with 
haemorrhages was observed at the injection site/needle tract (Figure 4.12 C). At 24 hpi 
(Figure 4.11, mouse A1 – A5), viral antigens/RNA were detected focally around the 
needle tract in the thalamus region, part of cerebral cortex (retrosplenial cortex and 
posterior parietal association cortex) (Figure 4.12 A) and around the corpus callosum 
(Figure 4.12 A, outlined). The antigen-positive cells were mostly non-neuronal cells 
such as glial cells and astrocytes. In addition, a few neurons in dentate gyrus of the 
hippocampus (Figure 4.12 B) were positive in 2 of the mice (Figure 4.11, mouse A2 and 
A4). There was no evidence of viral infection in other CNS regions. Inflammatory cells 
with viral antigens were seen in the meninges near to the injection site (Figure 4.12 D). 
Outside the CNS, brown adipose tissues and a few fibres in limb skeletal muscles were 
positive for viral antigens/RNA. Thus, at 24 hpi, there was already evidence of extra 
CNS infection. 
In mice sacrificed at 48 hpi (Figure 4.11, mouse A6 – A10), viral antigen density 
around the injected site was relatively lower than at 24 hpi. Well away from the injected 
site, the brainstem reticular formation and motor trigeminal nucleus were infected 
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bilaterally (Figure 4.12 E). Several different levels of spinal cords were infected in 3 of 
the mice, mainly involving anterior horn cells (Figure 4.11, mouse A6, A8 and A10). 
Brown adipose tissues and skeletal muscles were relatively more severely infected 
compared to 24 hpi. 
 In mice sacrificed at 72 hpi (Figure 4.11, mouse A11 – A15), viral 
antigens/RNA around the injected site were further reduced compared to 48 hpi and 24 
hpi (Figure 4.12 F). In other parts of the CNS, away from the injected site, there was 
even more extensive bilateral brainstem infection involving the midbrain (motor-related 
regions such as reticular nucleus, ventra tegmental area, periaqueductal gray, red 
nucleus, substantia nigra (reticular part), anterior tegmental nucleus), motor trigeminal 
nucleus (Figure 4.12 G and H), dentate nucleus and reticular formation compared to 48 
hpi. The viral antigen distribution within the midbrain and brainstem was similar to the 
IM-infected mice (Section 4.2.1.1, page 51). In the spinal cord, neurons in the anterior, 
intermediate and posterior horns were involved, although anterior horn cells were more 
severely infected. Infected CNS neurons showed neuronal damage and vacuolation with 
mild inflammation. Brown adipose tissues and skeletal muscles were all severely 
infected.  
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Figure 4.11: Approximation of the distribution of viral antigens in the CNS following IC-inoculation (right thalamus/hypothalamus*). At 24 
hpi, viral antigens were found in the injected site/needle tract only. At 48 and 72 hpi, distribution of viral antigens were mostly in the motor-related 
regions in the brainstem similar to IM (jaw/facial muscles) inoculated mice in Figure 4.3, (page 55). Each red dot represents the equivalent of a 
positive neuron/white matter axon. For each mouse, cross sections of cerebral cortex, diencephalon/cortex, midbrain/cortex, caudal 
pons/medulla/cerebellum, medulla/cerebellum, cervical, thoracic, and lumbar spinal cords are displayed. 
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
Figure 4.12: Pathological findings following IC-inoculation 
(thalamus/hypothalamus). Viral antigens were found in the cerebral cortex (A, 
arrows), corpus callosum (A, outlined), dentate gyrus of hippocampus (B, arrow) at the 
MAVS injected site. Neuronal tissue damage and haemorrhage (C, arrows); meningitis 
and viral antigens (D, arrow) were observed at/near the injected site. At 48 hpi, motor 
trigeminal nucleus were infected (E). At 72 hpi, viral antigens and RNA (F) density was 
lower at/near the injected site. However, motor trigeminal nucleus was severely infected 
(G and H). IHC with DAB chromogen and haematoxylin counterstain (A, B, D, E and 
G). H&E stain (C). ISH with haematoxylin counterstain (F and H). Original 
magnification: 20x objective (B, C inset, E, G and F); 10x objective (A, C, D and F). 
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4.3.1.2 Viral titration analysis 
Figure 4.13 shows the mean viral titres of sera and all harvested muscle tissues from IC-
inoculated (thalamus/hypothalamus) mice (n= 4). The sera mean viral titre was from 2.8 
to 3.0 log CCID50 throughout the experiment with no significant variations (P< 0.05) 
between time points. The mean viral titres from bilateral forelimb and hindlimb muscles 
were similar at each specific time points. However, mean muscle viral titres was lowest 
at 24 hpi ranging from 2.7 to 2.9 log CCID50, increasing rapidly and significantly (P< 
0.05) to 4.3 to 4.4 log CCID50 at 48 hpi to peak at 72 hpi with a range of 4.7 to 5.2 log 
CCID50.  
The mean viral titres for sera and CNS tissues (whole brainstem, upper and 
lower spinal cord segments) from the same mouse groups are shown in Figure 4.14. At 
24 hpi, the brainstem viral titre (1.08 log CCID50) was significantly lower (P< 0.05) 
compared to upper and lower spinal cord viral titres at 2.17 and 1.83 log CCID50, 
respectively. At 48 hpi, brainstem viral titre increased significantly (P< 0.05) to 2.25 log 
CCID50 and peaked at 72 hpi with 2.67 log CCID50. Upper and lower spinal cord mean 
viral titres were maintained at 2.42 log CCID50 at 72 hpi after a slight increase at 48 hpi. 
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Figure 4.13: Viral titres in muscle tissues and sera following IC-inoculation 
(thalamus/hypothalamus). Overall, mean viral titres of muscles were insignificant (P< 
0.05) different at each specific time point. Muscle tissues mean viral titres were 
increased over time and peak at 72 hpi. Mean viral titres are expressed as the log 
CCID50 ± standard error of mean. 
 
 
Figure 4.14: Viral titres in CNS tissues and sera following IC-inoculation 
(thalamus/hypothalamus). Brainstem mean viral titres were lower than upper and 
lower spinal cord at 24 hpi. In general, CNS and sera mean viral titres were increased 
gradually but insignificantly (P< 0.05) over time. Mean viral titres are expressed as the 
log CCID50 ± standard error of mean. 
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4.3.2 MAVS infection of neurons in IC-inoculated (pons/medulla) mice 
IC-inoculated (pons/medulla) mice were used to study the neuronal and non-neuronal 
cell susceptibility to direct viral infection. All MAVS infected mice (n= 7) developed 
mild paralysis in both hindlimbs at 72 hpi, but mock-infected mice (n= 6) were healthy 
throughout the experiment. 
 
4.3.2.1 Pathological studies 
The approximate topographic distribution of neuronal viral antigens/RNA or damaged 
neurons in CNS tissues in each mouse is shown in Figure 4.15. In mice (Figure 4.15, 
mouse A1 – A3) sacrificed at 24 hpi, viral antigens and RNA were only detectable 
focally around the needle tract in the brainstem (reticular nucleus) and also spinal cord 
anterior horn cells. Parenchymal damage with haemorrhage in the brainstem, due to the 
needle tract, was observable under light microscopy (Figure 4.16 A). Viral 
antigens/RNA were observed around the needle tract, and mainly associated with glial-
like or possibly small neuronal cells (Figure 4.16 B). Inflammatory cells with viral 
antigens/RNA were also found around the meninges near to the injection site. Other 
regions of the brain were negative for viral antigens/RNA, and appeared normal by light 
microscopy. A single anterior horn cell in the spinal cord was positive for viral antigens 
(Figure 4.15, mouse A1 – A3). Brown adipose tissue and a few fibres in both hindlimbs 
muscles were infected too. 
In all mice sacrificed at 48 hpi (Figure 4.15, mouse A4 – A6). Viral antigens 
around the needle tract were relatively less dense compared to 24 hpi (Figure 4.16 C - F) 
and mostly found in/around inflammatory cells. However, viral RNA remained dense in 
that area (Figure 4.16 G and H). The reticular formation and motor trigeminal nuclei 
also demonstrated positive IHC and ISH staining. Overall, the distribution of viral 
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antigens/RNA in the brain was mainly motor related neurons (motor trigeminal nucleus 
and reticular formation) and shared a lot in common with IM-infected mice (Section 
4.2.1.1, page 51). Cervical spinal cords were more severely infected in the posterior, 
intermediate and anterior horn cells compared to 24 hpi. Large skeletal muscle groups 
such as hindlimb and forelimb muscles were severely infected with advanced necrosis 
and myositis. A few muscle fibres in small skeletal muscles such as tongue and 
jaw/facial muscles were positive for viral antigens too. 
In mice sacrificed at 72 hpi (Figure 4.15, mouse A7 – A10), CNS infection was 
more extensive compared to 48 hpi. Again, viral distribution in CNS resembled findings 
in IM-infected mice (section 4.2.1.1, page 51). Viral antigens were found in the motor 
trigeminal nuclei (Figure 4.16 J), reticular formation, facial nuclei, thalamus, 
hypothalamus, red nucleus, dentate nucleus and motor cortex. The relative density of 
viral antigens/RNA around the needle tract was further reduced (Figure 4.16 I). 
However, spinal cord infection was mainly in the anterior horn cells (Figure 4.15, 
mouse A7, A8 and A10). All skeletal muscles were severely infected and had advanced 
necrosis and myositis. 
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Figure 4.15: Approximation of the distribution of viral antigens/RNA in the CNS following IC-inoculation (pons/medulla). At 24 hpi, viral 
antigens/RNA was only detectable in the brainstem (pons/medulla) at the injected site. Viral distribution at 48 and 72 hpi was mainly motor related 
neurons (motor trigeminal nucleus and reticular formation). Each red dot represents the equivalent of a positive neuron/white matter axon. For each 
mouse, cross sections of cerebral cortex, diencephalon/cortex, midbrain/cortex, caudal pons/medulla/cerebellum, medulla/cerebellum, cervical, 
thoracic, and lumbar spinal cords are displayed. 
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Figure 4.16: Pathological findings following IC-inoculation (pons/medulla). 
Neuronal tissue damage and haemorrhage (A, arrows). Viral antigens were found in the 
brainstem at the injection site at 24 hpi (B, arrows). At 48 hpi, mild inflammation was 
observed at the injection site (C and D, arrows). Viral antigens were reduced (E, arrows) 
compared to 24 hpi and an increase of inflammatory cells was observed (F, arrows). 
However, viral RNA was seen all around needle tract (G and H, arrows). At 72 hpi, 
viral antigens were minimal around the injected site (I, arrows) and few neurons in 
motor trigeminal nucleus were stained up (J, arrows). IHC with DAB chromogen and 
haematoxylin counterstain (B, E, F, I and J). H&E stain (A, C and D). ISH with 
haematoxylin counterstain (G and H). Original magnification: 20x objective (D, F, H 
and J); 4x objective (A - C, E, G and I).  
 
4.3.2.2 Viral titration analysis 
Figure 4.17 shows the mean viral titres of sera and all harvested limb muscle tissues 
from IC-inoculated (pons/medulla) mice (n= 4). Sera viral titres gradually increased 
over time ranging from 2.44 to 2.69 log CCID50, but showed no significant difference 
(P< 0.05) between time points. Mean viral titres from all muscle groups were similar at 
each specific time point. However, the mean muscle viral titres at 24 hpi ranging from 
2.63 to 2.94 log CCID50, increased significantly (P< 0.05) to 4.13 to 4.50 log CCID50 at 
48 and at 72 hpi, respectively.  
The mean viral titres of sera and all CNS tissues (whole brainstem, upper and 
lower spinal cord segments) derived from the same infected mice are shown in figure 
4.18. At 24 hpi, brainstem mean viral titre at 3.44 log CCID50 was significantly higher 
(P< 0.05) than upper and lower spinal cord viral titres at 2.69 and 2.81 log CCID50, 
respectively. At 48 hpi, brainstem, upper and lower spinal cord viral titres dropped 
significantly (P< 0.05) to 1.56, 1.00 and 1.88 log CCID50, respectively. Later, all CNS 
viral titres rose slightly to 2.19 log CCID50 at 72 hpi. 
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Figure 4.17: Viral titres in muscle tissues and sera following IC-inoculation 
(pons/medulla). Muscles mean viral titres were insignificant (P< 0.05) different at each 
specific time points. Over time, mean viral titres of all muscle types were increasing and 
peaked at 72 hpi. Mean viral titres are expressed as the log CCID50 ± standard error of 
mean. 
 
 
Figure 4.18: Viral titres in CNS tissues and sera following IC-inoculation 
(pons/medulla). CNS viral titres were high at 24 hpi and dropped significantly (P< 0.05) 
at 48 hpi. Subsequently, CNS titres increased slightly at 72 hpi. Mean viral titres are 
expressed as the log CCID50 ± standard error of mean. 
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4.3.3 MAVS infection of primary murine motor neurons 
Neuronal susceptibility to MAVS infection was further evaluated in a primary cell 
culture system. Primary motor neurons isolated from 14 day-old ICR mouse embryo 
were found to be only very rarely infected by MAVS. Less than 10 neurons were 
infected in a pool of 106 of cells incubated with MAVS of 1.13 x 105 CCID50/ml. Figure 
4.19 shows a single motor neuron cell positively stained for viral antigens. 
 
 
Figure 4.19: EV-A71 infection of primary murine motor neurons. A single primary 
motor neuron cell showed positive immunofluorescence signal (B) and nucleus 
counterstaining by DAPI (A). Phase contrast image was observed under white light (C) 
and images were superimposed in (D). 
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4.3.3.1 MAVS infection of primary murine motor neurons transfected with 
hSCARB2 
Since primary murine motor neurons were rarely infected by MAVS, the cells were 
transfected with hSCARB2 along with mCherry fluorescent protein as positive control, 
to increase EV-A71 infectivity. About 60% of the cell population were found to express 
hSCARB2 receptors and about 40% (of the hSCARB2 expressing cells) were infected 
by EV-A71 (Figure 4.20).  
 
 
 
 Figure 4.20: EV-A71 infection of primary murine motor neurons transfected with 
hSCARB2. Primary motor neuron isolated from ICR mice, transfected with hSCARB2-
mCherry gene (D and E) was infected by MAVS (B). Nucleus was counterstained with 
DAPI; MAVS were labelled with Alexafluor-488; hSCARB2 receptor was stained with 
Alexafloour-647; mCherry-protein served as transfection positive control. 
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4.4 Retrograde axonal transport in hSCARB2 primary murine motor neurons 
4.4.1 Primary motor neuron study 
As primary motor neuron cells from ICR mice were less susceptible and the transfection 
with hSCARB2 was not efficient (Section 4.3.3 (page 81)), primary motor neuron cells 
cultured from hSCARB2 Tg mouse embryo were seeded into a microfluidic chamber, to 
direct growth of axons away from respective neuronal bodies into a fluidically isolated 
environment. Alexa-555-labelled EV-A71 was introduced either into the chamber 
containing neuronal cell bodies or the chamber with axon terminals. EV-A71 was 
observed to travel from axon terminals towards the direction of neuronal cell bodies or 
retrograde transmission, 5 min post-infection (Figure 4.21). Conversely, viral 
transportation from cell bodies toward the axon terminals or anterograde transmission 
was never observed. Figure 4.22 shows co-localisation of hSCARB2 receptor and EV-
A71 in neuronal cell body when EV-A71 was introduced into the chamber with axon 
terminals.  
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Figure 4.21: Live cell imaging of infected primary motor neurons. Alexa-555 
labelled EV-A71 was seen along the axonal tract of primary motor neurons moving 
towards the cell body (retrograde axonal transport) at 60x objective magnification. 
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Figure 4.22: Double immunofluorescence staining of EV-A71 and hSCARB2. When 
EV-A71 was introduced into the chamber with axon terminals, neuronal cell body was 
infected, at 24 hpi.  
 
 
4.4.1.1 Viral titration analysis 
When virus was added into the chamber containing neuronal cell bodies, viral titres 
obtained from the axon terminal chamber were below detection limit at all-time points 
(Figure 4.23). However, when virus was added into the axon terminal chamber (Figure 
4.24), a mean viral titre of 0.3 log CCID50 was obtained from the neuronal cell body 
chamber, as early as 16 hpi, increasing to 3.0 log CCID50 at 48 hpi. In addition, the 
mean viral titres in the axon terminal chamber were significantly (P< 0.05) higher than 
the viral titres obtained from the neuronal cell body chamber at 0, 16 and 20 hpi (Figure 
4.24). At 48 hpi, the viral titres obtained from cell body chamber were similar to the 
original inoculated viral titre in the axon terminal chamber. 
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Figure 4.23: Mean viral titres from both neuronal cell body and axon terminal 
chambers, after introduction of virus into the cell body chamber. Viral titres 
obtained from the axon terminal chamber were below detection limit at all time points. 
Mean viral titres were expressed as mean viral titres ± standard error of mean. *ND= 
not detected. 
 
 
Figure 4.24: Mean viral titres from both neuronal cell body and axon terminal 
chambers, after introduction of virus into the axon terminal chamber. Viral titres 
obtained from cell body chamber were gradually increased over time. Mean viral titres 
were expressed as mean viral titres ± standard error of mean. *ND= not detected. 
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4.5 EV-A71 “Provocation poliomyelitis” 
4.5.1 MAVS infection in mice with experimentally-traumatised gastrocnemius 
muscles 
Since patients with muscle injury following IM-injection of vaccines or therapeutic 
agents have increased risks of developing “provocation poliomyelitis” due to poliovirus, 
EV-A71 infection may be associated with similar risks. To investigate this potential 
phenomenon in EV-A71 infection, half of IP-infected mice were traumatised 
experimentally in the both gastrocnemius muscles. All mice in the traumatised group 
(n= 5) and in the non-traumatised group (n= 5) infected with 1.78 x 102 CCID50 MAVS 
showed similar weakness in both hindlimbs at 72 hpi. However, the same mouse groups 
infected with a lower viral dose of 90 CCID50 of MAVS did not show any signs of 
infection throughout the experiment.  
 
4.5.1.1 Pathological studies  
Animals in the 4 mouse groups were sacrificed at 72 hpi for pathological examination. 
Overall, viral antigen densities were similar in all tissue types in traumatised (n= 5) and 
non-traumatised (n= 5) mice after infection with either 1.78 x 102 CCID50 or 90 CCID50, 
MAVS (Figure 4.25).  
 All mice (n= 10) infected with 1.78 x 102 CCID50 showed early infection in the 
CNS, specifically in the spinal cords where a few anterior horn cells were positive for 
viral antigens. In traumatised and non-traumatised mice there was no difference in viral 
density (Figure 4.25 E - H). Skeletal muscles were severely infected, with high viral 
antigen densities (Figure 4.25 A - D). There was no evidence of CNS infection in the 2 
mouse groups infected with 90 CCID50 of MAVS. However, muscles were severely 
infected and inflamed. 
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 Control mice (n= 6) were injected with WGA at 10 µg per mouse in 10 µL to 
verify that the experimentally-traumatised muscle could facilitate retrograde axonal 
transport. Traumatised mice showed a higher concentration of WGA in lower spinal 
cords segment compared to non-traumatised mice at 12 hpi (Figure 4.26). 
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Figure 4.25: Pathological findings following IP-inoculation, in gastrocnemius 
muscle-traumatised and non-traumatised mice. Viral antigens density was similar in 
traumatised and non-traumatised mice in comparable tissues. IHC with DAB 
chromogen and haematoxylin counterstain (A - H). Original magnification: 20x 
objective (G and H); 10x objective (C and D); 4x objective (A, B, E and F). 
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Figure 4.26: IHC detection of WGA dot blotted onto nitrocellulose membrane. 
WGA concentration in the lower spinal cord was higher in the experimentally-
traumatised mice (G) compared to non-traumatised mice (C), suggesting WGA was 
retrograde axonally transported at a faster rate into lower spinal cords in experimentally-
traumatised mice. 1 µg of WGA served as positive control (I). 
 
4.5.1.2 Viral titration analysis 
In all mice (n= 10) infected with 90 CCID50 MAVS, all CNS viral titres were below 
detection limits at 72 hpi (Figure 4.27B). The mean viral titres for muscle tissues in 
non-traumatised mice (n= 5) were insignificantly different (P< 0.05) from traumatised 
mice (n= 5), and ranged from 2.4 to 2.5 log CCID50. Viral titres in all tissues of mice 
(n= 10) infected with 1.78 x 102 CCID50 MAVS, were insignificantly different (P< 0.05) 
between traumatised (n= 5) and non-traumatised (n= 5) mice (Figure 4.27A). Lower 
spinal cord segments and muscle tissues showed mean viral titres at 1.1 and 3.5 to 3.9 
log CCID50, respectively (Figure 4.27A). 
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Figure 4.27: Viral titres in CNS and muscle tissues following IP-inoculation at 1.78 
x 102 CCID50 (A) and 90 CCID50 (B), in gastrocnemius muscle-traumatised and 
non-traumatised mice. Mean viral titres were insignificantly (P< 0.05) different 
between traumatised and non-traumatised mice in all type of tissues regardless of 
MAVS dose. Mean viral titres are expressed as the log CCID50 ± standard error of mean. 
*ND= not detected. 
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4.5.2 Infection studies with light-sensitive MAVS 
4.5.2.1 Viral titration analysis 
Light-sensitive MAVS was inoculated into the gastrocnemius muscle of ICR mice to 
provide further insights into viral replication and transmission into the CNS. Since 
newly-synthesised virus in vivo is not sensitive to light, light treatment could be used to 
distinguish it from the original inoculum. Figure 4.28 shows mean viral titres of 
hindlimb muscles, whole brainstem and upper and lower spinal cord segments at 24 hpi, 
48 hpi and 72 hpi (Figure 4.28). Overall, all mean viral titres from light-protected 
samples (mixture of original inoculum and newly synthesised virus) were not 
significantly (P< 0.05) different from corresponding light-treated samples (newly 
synthesised virus).  
At 24 hpi, all CNS viral titres (n= 5) were below detection levels whereas, 
hindlimb muscle titres were 2.75 log CCID50 and 2.42 log CCID50 for light-protected 
and light-treated samples, respectively (Figure 4.28A). At 48 hpi, viral titres from upper 
and lower spinal cord segments (n= 5 each) were 1.5 log CCID50 and 0.5 log CCID50 in 
light-protected samples and in light-treated samples were 1.42 and 0.5 log CCID50, 
respectively. Whereas, muscle titres increased to 4.6 log CCID50 and 4.1 log CCID50 in 
light-protected samples and in light-treated samples, respectively (Figure 4.28B). At 72 
hpi (n= 5), CNS infection, including brainstem infection, was established but brainstem 
viral titres were the same at 1.67 log CCID50 for both light-protected and light-treated 
samples. Conversely, muscles titres increased slightly to 4.7 log CCID50 and 4.2 log 
CCID50 in light-protected samples and in light-treated samples, respectively, and yet 
was not significant in between two samples (Figure 4.28C). Hence, viruses isolated 
from the CNS were mostly “newly-synthesised viruses”. 
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Figure 4.28: Viral titres in muscle tissues and CNS following IM-inoculation, 
sacrificed at 24 (A), 48 (B) and 72 hpi (C). Mean viral titres were not significant (P< 
0.05) different between light-protected and light-treated samples in all type of tissues 
and time. Mean viral titres are expressed as the log CCID50 ± standard error of mean. 
*ND= not detected. 
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4.6 Prevention and treatment of MAVS infection using neutralising antibodies 
4.6.1 Hyperimmune sera treatment of MAVS-infected mice with CNS involvement 
4.6.1.1 Survival analysis  
Hyperimmune sera which showed a high neutralising titre against EV-A71 at 1/512 
dilution in VERO cells, were IP-inoculated into mice infected via the right jaw/facial 
muscles to evaluate the effectiveness of hyperimmune sera in preventing and treating 
CNS infection. All treated groups (n= 4 for each group) and mock-treated mice (n= 4) 
were kept and observed daily for 21 days (Figure 4.29). The mouse group receiving 200 
µL of hyperimmune serum at 4 hr pre-infection did not show any signs of infection. In 
the group receiving hyperimmune sera at 12 hpi, two out of four mice showed ruffled 
fur and weight loss with no observable paralysis from day 8 onwards but died on day 13 
(Figure 4.29). Two out of the four mice in the group receiving hyperimmune sera at 24 
hpi, showed ruffled fur and mild paralysis of one hindlimb from 72 hpi onwards and 
died on day 10 (Figure 4.29). One additional mouse from this group which showed only 
weight loss from day 6, died on day 11 (Figure 4.29). The mock-treated control mice all 
showed signs of infection such as back hunching, fur ruffling and obvious paralysis in 
both hindlimbs from 60 hpi onward, becoming more severe at 72 hpi and progressed to 
moribund/death stage at 96 hpi (Figure 4.29). 
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Figure 4.29: Survival graph of infected animals in mock-treated, 12 hpi treated, 24 
hpi treated, and pre-infection immunised groups followed for 21 days. Treated mice 
showed improved survival, whereas all mock-treated animals died. Pre-infection 
immunised mice all survived. 
 
 
4.6.1.2 Pathological studies 
Figure 4.30 shows the approximate topographic distribution of viral antigens in CNS 
tissues in each mouse (A1 – A16) sacrificed at 72 hpi. In mice receiving 200 µL of 
hyperimmune serum at 4 hr pre-infection, viral antigens/RNA were not detectable in the 
muscles (Figure 4.31 B and F), CNS (Figure 4.30, mouse A1 – A4; Figure 4.31 J and N) 
or other tissues. However, mice receiving early treatment at 12 hpi (Figure 4.30, mouse 
A5 – A8) and 24 hpi (Figure 4.30, mouse A9 – A12) showed very focal viral 
antigens/RNA exclusively in the brainstem, involving bilateral motor trigeminal nuclei 
(Figure 4.31 K and O), reticular formation and facial nuclei, except for a slightly higher 
density of viral antigens/RNA in the latter (Figure 4.31 D, H, L and P). Overall, viral 
antigens/RNA density in the CNS was very much less in the 2 post-infection treated 
groups compared to the mock-treated controls (Figure 4.30, A13 – A16; 4.31 A, E, I 
and M). Infected neurons showed vacuolation with minimal or no inflammation. 
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Skeletal muscles throughout the body were most extensively and severely 
infected in mock-treated animals followed by mice treated at 24 hpi and 12 hpi, 
respectively (Figure 4.31 A - H). 
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Figure 4.30: Approximation of the distribution of viral antigens/RNA in the CNS following unilateral right jaw/facial muscles inoculation in 
treated and mock-treated mice. In the groups treated at 12 and 24 hpi, the brainstem was much less involved compared to the mock-treated group. 
The pre-infection immunised mice were totally protected. Each red dot represents the equivalent of a positive neuron/white matter axon. For each 
mouse, cross sections of cerebral cortex, diencephalon/cortex, midbrain/cortex, caudal pons/medulla/cerebellum, medulla/cerebellum, cervical, 
thoracic, and lumbar spinal cords are displayed.  
98 
 
 
Figure 4.31: Viral antigens in 
mock-treated, 12 hpi treated, 24 
hpi treated, and pre-infection 
immunised mice. Viral antigens 
were greatly reduced in both post-
treated animals. CNS infection was 
prevented in pre-infection 
immunised mice. Viral antigens 
were very focal (C circles) in 
infected muscle of 12 hpi treated 
mice. Motor trigeminal nucleus 
showed minimal viral antigens 
positive cells in 12 hpi (K arrows) 
and 24 hpi (L arrows) treated mice. 
IHC with DAB chromogen and 
haematoxylin counterstain (A – P). 
Original magnification: 20x 
objective (M - P); 10x objective (E - 
L); 4x objective (A - D). 
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4.6.1.3 Viral titration analysis 
Mean viral titres in the CNS and sera from mock-treated and treated mice are shown in 
Figure 4.32. Viral titres were below detection limit in all tissues of mice receiving pre-
infection hyperimmune sera, at all times, except for the brainstem of a mouse (out of 4 
mice) which showed a low titre of 0.25 log CCID50. Moreover, CNS mean viral titres 
(brainstem, upper and lower spinal cord segments) in all treated mice were significantly 
lower than the mock-treated control group (P< 0.05). In general, mice treated at 12 hpi 
had lower mean viral titres compared to mice treated at 24 hpi although the difference 
was only significant for the upper spinal cord and the lower spinal cord (P< 0.05).  
 
 
Figure 4.32: Viral titres in CNS tissues and sera following IM-inoculation and 
treated at 12 and 24 hpi, sacrificed at 72 hpi. Viral titres were all signiﬁcantly (P< 
0.05) lower in the groups treated at 12 hpi and 24 hpi against the controls for all the 
different CNS tissues and sera, respectively. Mean viral titres are expressed as log 
CCID50 ± standard error of mean. 
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4.6.2 MAb in the treatment of MAVS-infected mice with CNS involvement 
4.6.2.1 MAb production and characteristics 
Anti-EV-A71 MAb was generated as a substitution for polyclonal antibodies in 
hyperimmune serum since production of polyclonal antibodies is often inconsistent. The 
MAb (designated as “3D1”) was found to be an Ig-M isotype antibody with a 
concentration of 0.6 g/L. This MAb showed cross-neutralising activities against all the 
EV-A71 subgenotypes tested (Table 4.1). However, genotypes B3, B4, B5 and C5 
showed lower neutralising titres at 1:16. 
 
Table 4.1: Summary of the monoclonal antibody (3D1) neutralising titres against 
various EV-A71 subgenotypes 
 
No. Genbank Number Name Genotype Titre 
1. AY207648 13903 B3 1:64 
2. - MAVS* B3 1:16 
3. AF376067 A10/4 B4 1:16 
4. - 18431 B5 1:16 
5. AY126012 8M/6/99 C2 1:128 
6. AY125966 001-KOR-00 C3 1:32 
7. AM490152 VN5559 C4 1:256 
8. AM490158 VN5784 C5 1:16 
*MAVS was used for MAb generation. 
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4.6.2.2 Survival analysis 
Mice IP-infected by MAVS were treated with various concentrations of MAb at 
different time points also via an IP route. All mock-treated mice (n= 4) challenged with 
MAVS started to show signs of disease such as hunching back and hindlimb weakness 
at 72 hpi and progressed to severe paralysis at 96 hpi. All mice were moribund/dead at 
120 hpi (Figure 4.33 and 4.34).  
Mouse groups (n= 4 each), treated daily with 120 µg of MAb at 24 and 48 hpi 
(D1 - 2), respectively, survived without any signs of infection after 21 dpi (Figure 
4.33A and 4.34A). Whereas, mice (n= 4) treated with 60 µg of MAb started to show 
mild paralysis on both hindlimbs on 5 dpi, and started to recover on 8 - 9 dpi (Figure 
4.34A). Weight loss was observed in 2 out of 4 mice at 6 dpi. Mice (n= 4) receiving 30 
µg of MAb started to show paralysis at both hindlimbs at 4 dpi (Figure 4.34A). Half of 
the mice were moribund/dead on 8 - 9 dpi and another half recovered on 13 dpi (Figure 
4.33A and 4.34A). 
 Treatment given daily at 72 and 96 hpi (D3 – 4), was still effective at higher 
MAb amounts. When given 120 µg of MAb, mice (n= 4) developed paralysis on both 
hindlimbs on 4 - 5 dpi, and partially recovered on 10 dpi with minor hindlimb weakness 
on 21 dpi; except for 1 mouse which was moribund/dead on 8 dpi (Figure 4.33B and 
4.34B). For mice (n= 4) receiving 60 µg of MAb, paralysis was observed on 4 - 5 dpi, 
and 2 out of 4 mice were moribund/dead on 8 dpi (Figure 4.33B and 4.34B). The 
survivors showed minor hindlimb weakness on 21 dpi (Figure 4.34B). Whereas, mice 
(n= 4) receiving 30 µg of MAb developed paralysis on 4 - 5 dpi and were all 
moribund/dead on 5 - 6 dpi (Figure 4.33B and 4.34B). 
 In Experiment 3, mice (n= 4) treated daily with 120 µg of MAb at 24, 48 and 72 
hpi (D1 – 3) remained healthy with no visible illness throughout the experiment (Figure 
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4.34C). Two out of 4 mice treated daily with 120 µg of MAb at 72, 96 and 120 hpi (D3 
– 5) showed mild paralysis on 4 - 5 dpi and gradually recovered on 6 dpi (Figure 4.34C). 
All 4 mice survived but one of them showed minor hindlimb weakness on 21 dpi 
(Figure 4.33C and 4.34C). Thus MAb treatment seems to be helpful to ameliorate 
disease severity and to lower mortality (Figure 4.33 - 4.34). 
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Figure 4.33: Survival graph of infected animals in mock-treated, and treated at 24 
and 48 hpi (A); treated at 72 and 96 hpi (B); and treated daily for 3 consecutive 
days at 120 µg of MAb (C), for 21 days. Mice treated at 24 and 48 hpi (D1 – 2) (A) 
showed greatly improved survival. However, when mice were treated later at 72 and 96 
hpi (D3 – 4), only mice receiving 60 µg and 120 µg of MAb showed improved survival 
rate (B). All mice treated daily for 3 consecutive days at 120 µg of MAb showed 
improved survival rate even though first treatment started at 72 hpi. All mock-treated 
animals died at 120 hpi. *CTL= mock-treated; D1-2= treated at 24 and 48 hpi; D3-4= 
treated at 72 and 96 hpi; D1-3= treated at 24, 48 and 72 hpi; D3-5= treated at 72, 96 and 
120 hpi. 
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Figure 4.34: Clinical scores of infected animals in mock-treated, and treated at 24 
and 48 hpi (A); treated at 72 and 96 hpi (B); and treated daily for 3 consecutive 
days at 120 µg of MAb (C), for 21 days. All mice treated at 120 µg of MAb showed 
improved clinical scores even though 1st treatment started at 72 hpi. Clinical scores 
were graded as follows: 0, healthy; 1, weight loss; 2, limb weakness; 3, hindlimb 
paralysis; and 4, moribund and death. Log-rank test analysis showed that all treated 
groups demonstrated statistically significant (P< 0.05) in survival from the control 
group. *CTL= mock-treated; D1-2= treated at 24 and 48 hpi; D3-4= treated at 72 and 96 
hpi; D1-3= treated at 24, 48 and 72 hpi; D3-5= treated at 72, 96 and 120 hpi. 
 
 
4.6.2.3 Pathological studies 
Figure 4.35 shows the approximate topographic distribution of neuronal viral 
antigens/RNA or damaged neurons in CNS tissues in each mouse. In all 4 IP-infected, 
mock-treated mice sacrificed at 24 hpi (Figure 4.35, mouse C1 – C4), viral antigens 
could only be detected in the large skeletal muscles such as forelimb and hindlimb 
muscles and myositis was minimal. All other tissues including the CNS were negative 
and appeared normal under microscopic observation.  
Viral antigens began to appear in CNS tissues in mice sacrificed at 72 hpi 
(Figure 4.35, mouse C5 – C8; Figure 4.36 I, M and Q), especially involving bilateral 
spinal cords (Figure 4.36 Q), where anterior horn cells were most severely infected 
(Figure 4.35, mouse C5 – C8). Furthermore, white matter axons immediately adjacent 
to infected anterior horn cells at or near the site where peripheral motor nerves usually 
exit, were positive for viral antigens too. Bilateral involvement of motor trigeminal 
nucleus, reticular formation and thalamus were observed. Severe myositis with dense 
viral antigens and inflammatory cells were observed in skeletal muscles (Figure 4.36 A 
and E). Brown adipose tissues showed some viral antigens with minimal inflammation. 
Mice sacrificed at 96 hpi (Figure 4.35, mouse C9 – C12) showed similar 
infection to mice sacrificed at 72 hpi although the motor trigeminal nucleus and 
reticular formation were more severely involved. Similarly, skeletal muscles (Figure 
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4.36 B and F) and brown adipose tissues were also more severely infected. Infected 
neurons showed neuronal vacuolation and damage (Figure 4.36 J, N and R). 
In mouse groups treated daily at 24, 48 and 72 hpi (Day 1 to day 3 (D1-3)) and 
sacrificed at 96 hpi (Figure 4.35, mouse A1 – A4; and Figure 4.38 K, O and S), there 
was no evidence of CNS infection. A few large skeletal muscles such as hindlimb 
muscles were positive for viral antigens (Figure 4.36 C and G). Viral antigens and 
inflammation were absent in all other tissues. 
Overall, animals treated daily at 72, 96 and 120 hpi (D3-5) and sacrificed at 144 
hpi (Figure 4.35, mouse A5 – A8), showed lower viral antigens density compared to 
mock-treated mice sacrificed at 72 and 96 hpi, respectively (Figure 4.35, mouse C5 – 
C12; and Figure 4.36). Viral antigens were observed mainly in the anterior horn cells of 
the spinal cords (Figure 4.36 T), motor trigeminal nucleus (Figure 4.36 L and P), 
reticular formation and hypothalamus of the brain. Infected neurons showed neuronal 
vacuolation and damage (Figure 4.36 L). A few fibres in systemic skeletal muscles 
(Figure 4.36 D and H) and brown adipose tissues were infected and inflamed. 
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Figure 4.35: Approximation of the distribution of viral antigens in the CNS 
following IP-inoculation in mock-treated and treated animals. Viral antigens were 
not detectable in mice treated before CNS infection (A1-A4). In mice treated after CNS 
infection (A5-A8), viral antigens were far less than mock-treated mice (C9-C12). Each 
red dot represents the equivalent of a positive neuron/white matter axon. For each 
mouse, cross sections of cerebral cortex, diencephalon/cortex, midbrain/cortex, caudal 
pons/medulla/cerebellum, medulla/cerebellum, cervical, thoracic, and lumbar spinal 
cords are displayed.
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Figure 4.36: Pathological findings following IP-
inoculation in mock-treated and treated animals at 
different hpi. Viral antigens were much less in all treated 
animals for all types of tissues. Viral antigens were not 
found in any CNS tissue in mice treated before CNS 
infection (K, O and S). H&E stain (A – D, I - L). IHC with 
DAB chromogen and haematoxylin counterstain (E – H, 
M - T). Original magnification: 40x objective (M, N and 
P); 20x objective (A – D, I – L, Q, R and T); 10x objective 
(O and S); 4x objective (E - H). 
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4.6.2.4 Viral titration analysis 
In infected, mock-treated mice (n= 4, for each time point), virus was detectable in all 
muscles tissues examined as early as 24 hpi and titres increased over time (Figure 4.37). 
From 72 hpi onwards, virus was detectable in all the CNS tissues with highest titres in 
the lower spinal cord, upper spinal cord segment and brainstem with titres of 2.0, 1.8 
and 1.3 log CCID50, respectively (Figure 4.38).  
CNS viral titres in mice (n= 4) treated daily at 24, 48 and 72 hpi were below 
detection limit (Figure 4.38). The left and right hindlimb muscles showed very low viral 
titres at 0.5 and 0.3 log CCID50, respectively (Figure 4.37).  
Although MAb treatment given daily at 72, 96 and 120 hpi was not as effective 
as mice treated at 24, 48 and 72 hpi, the mean viral titres in all tissues were still 
significantly lower (P< 0.05) compared to infected mock-treated mice at 96 hpi. 
Brainstem, upper and lower spinal cord viral titres that ranged from 1.2 - 1.4 log 
CCID50 were significantly lower than the 3.4 to 4.1 log CCID50 (Figure 4.38) range 
found in infected, mock-treated mice.  
 
 
 
111 
 
 
Figure 4.37: Viral titres in muscle tissues following IP-inoculation in mock-treated 
and treated animals. Mean viral titres of all treated animals were signiﬁcantly lower 
(P< 0.05) against mock-treated groups. Mean viral titres are expressed as log CCID50 ± 
standard error of mean. *ND= not detected. 
 
 
 
 
Figure 4.38: Viral titres in CNS following IP-inoculation in mock-treated and 
treated animals. Mean viral titres of all treated animals were signiﬁcantly lower (P< 
0.05) against mock-treated groups. Similar as mock-treated mice sacrificed at 24hpi, 
CNS viral titres from mice treated at 24, 48 and 72 hpi were all below detection limit. 
Mean viral titres are expressed as log CCID50 ± standard error of mean. *ND= not 
detected. 
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4.6.2.5 Real-time PCR (qPCR) analysis 
Overall, qPCR analysis (Figure 4.39 and Figure 4.40) shared a lot of similarity with 
viral titration assays. Viral copy numbers of all tissues from MAb treated mice (n= 4, 
for each group) were significantly lower (P< 0.05) than mock-treated mice. Whereas, 
viral copy numbers of all tissues from mice treated daily at 24, 48 and 72 hpi were all 
significantly lower (P< 0.05) compared to mice treated daily at 72, 96 and 120 hpi. In 
addition, no viral RNA was detected in the CNS tissues from mice treated before CNS 
infection (Figure 4.40).  
 
 
 
Figure 4.39: Viral copy number of muscle tissues following IP-inoculation in mock-
treated and treated animals. Mean viral copy number of all type of tissues from all 
treated animals were signiﬁcantly lower (P< 0.05) against mock-treated groups. Mean 
viral copy number of all tissues from mice treated at 24, 48 and 72 hpi were 
significantly lower (P< 0.05) compared to mice treated at 72, 96 and 120 hpi. Mean 
viral copy number are expressed as mean viral copy number ± standard error of mean. 
*ND= not detected. 
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Figure 4.40: Viral copy number of CNS tissues following IP-inoculation in mock-
treated and treated animals. Mean viral copy number of all type of tissues from all 
treated animals were signiﬁcantly lower (P< 0.05) against mock-treated groups. Mean 
viral copy number of all tissues from mice treated at 24, 48 and 72 hpi were 
significantly lower (P< 0.05) compared to mice treated at 72, 96 and 120 hpi. Mean 
viral copy number are expressed as mean viral copy number ± standard error of mean. 
*ND= not detected. 
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5.0 Discussion 
5.1 Enterovirus 71 Brainstem Infection via Cranial Nerves 
EV-A71 infection can cause a diverse spectrum of diseases that are dermatotropic 
and/or neurotropic in nature (Solomon et al., 2010). Although CNS infection is rare, 
children with severe EV-A71 encephalomyelitis usually die from rapid cardio-
respiratory collapse, often within a few hours of hospital admission (K. T. Wong et al., 
2008). Recent findings from human autopsies or animal models of EV-A71 
encephalomyelitis had suggested that retrograde axonal transport in motor nerves play 
an important role in EV-A71 neuroinvasion (Arita et al., 2007; C. S. Chen et al., 2007; 
Fujii et al., 2013; Lu et al., 2009; Ong et al., 2008; Tan et al., 2014; Wei et al., 2010; K. 
T. Wong et al., 2008; K. T. Wong et al., 2012; Yan, Wang, Liu, Yang, & Su, 2000; 
Yang et al., 2009). Hence, cranial nerves, in particular, motor components of these 
nerves, might be involved in rapid and direct EV-A71 invasion into the brainstem to 
cause sudden cardio-respiratory collapse. 
 After unilateral jaw/facial muscle injection, the results (Section 4.2, page 51) 
suggest that EV-A71 was indeed able to enter and directly infect the murine brainstem 
via cranial nerves, most likely by retrograde axonal transport rather than by the 
haematogenous route (via the blood-brain-barrier). Based on pathological findings 
(Section 4.2.1.1, page 51), viral antigens and RNA were first visualised within the 
cranial nerves and brainstem ipsilateral to the injected side as early as 24 hpi. This is the 
first time cranial nerve involvement has been demonstrated. The infected ipsilateral 
brainstem regions included motor trigeminal nucleus, reticular formation and facial 
nucleus, are mostly motor-related regions. We believe that inoculated MAVS after 
infecting skeletal muscles crossed the neuromuscular junctions into the distal motor 
nerve terminals. From there, virus travelled by retrograde axonal transport up motor 
nerves of the 5th and 7th cranial nerves to infect the motor trigeminal nucleus and facial 
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nucleus, respectively. In human EV-A71 acute flaccid paralysis, MRI examinations of 
the CNS have shown hyperintensities in ventral nerve roots and anterior horn areas of 
the spinal cord (F. Chen et al., 2013; Zeng et al., 2012). So far, brain MRI scans have 
not shown similar hyperintensities in cranial nerves. Previously, Ong et al. (2008) had 
also shown that the virus could enter the spinal cord via peripheral spinal motor nerves 
after unilateral thigh muscle infection in the same mouse model. Furthermore, the viral 
titration assays (section 4.2.1.2, page 59) demonstrated that brainstem viral titres were 
significantly higher (P< 0.05) than both upper and lower spinal cord segments up to 48 
hpi, consistent with early infection of the brainstem. Taken together, we believe that 
EV-A71 was able to enter the CNS (brainstem and spinal cord) via retrograde axonal 
transport in peripheral motor nerves.  
Following brainstem infection, the results showed greater involvement of the 
motor cortex compared to other cerebral areas (Figure 4.3, page 55) suggesting that 
within the CNS, the motor pathways (corticospinal/corticobulbar tracts) could spread 
virus beyond the brainstem and spinal cord. This is consistent with findings from other 
animal and human studies (Ong et al., 2008; K. T. Wong et al., 2008). The severely 
involved reticular formation is likely to facilitate viral spread within the CNS to the 
hypothalamus, other brainstem areas and beyond. Lateral cerebellar nucleus 
involvement could be via pathways that connect it to the red nucleus and the medulla. 
Similarly, the thalamus and other sensory neurons could become infected via the 
complex interlinks of other neural pathways in the CNS.  
Viraemia was detected as early as 12 hpi, probably from the viral replication in 
the injected muscles and/or leakage of the site of inoculation. Viraemia was likely to 
have spread infection to contralateral and other skeletal muscles as early as 12 hpi 
(Figure 4.5, page 60). Viral titres in the blood were significantly (P < 0.05) higher than 
the titres in CNS tissues at all times. We speculate that following bilateral skeletal 
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muscle infection, MAVS continued to travel up respective motor nerves to involve other 
parts of the CNS (both ipsilateral and contralateral sides) as seen at later time points 
from 36 hpi onwards. There was bilateral marked increase of anterior horn cell infection 
in the spinal cords (Figure 4.3, page 55). Moreover, the role of viraemia to cause 
widespread CNS infection was clearly shown in section 4.2.3 (page 64), where infected 
mice in which viraemia was prevented/reduced by hyperimmune sera demonstrated only 
ipsilateral brainstem and muscle infection/inflammation; the contralateral CNS and 
other skeletal muscles were uninfected. If CNS infection occurred by the 
haematogenous route, one might expect early bilateral infection of the CNS at early 
time points and a similar degree of infection in the cerebral cortex, hippocampus, 
thalamus, hypothalamus and other brain regions due to simultaneous exposure to virus.  
 Following unilateral jaw/facial muscle injection, (Section 4.2, page 51) the 
motor trigeminal nucleus and reticular formation were the first sites of infection in the 
brainstem. Infection of the reticular formation was most likely via the rich and extensive 
neuronal inter-connections with the motor trigeminal and facial nuclei. Since the 
reticular formation extends to the whole brainstem, including the medulla, viral spread 
to medullary nuclei via the reticular formation is entirely possible (Conn & 
SpringerLink, 2008; Heimer, 1995; Wilson-Pauwels, Akesson, & Stewart, 2002). 
Although direct medullary infection via 9th and 12th cranial nerves was not done in these 
studies because of technical difficulties injecting muscle groups innervated by these 
nerves, viral transmission from motor trigeminal and facial nuclei to the medulla is 
likely to have occurred. In human infections, brain MRI examination revealed lesions 
mainly in dorsal pons and the whole medulla oblongata, findings that were confirmed 
by autopsy of patients with fatal encephalomyelitis (K. T. Wong et al., 2008; Zeng et al., 
2012). Direct medullary infection, via 9th and 12th cranial nerves (motor components) 
could cause sudden death as a result of the involvement and inflammation of medullary 
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cardio-respiratory centres (Baker, 1957; Fu et al., 2004; Fu et al., 2006; Hoff, Nishimura, 
Garcia-Uria, & Miranda, 1981). The fact that patients with fatal encephalomyelitis 
almost always suffer a catastrophic terminal event, often within a few hours of hospital 
admission, is consistent with direct brainstem infection and destruction of the cardio-
respiratory centres. Following medullary inflammation and damage, high levels of 
norepinephrine and epinephrine could be released to raise the pulmonary vascular 
pressure, leading to cardiac damage and arrhythmia, and neurogenic pulmonary oedema 
(Kao, Yang, Hsu, & Chen, 2004; Yang et al., 2009).  
 Another theory suggests that the terminal events in fatal encephalomyelitis is 
associated with a “cytokine storm”. In many human studies, increased inflammatory 
cytokines including IL-1β, IL-6, IL-10, IL-13 and IFN-γ had been reported. These 
cytokines are believed to increase pulmonary vascular permeability leading to 
pulmonary oedema and death (T. Y. Lin, Chang, Huang, et al., 2002; S. M. Wang et al., 
2003; S. M. Wang, Lei, & Liu, 2012). However, none of the animal models studied so 
far has demonstrated pulmonary oedema, including the current study (Y. F. Wang & Yu, 
2014). The inflammatory cytokines could be associated with severe/terminal infection 
rather than the direct cause of death. Some authors believe direct brainstem infection to 
be more important than “cytokine storm”-induced pulmonary oedema/functional 
dysregulation as a cause of death (T. Y. Lin, Hsia, Huang, Wu, & Chang, 2003; S. M. 
Wang et al., 2003; S. M. Wang et al., 2012). Further investigations are needed to 
confirm this. Lastly, the possibility of myositis causing respiratory muscular paralysis 
and failure, and thereby contributing to death in mouse models cannot be ignored. 
However, myositis has not been reported in human EV-A71 encephalomyelitis. 
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5.2 Infectivity of EV-A71 in Neuronal Cells  
The stereotyped distribution of inflammation and antigens/RNA in the human and 
murine CNS (Ong et al., 2008; K. T. Wong et al., 2008) could be due to at least two 
possibilities. Firstly, upon entering the spinal cord and brainstem via retrograde motor 
nerve transmission, viruses first infect the motor neuronal cell bodies in the spinal cord 
(anterior horn cells) and brainstem (e.g. cranial nerve nuclei) and spread from these 
neurons to other regions via established neural pathways. Secondly, assuming that 
haematogenous spread occurs, and there is an equitable distribution of virus, there may 
be different neuronal susceptibility in different CNS regions depending on the 
density/availability of SCARB2 receptors. The SCARB2 receptor is probably a primary 
determinant of viral entry into cells and hence, play an important role in tissue tropism 
(P. Chen et al., 2012; Yamayoshi et al., 2014; Yamayoshi et al., 2009). After virus has 
entered the CNS parenchyma either by peripheral nerves or haematogenous route, it is 
also possible that more distant neurons or groups of neurons with a higher density of 
viral receptors will more likely be infected in contrast to neurons with fewer SCARB2 
receptors. 
To investigate viral spread within the murine CNS, MAVS was inoculated into 
thalamus/hypothalamus and pons/medulla regions by an IC route (Section 4.3, page 68). 
The thalamus/hypothalamus and pons/medulla regions were chosen because according 
to the Allen Brain Atlas Data Portal, the C57BL/6J mouse at 56 days of age, expresses 
SCARB2 receptor in all parts of brain with the highest expressions in the pons, 
hypothalamus and medulla regions (Table 5.1) (Lein et al., 2007). We assume that this 
also applies to the ICR mice used in our experiments. 
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Table 5.1: Summary of SCARB2 expression in 12 major mouse brain 
structures/areas (Adapted from Lein et al., 2007). 
 No. Brain Structure/Area Expression Energy Value* Log2@ 
1. Isocortex 10.75 3.43 
2. Olfactory area 7.67 2.94 
3. Hippocampal formation 9.00 3.17 
4. Cortical subplate 8.37 3.07 
5. Striatum 6.09 2.61 
6. Pallidum 8.98 3.17 
7. Thalamus 11.85 3.57 
8. Hypothalamus 12.40 3.63 
9. Midbrain 12.17 3.60 
10. Pons 12.71 3.67 
11. Medulla 12.32 3.62 
12. Cerebellum 6.35 2.67 
 * Expression energy was calculated and derived from SCARB2 RNA as detected by 
ISH in various brain areas.  
@ Log2 of the expression energy value defines the fold changes of SCARB2 expression. 
The areas chosen for IC inoculation (thalamus/hypothalamus and pons/medulla) have 
among the highest SCARB2 expressions. 
 
  
In both IC-infected mice (thalamus/hypothalamus and pons/medulla), MAVS 
was first detected around the injection site at 24 hpi. Infected cells were mainly close to 
the needle tract and comprised non-neuronal cells such as microglial cells or astrocytes 
with a minority of small neurons (Figure 4.12A (page 71) and Figure 4.16B (page 78)). 
In thalamus/hypothalamus inoculated mice, viral antigens/RNA were detected focally 
around the needle tract in the thalamus region, part of cerebral cortex (retrosplenial 
cortex and posterior parietal association cortex) (Figure 4.12A) and around the corpus 
callosum (Figure 4.12A). There was no evidence of viral infection in other CNS regions. 
Interestingly, although the needle tract passed through the pyramidal layer of the 
Ammon’s horn and granular cell layer of dentate gyrus, both components of the 
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hippocampal formation, which demonstrate the strongest SCARB2 expression (Lein et 
al., 2007), there was very little infection of the neuronal cells. Only a few dentate gyrus 
neurons were positive for viral antigens/RNA in 2 mice (Figure 4.11, mouse A2 and A4, 
page 70).  
In pons/medulla inoculated mice, viral antigens/RNA were only detectable 
focally around the needle tract in the brainstem reticular formation. Although the needle 
tract passed through the purkinje cell layer of the cerebellum which demonstrate the 
strongest SCARB2 expression (Lein et al., 2007), there was no infection of these 
neuronal cells.  
At 48 and 72 hpi, around the needle tract, viral antigens/RNA were found to be 
reduced. These findings suggested that there was little, if any cell-to-cell viral spread 
(centrifugal spread) from the needle tract to surrounding neurons. It is assumed that 
following cytolysis of infected neurons, the released virus in the 
microenvironment/neurophil could infect the adjacent neurons, but this was not 
observed in our experiment. The reason for this surprising finding is unknown. It is 
possible that an innate immune response may inhibit the entry and replication to limit 
virus spread in adjacent neurons. Although strong neuronal mSCARB2 expression has 
been reported in the Allen Brain Atlas Data Portal (Lein et al., 2007), it is possible that 
the MAVS after adaptation, may not use mSCARB2 efficiently for viral entry. Using 
transfected L-929 (murine fibroblast cells), Yamayoshi et al. (2009) have reported that 
mSCARB2 may not be a functional receptor for EV-A71, due to its low efficiency for 
viral entry compared to hSCARB2. Furthermore, using IHC, Yu et al. (2014) found no 
correlation between the distribution of mSCARB2 and EV-A71 antigens in their mouse 
model. Hence, it is possible that our MAVS utilised an unknown receptor(s) for 
neuronal entry instead of mSCARB2. This unknown receptor(s) may not be present in 
sufficient quantities to support cell-to-cell virus spread in the thalamus/hypothalamus 
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and pons/medulla regions. Alternatively, an unknown viral co-receptor may be absent in 
these cells without which mSCARB2 alone is insufficient for viral entry as was shown 
in HIV infection (Fields et al., 2013). Further investigations are needed to confirm this.  
At 48 hpi, viral antigens/RNA distribution away the needle tract was similar in 
both intra-thalamus/hypothalamus and intra-pons/medulla inoculated mice. The motor-
related regions such as motor trigeminal nucleus and reticular formation, were positive 
for viral antigens/RNA bilaterally (Figure 4.11 (page 71) and Figure 4.15 (page 77)). 
We believe that retrograde transport from peripheral nerves is likely to have caused 
infection in these areas. This is because, these infected motor regions were further away 
from the thalamus/hypothalamus inoculated site compared to pons/medulla, but yet both 
showed similar bilateral neuronal involvement. As was shown in IM-inoculated mice 
(Section 4.2, page 51), the motor trigeminal nucleus and reticular formation were the 
first brainstem neurons to be infected at 24 hpi after retrograde axonal transmission. 
Bilateral infection of these regions was observed at 48 hpi, and the pattern of brainstem 
involvement was very similar to both intra-thalamus/hypothalamus and intra-
pons/medulla inoculated mouse brains. Hence, the infection of these areas was similar 
to IM-inoculated mice, and probably originated from leaked MAVS into the blood 
causing viraemia. Disseminated viruses caused systemic skeletal muscle infection 
followed by retrograde viral transmission into the brainstem and spinal cord.  
 At 72 hpi, viral antigens/RNA distribution away the needle tract was again 
similar in both intra-thalamus/hypothalamus and intra-pons/medulla inoculated mice. 
Compared to 48 hpi, the same regions were also involved but other regions such as 
thalamus, hypothalamus, red nucleus, dentate nucleus and motor cortex were more 
severely infected. Compared to IM-inoculated mice at 72 hpi, viral antigens/RNA 
distribution was also similar.  
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Table 5.2 summarises the pathological changes in systemic skeletal muscles and 
motor trigeminal nucleus over various time points in IM, intra-thalamus/hypothalamus 
and intra-pons/medulla inoculated mice. The severity of the skeletal muscle and motor 
trigeminal nucleus infection over time were used as an indicator of systematic viral 
spread and retrograde viral transmission, respectively. As early as 24 hpi, systemic 
skeletal muscles showed evidence of viral antigens/RNA because of viraemia (serum 
viral titres always positive). In general, the density of viral antigens/RNA in skeletal 
muscles were always higher than in the CNS (brainstem/spinal cord) for all time points, 
especially at 48 and 72 hpi. However, intra-thalamus/hypothalamus and intra-
pons/medulla inoculated mice demonstrated delayed skeletal muscle and corresponding 
CNS infection most likely due to lower serum viral titres. On the contrary, higher 
viraemia and earlier viral replication in skeletal muscles accelerated retrograde viral 
transport into the motor trigeminal nucleus to cause the earlier infection and higher 
brainstem viral titres in IM-inoculated mice (Table 5.2).  
Serum viral titres in IM-inoculated mice were significantly higher than both 
intra-thalamus/hypothalamus and intra-pons/medulla inoculated mice at earlier and 
subsequent time points (Figure 4.5 (page 60), Figure 4.13 (page 73), Figure 4.17 (page 
80)). This suggested that viraemia occurred earlier, either from increased viral leakage 
from injection site, early primary replication in injected muscles or other unknown 
factors. Presumably, the earlier and more severe involvement of the skeletal muscles 
and motor trigeminal nucleus could have caused earlier limb paralysis in IM-inoculated 
mice. 
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Table 5.2: Comparison of pathological findings in intra-muscular, intra-
thalamus/hypothalamus and intra-pons/medulla inoculated mice. 
Hours post-
infection 
Viral antigens in tissues 
 Route of infection 
Intra- 
muscular 
(n= 4) 
Intra- 
thalamus/ 
Hypothalamus 
(n = 5) 
Intra-
pons/medulla 
(n= 3) 
 
24 Systemic Muscles ++ + + 
Motor trigeminal 
nucleus 
+ - - 
48 Systemic Muscles +++ ++ ++ 
Motor trigeminal 
nucleus 
++ + + 
72 Systemic Muscles +++ +++ +++ 
Motor trigeminal 
nucleus 
+++ ++ ++ 
In systemic muscle,  
+ indicates viral antigens in only a few fibres of skeletal muscle with mild myositis 
++ indicates less than half skeletal muscle fibres with viral antigens, and severe myositis 
+++ indicates more than half skeletal muscle fibres with viral antigens, and severe myositis 
In motor trigeminal nucleus,  
+ indicates viral antigens in only a few neurons 
++ indicates less than half neurons with viral antigens along with neuronal damage and 
degeneration 
+++ indicates more than half neurons with viral antigens along with neuronal damage and 
degeneration 
 
 
 Figure 5.1 shows a comparison of brainstem viral titres from intra-muscular, 
intra-thalamus/hypothalamus and intra-pons/medulla inoculated mice sacrificed at 24, 
48, and 72 hpi. At 24 hpi before significant retrograde transmission in cranial nerves 
occurred, brainstem viral titres in intra-pons/medulla inoculated mice were the highest. 
This is possibly due to the presence of the original inoculated virus, with probably little 
contribution from newly-synthesised virus, or virus from retrograde transmission. The 
higher brainstem titres in IM-inoculated mice compared to intra-thalamus/hypothalamus 
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inoculated mice was most likely due to virus reaching the brainstem earlier via cranial 
nerves.  
At 48 hpi, both IC-inoculated mice showed similar (P< 0.05) viral titres 
confirming comparable early viral transmission rate into the brainstem from the 
peripheral nerves (Figure 5.1). Brainstem viral titres in intra-pons/medulla inoculated 
mice were lower than the titres obtained at 24 hpi, confirming that there is minimal in 
situ replication around the needle tract (inoculation site). Viral titres in IM-inoculated 
mice were significantly higher than both suggesting that the retrograde viral 
transmission from peripheral nerves, as previously described, contributed significantly 
to the viral titres. At 72 hpi, the same pattern of viral titre increase was observed. 
As was discussed earlier, other unknown receptors may be present in our MAVS 
mouse system to facilitate viral entry into neurons, and this may also apply to viral 
transmission into the neuromuscular junction and nerve terminal from infected muscles, 
to lead to retrograde axonal transmission. We speculate that either an unknown receptor 
or co-receptor may be present within the neuromuscular junction in sufficient quantities 
to support viral entry. In poliovirus infection, human poliovirus receptor CD155-
independent endocytosis and transport had been observed in mouse neuromuscular 
junction. Alternatively, CD155-independent endocytosis via an unknown receptor could 
also promote viral transmission through the neuromuscular junction (Ohka et al., 2009). 
Further investigations are needed to investigate how EV-A71 gains entry into the 
peripheral nerve terminal. 
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Figure 5.1: Comparison of brainstem viral titres from intra-muscular, intra-
thalamus/hypothalamus and intra-pons/medulla inoculated mice sacrificed at 24, 
48, and 72 hpi. Brainstem mean viral titres were increasing gradually over time for 
both intra-muscular and intra-thalamus/hypothalamus inoculated mice. Whereas, 
brainstem mean viral titres from intra-pons/medulla inoculated mice were highest at 24 
hpi and dropped significantly (P< 0.05) at 48 hpi. Mean viral titres are expressed as the 
log CCID50 ± standard error of mean. 
  
As motor neurons appear to be a primary target of EV-A71 infection, primary 
motor neuron cells were used in in vitro experiments to investigate neuronal 
susceptibility and viral transport. Surprisingly, direct MAVS infection of ICR mouse 
derived primary motor neuron cells was minimal (< 1%) (Section 4.3.3, page 81). Since, 
previous studies suggested that EV-A71 could use hSCARB2 more efficiently than 
mSCARB2 receptor (Yamayoshi et al., 2009) to enter cells, we repeated the same 
experiment with primary motor neuron cells derived from hSCARB2 Tg mice. 
Although EV-A71 (non-MAVS) infection in primary motor neurons isolated from 
hSCARB2 Tg mice was higher (< 50%) than the ICR derived motor neuron cells, the 
infection was still not extensive (Figure 4.22 (page 85)) when compared to VERO or 
RD cells in which full infection (nearly 100%) was commonly achieved. Hence, it is 
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possible that our murine primary motor neuron cells derived from hSCARB2 Tg mice 
were more susceptible to EV-A71 infections, because the hSCARB2 was more efficient 
for viral entry compared to mSCARB2 (Yamayoshi et al., 2009). The relatively lower 
infection rate of hSCARB2 Tg mouse neurons compared to VERO and RD cells were 
similar to in vitro findings reported by H. I. Huang et al. (2014) and Yap et al. (2016). 
Using motor neurons derived from human neural stem cell or neural progenitor cells, 
they reported that differentiated neuronal cells were less susceptible to EV-A71 
infection. They speculated that poor susceptibility of differentiated cells could be 
associated with deﬁciency of appropriate EV-A71 receptors, or reduced mitotic rate of 
these cells as was shown in Coxsackievirus infection. These may partially explain the 
pathological findings in both IC inoculated mice (thalamus/hypothalamus, section 
4.3.1.1 (page 68), and pons/medulla, section 4.3.2.1 (page 74)), where non-neuronal 
cells around the needle tract such as glial cells or astrocytes were more infected than 
neuronal cells with apparently little or no cell-to-cell viral spread (centrifugal spread). 
Using the microfluidic chamber culture system, axons of hSCARB2 motor 
neurons were directed to grow away from respective neuronal bodies into a fluidically 
isolated environment, designated as axon terminal chamber (contained only axon 
terminals). Whereas, the original motor neuron cells seeding chamber was designated as 
cell body chamber (contained mainly cell bodies). When virus was introduced into the 
axon terminal chamber, replicating virus was detected in the cell body chamber (Figure 
4.23 page 86). In contrast, no replicating virus was detected in the axon terminal 
chamber after introduction of virus into the cell body chamber. In addition, cell body 
chamber viral titres did not show significant differences at all timepoints implying 
replication of EV-A71 in neuronal cells may be limited. Overall, this strongly suggests 
retrograde axonal transport of virus from axon terminal to cell body but not in the 
reverse direction. It is well known that microtubules are oriented with the (+) end at 
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axon terminal, and the (−) end toward the cell body. The kinesin family of motor 
proteins generally mediates (+) end-directed anterograde transport (from the cell body 
to the axon terminus), and dynein motor complexes generally mediate (−) end-directed 
retrograde transport (from axon terminus to cell body). If it is true that EV-A71 is 
transported in a retrograde fashion, after axonal terminal entry, virus particles must use 
the dynein motor complexes to move along microtubules toward the cell body (Kapitein 
& Hoogenraad, 2011). It has been found that another picornavirus, poliovirus, binds the 
dynein light chain Tctex-1 to engage the retrograde transport machinery (Ohka et al., 
2004) via the poliovirus cellular receptor, CD155, which is endocytosed along with the 
virion. However, other neurotropic viruses such as the rabies virus could directly bind to 
the LC8 dynein light chain (part of the dynein motor complexes) for retrograde 
transport, without endocytic vesicles. As there is no information about EV-A71 
retrograde transport to date, further investigations are needed. We also speculate that the 
virus may not utilise the kinesin motor complexes for anterograde transport as shown by 
our microfluidic chamber data.  
Another possible explanation for no apparent anterograde transport of virus from 
the neuronal cell body to the axon terminal (Figure 4.23 (page 86)) may be that viral 
receptors, like SCARB2 and other receptor(s), are under or not expressed on the cell 
body. It has been reported that many viral endocytic cellular receptors are concentrated 
at nerve or axonal terminals including CD155 for poliovirus, and adenovirus receptor 
for coxsackievirus (Koyuncu, Hogue, & Enquist, 2013) thus favouring retrograde 
transport. Currently, we have no information on the distribution/expression of EV-A71 
receptors on neuronal cell bodies and axon terminals in our Tg mouse. 
In conclusion, at least in this mouse model, we believe the viral transmission 
into the CNS is mainly due to retrograde axonal transport from peripheral nerves. Virus 
spread into the CNS by a haematogenous/BBB route cannot be excluded completely, 
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since Volle et al. (2015) has found that human cerebral microvascular endothelial cells 
were infectable by EV-A71. If a haematogenous/BBB route into the CNS is involved, 
following viraemia, all CNS neurons should be theoretically more or less equally 
exposed to virus, and therefore have a similar chance to be infected. In all our mouse in 
vivo infection experiments, although there was high viraemia, widespread neuronal 
infection, for example, in the isocortex (cerebral hemisphere), was not observed at all 
time points. Instead, spinal cords and brainstem neurons were the most severely infected. 
As we have discussed earlier, we also believe that neuronal infection may not be related 
to the distribution/density of mSCARB2 (Yu et al., 2014). Moreover, our MAVS may 
use an unknown non-mSCARB2 receptor (s) (Fields et al., 2013) for viral entry.  
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5.3 Enterovirus 71 Provocation Acute Flaccid Paralysis 
Provocation poliomyelitis had been linked to multiple IM-injections of various 
therapeutic agents or vaccines administered, predisposing patients who have concurrent 
poliovirus infection to AFP (Gromeier & Wimmer, 1998). It was thought that injured 
muscle tissues may increase poliovirus propagation and retrograde axonal transport up 
the peripheral nerves to cause this phenomenon. We speculated that muscle trauma 
could likewise predispose patients with EV-A71 infection to AFP similar to provocation 
poliomyelitis. 
 Using a mouse model developed for the study of EV-A71 provocation AFP 
(Section 4.5.1, page 87), the non-traumatised control mice only showed paralysis from 
72 hpi onwards. In the repeatedly traumatised mouse group, the onset of paralysis was 
no different from the control group. The degree of myositis and density of viral antigens 
in skeletal muscles were the same between traumatised and non-traumatised groups. 
Similarly, viral antigens in the spinal cords were the same. Hence, the results showed 
that muscle injury did not seem to lead to increased viral replication in skeletal muscles 
and spinal cords, or increased retrograde transmission, suggesting that EV-A71 
provocation AFP did not occur.  
Using an IV-inoculated, CD155-Tg mouse model for poliovirus infection, it was 
found that poliovirus replicated efficiently in the traumatised muscles but not at all in 
non-traumatised muscles (Gromeier & Wimmer, 1998). This increase of virus growth in 
traumatised muscles was thought to increase retrograde axonal transport of poliovirus 
into the spinal cord to give rise to provocation poliomyelitis. The authors speculated 
that this may be due to increased poliovirus cellular binding in the muscles or increased 
viral load within inflamed muscle as a result of infiltrating inflammatory cells which 
were virus infected (Gromeier & Wimmer, 1998). Although EV-A71 possibly shares 
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the same retrograde axonal transmission pathway into the CNS, we are uncertain why 
our model did not show any evidence of provocation AFP. One possible reason may be 
the early and extensive infection in non-traumatised skeletal muscle seen in our model, 
may have obscured any further increase of viral replication as a result of trauma. As far 
as we are aware, EV-A71 provocation AFP has never been reported in humans but we 
believe it still remains a possibility. In human EV-A71 infection, there is apparently no 
evidence of myositis or skeletal muscle infection (Ong & Wong, 2015) but just like in 
the poliovirus Tg mouse model, IM-injections may increase viral replication in skeletal 
muscles leading to provocation paralysis.  
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5.4 Infectivity of EV-A71 (MAVS) in non-neuronal tissues  
In our MAVS mouse model, skeletal muscle ﬁbres showed remarkable degeneration, 
necrosis, varying degrees of inﬂammation and viral antigens/RNA. Although skeletal 
muscle infection has not been found in humans so far, EV-A71 had been reported to 
exhibit strong myotropism in mouse, hamster, monkey and gerbil models infected with 
clinical isolates of EV-A71 and/or adapted virus strains (Phyu et al., 2016; Y. F. Wang 
& Yu, 2014). Tg and immuno-deficient mouse models also showed myotropism (Y. F. 
Wang & Yu, 2014). Interestingly, skeletal muscle infection was reported in younger 
mice only (Y. F. Wang & Yu, 2014). In addition, human rhabdomyosarcoma cell lines 
(neoplastic cells with skeletal muscle differentiation) are readily susceptible to EV-A71, 
and have been used extensively by other investigators and us for virus isolation and 
detection (Leong & Chow, 2006).  
We produced a light-sensitive virus which could infect and replicate in cells as 
usual, but newly-synthesised viruses will not be light-sensitive. Therefore, light-
protected virus titres would include both original and newly-synthesised virus, whereas 
light-treated virus titres were all newly-synthesised viruses. The results in section 4.5.2 
(page 92) demonstrated a high replication rate of virus in skeletal muscles, and light-
treated virus titres were not significantly (P< 0.05) different from light-protected titres 
at all time points. Thus, most of the isolated viruses were newly-synthesised (> 90%). 
Furthermore, virus isolated from the lower spinal cords were mostly newly-synthesised 
viruses (Figure 4.27, page 91). These results suggested that the inoculated virus 
replicated very efficiently in the injected muscles to produce a large amount of virus 
progeny which then underwent retrograde transport to the lower spinal cord. These 
observations confirmed the IHC and ISH findings that skeletal muscles are highly 
susceptible to infection. The exact pathogenic mechanisms involved in the skeletal 
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muscle infection and injury by EV-A71, and its role in retrograde axonal transport into 
the CNS is currently unknown (section 5.1, page 114). 
Similar to the skeletal muscle infection, EV-A71 could replicate extensively in 
murine brown adipose tissues, which was also seen in coxsackieviruses, 
cytomegalovirus and rabies (Aronson & Shwartzman, 1956; Botvinkin, Nikiforova, & 
Sidorov, 1985; Bruggeman, Bruning, Grauls, van den Bogaard, & Bosman, 1987; 
Roberts & Boyd, 1987). In the mouse model, both skeletal muscle and brown adipose 
tissue infection are probably important primary replication sites contributing to 
persistent high viraemia. Again, there is no information on viral replication in human 
adipose tissues so far. If human brown adipose tissues could be readily infected by EV-
A71, it is conceivable that the young children who have higher amounts of brown 
adipose tissues, could be predisposed to higher viraemia, and presumably more severe 
infection.  
In our mouse model, skin lesions were absent with no evidence of squamous 
epithelial cell infection. A few researchers had made observations of skin lesions in 
their animal models. However, to date, only 2 groups had found viral antigens/RNA in 
skin epidermis in a hamster model (Phyu et al., 2016) and a Tg mouse model (Fujii et 
al., 2013). Currently, there is no data on human epidermal squamous cell infection but 
virus has been cultured in fluid from skin vesicles suggesting that human epidermis is 
also susceptible to infection. Hence, the epidermis could be an important secondary 
viral replication site contributing significantly to viraemia. 
  In our mouse model, other major organs, including oral mucosa, gastrointestinal 
tissues, pancreas, liver, heart, lung, kidney, thymus, lymph nodes, Peyer’s patches and 
spleen were all negative for viral antigens/RNA. These observations had been reported 
in many different mouse models (Y. F. Wang & Yu, 2014). Interestingly, using the 
133 
 
same MAVS on a hamster model, Phyu et al. (2016), found widespread viral 
antigens/RNA in the squamous epithelium of the oral cavity and tongue but not in any 
large extent in gastrointestinal mucosa. Similarly, Fujii et al. (2013) also reported viral 
antigens in oral mucosa of a Tg mouse model. These recent findings are consistent with 
oropharyngeal lesions in HFMD and herpangina, and the fact that viruses could be 
readily isolated from throat swabs. In fact, higher oral viral yields than rectal swabs 
were often obtained (M. H. Ooi, Solomon, et al., 2007). Hence, it is probable that the 
virus first infects and undergoes primary replication in the oral cavity, although viral 
antigens within human oral mucosa has not been demonstrated before. Recently, Y. He 
et al. (2014) had shown the presence of viral antigens/RNA in human tonsillar crypt 
squamous epithelia, and suggested this as another important source of primary 
replication and oral viral shedding. In addition, salivary and lacrimal gland acinar cells 
in the hamster model can be infected suggesting that salivary and tear secretions could 
contribute to virus shedding, respectively.   
 In our mouse and other animal models, myocarditis and/or viral antigens/RNA 
were generally absent, or if present, usually very mild and focal, similar to human 
findings. Lymphoid cells found in lymph nodes, spleen, and Peyer’s patches (small 
intestine) may showed focal viral antigens/RNA and positive virus isolation in some of 
the animal models (Khong et al., 2012; Y. F. Wang & Yu, 2014; Zhang et al., 2011), 
including the Tg mouse model (Fujii et al., 2013) but so far there is no convincing 
evidence for antigens/RNA localisation in human lymphoid tissues. Further studies are 
needed to conﬁrm if lymphoid tissues are significant replication sites as was assumed to 
be the case in poliovirus infection. 
In conclusion, despite the relatively restricted tissue tropism compared to the 
hamster model and Tg mouse model, we believe our mouse model is useful to study 
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neuroinvasion and neuropathogenesis because the CNS findings were very similar to the 
pathology of human EV-A71 encephalomyelitis.  
 
5.5 Prevention and treatment of EV-A71 CNS infection 
Fatal EV-A71 encephalomyelitis and AFP often occur suddenly and within a few days 
of infection. Clinical observations suggested that some patients who are more likely to 
develop severe or fatal complications can be identified (C. C. Huang et al., 1999). In 
these patients, early preventive antiviral treatment could potentially reduce mortality 
and serious sequelae (M. H. Ooi, Wong, Lewthwaite, Cardosa, & Solomon, 2010). 
Since no licensed vaccines or effective antivirals are available, neutralising antibodies 
and other treatment modalities may be useful for this purpose.   
Several recent studies have demonstrated that treatment with specific polyclonal 
antibodies and MAbs were able to confer partial or complete protection to 
experimentally-infected mice, when given shortly after or before EV-A71 challenge 
(Table 5.3) (Bek et al., 2011; G. H. Chang et al., 2010; H. W. Chang et al., 2013; Foo et 
al., 2007; Y. X. Li et al., 2014; Z. Li et al., 2014; Liou et al., 2010; Ng et al., 2015; Tian 
et al., 2012; Xu et al., 2014). However, none of these studies have evaluated the 
effectiveness of treatment after encephalomyelitis has been established by CNS viral 
culture and/or demonstration of viral antigens/RNA. Instead, previous studies evaluated 
the effectiveness of treatment based solely on survival/health scores of murine models. 
This may not be sufficient since myositis as well as CNS infection is often severe in 
these models, and observed limb weakness/paralysis could be due to myositis and/or 
CNS infection. Incidentally, human EV71-associated myositis has not been reported so 
far, and encephalomyelitis is believed to be one of the major causes of death in EV71 
infection (K. T. Wong et al., 2008).  
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Our results showed that polyclonal antibodies could improve the survival rate of 
IM-infected mice with proven encephalomyelitis, by significantly reducing CNS viral 
titres and viral antigens/RNA (Figure 4.31, page 98; Figure 4.32, page 99). Furthermore, 
the distribution of viral antigens/RNA were more restricted compared to mock-treated 
controls. In addition, when polyclonal antibodies were given before MAVS infection, 
CNS infection was prevented (4 hr before infection). This was also shown in other 
studies (Deng et al., 2015; Dong et al., 2011; Kiener et al., 2014; Ong et al., 2010; Tian 
et al., 2012; Zhao et al., 2013). Polyclonal antibodies seem to be able to control and 
ameliorate CNS infection in a dose- and time- dependent manner.  
Polyclonal antibodies are subject to limited quantities, and poor reproducibility 
due to batch-to-batch variability in neutralising properties. In addition, inappropriate use 
of polyclonal antibodies could lead to allergic reactions, kidney failure and other serious 
complications (Orbach, Katz, Sherer, & Shoenfeld, 2005). Hence, we produced a MAb 
against EV-A71 to test on our IP-infected, 2-week-old mouse model, which consistently 
developed CNS infection (as confirmed by viral titres and pathological analysis) as 
early as 72 hpi and rapidly died at 120 hpi (Section 4.6.2, page 100).  
 All mice IP-treated at maximum doses of 120 µg of MAb before CNS infection 
(treated at 24, 48 and 72 hpi) remained healthy throughout the experiment. Skeletal 
muscle and brown adipose tissue infection were minimal, and CNS infection was 
prevented (Figure 4.36, page 109). The absence of CNS viral titres and viral 
antigens/RNA suggested that there was no significant CNS infection or retrograde 
axonal viral transmission up peripheral motor nerves. Inhibition of viraemia and viral 
replication by MAb were most probably responsible for this. Other previous studies in 
which pre-infection antibody treatments were given also prevented limb paralysis with 
no reported mortality (Deng et al., 2015; Dong et al., 2011; Kiener et al., 2014; Ng et al., 
2015; Ong et al., 2010; Tian et al., 2012; Zhao et al., 2013).  
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Table 5.3: Summary of studies on post-infection passive immunisation and treatment modalities in EV-A71 infected mice 
No. 
Treatment 
modality++ 
Mouse type 
Age at infection 
(days) /route* 
Untreated group Treated group 
CNS infection 
demonstrated@ 
Reference Duration of 
survival (days) 
Survival rate 
(%) 
Treatment 
started (hpi) 
Survival rate 
(%) 
1 Polyclonal Balb/c 1 / IP 1 - 7 0 1 70 ND¤ (Tian et al., 2012) 
2 Polyclonal Balb/c Neonatal / IC 5 - 9 0 4 100 ND (Y. X. Li et al., 2014) 
3 Polyclonal Balb/c 1 / IP 3 - 10 0 24 100 ND (Bek et al., 2011) 
4 Polyclonal Balb/c 1 / IP 3 - 10 0 24 80 ND (Foo et al., 2007) 
5 MAb Balb/c 1 / IP 5 - 12 9 24 100 ND (Xu et al., 2014) 
6 MAb Balb/c 2 / IP 3 - 8 0 24 69 ND 
(G. H. Chang et al., 
2010) 
7 MAb Balb/c 1 / IP 5 - 9 0 
24 100 
ND (Z. Li et al., 2014) 
72 100 
96 20 
96, 120, 144 50 
120, 144, 168 20 
8 MAb 
hSCARB2 
Tg 
7 / SC 6 - 7 0 
3 100 
ND 
(H. W. Chang et al., 
2013) 
24 90 
48 0 
9 IgY ICR 1 / IP nil 0 - 20 
24, 48, 72 100 
ND (Liou et al., 2010) 48, 72, 96 79 
72, 96, 120 20 
          
10 Polyclonal ICR 14 / IM 4 0 
12 50 
Yes 
Current study (Section 
4.6.1, page 94)  24 25 
11 MAb ICR 14 / IP 5 0 
24, 48 100 
No 
Current study (Section 
4.6.2, page 100) 
24, 48, 72 100 
72, 96 75 
Yes 
72, 96, 120 100 
++ polyclonal= polyclonal antibodies; MAb= monoclonal antibodies; IgY= functionality similar to mammalian IgG, is the major antibody in bird. 
* IP= intra-peritoneal; IC= intra-cerebral; SC= subcutaneous; IM= intra-muscular 
@ CNS infection demonstrated via histopathology analysis (IHC and ISH), virus titres and/or viral copy numbers (real-time PCR). 
¤ ND = Not done
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We found that optimal MAb treatment was still useful to ameliorate disease 
even after CNS infection was established at 72 hpi. Mice given the 3-dose regime (at 72, 
96 and 120 hpi) (Table 5.3) showed lower clinical scores compared to mock-treated 
control mice (all mice were moribund and sacrificed at 96 hpi) (Figure 4.34, page 105). 
Even at 144 hpi (a day after the treatment was completed), viral titres/RNA and antigens 
from sacrificed animals were significantly lower in all tissues examined compared to 
mock-treated animals sacrificed at 96 hpi (Figure 4.37 (page 111), 4.38, (page 111), 
4.39, (page 112)). Moreover, viral antigens/RNA were restricted to smaller areas of the 
brainstem and hypothalamus (Figure 4.35, page 108). In the 4 animals from the same 
experiment which were not sacrificed at 144 hpi but followed up for 21 dpi, only a 
single mouse showed minor weakness on both hindlimbs, while the others recovered 
completely from limb paralysis. As expected, mice treated earlier at 24, 48 and 72 hpi, 
presented better clinical scores and no evidence of CNS infection (Table 5.3).  
Although not directly comparable to our studies, most other studies showed a 
similar dose- and time-dependent response to treatment (Table 5.3). Z. Li et al. (2014) 
tested a 3-dose treatment protocol on infected mice, in a study whose design is similar 
to ours although their untreated mice survived infection longer, from 5 to 9 dpi. An 
increase in treatment dose and frequency, had increased the survival rate from 20% to 
50%. Surviving mice were either healthy throughout the experiment or showed only 
minor paralysis/reduced body weight, followed by complete recovery at 21 dpi. 
Unfortunately, no information on CNS infection was available. 
Although the mechanism of virus elimination from the CNS is uncertain, 
theoretically, the antibodies could i) reduce neuronal infection, by reducing retrograde 
axonal transport into the CNS; ii) by eliminating viruses in infected neurons; and iii) by 
preventing viral spread from infected to uninfected neurons. Whether these antibodies 
were involved in virus elimination from infected neurons or prevention of virus spread 
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in the CNS parenchyma is uncertain, as it is generally assumed that IgM is too large to 
cross the healthy BBB into the CNS. However, alteration of BBB permeability as a 
result of pro-inflammatory cytokines such as TNF, IL-1β and IL-6, could allow 
antibodies to enter the CNS parenchyma (de Vries, Kuiper, de Boer, Van Berkel, & 
Breimer, 1997). Alternatively, as shown in, previous studies the rat BBB is not fully 
developed until four weeks postnatal (Schulze & Firth, 1992). The immature BBB in 2-
week-old mice may facilitate movement of antibodies into the parenchyma (Saunders, 
Liddelow, & Dziegielewska, 2012). Whether some or all these factors could impact on 
future successful development of antibody therapy using the same approach in patients 
needs to be further investigated. 
In conclusion, our results highlight the potential use of MAbs as an effective 
treatment for EV-A71 before and after CNS infection in our mouse model. Further 
investigations are needed to determine the usefulness of a humanised monoclonal IgG 
as a prophylactic and/or therapeutic agent against EV-A71 encephalomyelitis. 
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6.0 Conclusion 
EV-A71 could cause rapid and direct brainstem infection, most likely via retrograde 
axonal transport in the motor components of cranial nerves in our EV-A71 
encephalomyelitis mouse model. Surprisingly, direct inoculation of virus into the CNS 
parenchyma, including the brainstem, did not result in efficient neuron-to-neuron 
centrifugal spread from the needle tract. Moreover, there appears to be no clear 
correlation between mSCARB2 and EV-A71 antigen distribution suggesting possible 
involvement of other unknown viral entry receptors and/or co-receptors. EV-A71 
provocation AFP, if any, could not be demonstrated in our mouse model as there was no 
significant increased viral infection of the spinal cord following muscle traumatic injury. 
CNS infection by EV-A71 can be prevented and established CNS infection ameliorated 
by neutralising MAb. All treated mice with CNS infection survived with better clinical 
scores and less pathological changes and evidence of virus infection. 
 
7.0 Limitation and future studies 
1. Experimentally infected mice may not be able to model human infection completely.  
Since pulmonary oedema and skin lesions were not observed in our mouse model. 
However neuronotropism in the CNS shared many features with human 
encephalomyelitis. Hence, our mouse model remains valid and useful for gaining 
further insights into EV-A71 neuropathogenesis. Nonetheless, our findings should 
be confirmed in more recently described transgenic mouse model (Fujii et al., 2013) 
or orally-infected hamster model (Phyu et al., 2016). 
2. The mechanisms of retrograde axonal transport in EV-A71 CNS infection,viral 
transport across neuromuscular junction and transsynaptic transmission need to be 
investigated. 
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3. The relatively low infectivity of motor neuron cell bodies should be further 
investigated. 
4. EV-A71 provocation AFP was not shown in our mouse model could be due to early 
and extensive infection in non-traumatised muscle. The experiment could be 
repeated with transgenic mouse model which demonstrated lesser muscle infection 
(Fujii et al., 2013). 
5. Mouse MAb was not fully characterised and its mechanism of action is not clear. 
Further investigations are needed to determine the usefulness of a humanised MAb 
as a therapeutic agent against human EV-A71 encephalomyelitis.
141 
 
References 
Adams, M. J., King, A. M., & Carstens, E. B. (2013). Ratification vote on taxonomic 
proposals to the International Committee on Taxonomy of Viruses (2013). Arch 
Virol, 158(9), 2023-2030. 
 
Arita, M., Ami, Y., Wakita, T., & Shimizu, H. (2008). Cooperative effect of the 
attenuation determinants derived from poliovirus sabin 1 strain is essential for 
attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol, 
82(4), 1787-1797. 
 
Arita, M., Nagata, N., Iwata, N., Ami, Y., Suzaki, Y., Mizuta, K., . . . Shimizu, H. 
(2007). An attenuated strain of enterovirus 71 belonging to genotype a showed a 
broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus 
monkeys. J Virol, 81(17), 9386-9395. 
 
Arita, M., Shimizu, H., Nagata, N., Ami, Y., Suzaki, Y., Sata, T., . . . Miyamura, T. 
(2005). Temperature-sensitive mutants of enterovirus 71 show attenuation in 
cynomolgus monkeys. J Gen Virol, 86(5), 1391-1401. 
 
Aronson, S. M., & Shwartzman, G. (1956). The histopathology of brown fat in 
experimental poliomyelitis. Am J Pathol, 32(2), 315-333. 
 
Baker, A. B. (1957). Poliomyelitis. 16. A study of pulmonary edema. Neurology, 7(11), 
743-751. 
 
Bedard, K. M., & Semler, B. L. (2004). Regulation of picornavirus gene expression. 
Microbes Infect, 6(7), 702-713. 
 
Bek, E. J., Hussain, K. M., Phuektes, P., Kok, C. C., Gao, Q., Cai, F., . . . McMinn, P. C. 
(2011). Formalin-inactivated vaccine provokes cross-protective immunity in a 
mouse model of human enterovirus 71 infection. Vaccine, 29(29-30), 4829-4838. 
 
Botvinkin, A. D., Nikiforova, T. A., & Sidorov, G. N. (1985). Experimental rabies in 
hibernator rodents. Acta Virol, 29(1), 44-50. 
 
Brown, B. A., Oberste, M. S., Alexander, J. P., Jr., Kennett, M. L., & Pallansch, M. A. 
(1999). Molecular epidemiology and evolution of enterovirus 71 strains isolated 
from 1970 to 1998. J Virol, 73(12), 9969-9975. 
 
Bruggeman, C. A., Bruning, J. H., Grauls, G., van den Bogaard, A. E., & Bosman, F. 
(1987). Presence of cytomegalovirus in brown fat. Study in a rat model. 
Intervirology, 27(1), 32-37. 
 
Caine, E. A., Partidos, C. D., Santangelo, J. D., & Osorio, J. E. (2013). Adaptation of 
enterovirus 71 to adult interferon deficient mice. PLoS One, 8(3), e59501. 
 
Cao, R., Han, J., Deng, Y., Yu, M., Qin, E., & Qin, C. (2010). Presence of high-titer 
neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin 
manufactured from Chinese donors. Clin Infect Dis, 50(1), 125-126. 
142 
 
Cao, R., Han, J., Qin, E., & Qin, C. (2011). [Mechanism of intravenous 
immunoglobulin therapy for severe hand-foot-mouth disease: a review]. Sheng 
Wu Gong Cheng Xue Bao, 27(5), 712-716. 
 
Cao, R. Y., Dong, D. Y., Liu, R. J., Han, J. F., Wang, G. C., Zhao, H., . . . Qin, C. F. 
(2013). Human IgG subclasses against enterovirus Type 71: neutralization 
versus antibody dependent enhancement of infection. PLoS One, 8(5), e64024. 
 
Cardosa, M. J., Perera, D., Brown, B. A., Cheon, D., Chan, H. M., Chan, K. P., . . . 
McMinn, P. (2003). Molecular epidemiology of human enterovirus 71 strains 
and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 
and VP4 genes. Emerg Infect Dis, 9(4), 461-468. 
 
Chang, G. H., Luo, Y. J., Wu, X. Y., Si, B. Y., Lin, L., & Zhu, Q. Y. (2010). 
Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice 
against lethal EV71-Hn2 virus infection. Virol J, 7, 106. 
 
Chang, H. W., Lin, Y. W., Ho, H. M., Lin, M. H., Liu, C. C., Shao, H. Y., . . . Chow, Y. 
H. (2013). Protective efficacy of VP1-specific neutralizing antibody associated 
with a reduction of viral load and pro-inflammatory cytokines in human 
SCARB2-transgenic mice. PLoS One, 8(7), e69858. 
 
Chang, S. C., Lin, J. Y., Lo, L. Y., Li, M. L., & Shih, S. R. (2004). Diverse apoptotic 
pathways in enterovirus 71-infected cells. J Neurovirol, 10(6), 338-349. 
 
Chen, C. S., Yao, Y. C., Lin, S. C., Lee, Y. P., Wang, Y. F., Wang, J. R., . . . Yu, C. K. 
(2007). Retrograde axonal transport: a major transmission route of enterovirus 
71 in mice. J Virol, 81(17), 8996-9003. 
 
Chen, F., Li, J. J., Liu, T., Wen, G. Q., & Xiang, W. (2013). Clinical and neuroimaging 
features of enterovirus71 related acute flaccid paralysis in patients with hand-
foot-mouth disease. Asian Pac J Trop Med, 6(1), 68-72. 
 
Chen, H., Zhang, Y., Yang, E., Liu, L., Che, Y., Wang, J., . . . Li, Q. (2012). The effect 
of enterovirus 71 immunization on neuropathogenesis and protein expression 
profiles in the thalamus of infected rhesus neonates. Virology, 432(2), 417-426. 
 
Chen, N., & Reis, C. S. (2002). Distinct roles of eicosanoids in the immune response to 
viral encephalitis: or why you should take NSAIDS. Viral Immunol, 15(1), 133-
146. 
 
Chen, P., Song, Z., Qi, Y., Feng, X., Xu, N., Sun, Y., . . . Li, W. (2012). Molecular 
determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 
protein interacts with variable region on scavenge receptor B 2. J Biol Chem, 
287(9), 6406-6420. 
 
Chen, Y. C., Yu, C. K., Wang, Y. F., Liu, C. C., Su, I. J., & Lei, H. Y. (2004). A murine 
oral enterovirus 71 infection model with central nervous system involvement. J 
Gen Virol, 85(1), 69-77. 
 
143 
 
Chu, W. M., Ostertag, D., Li, Z. W., Chang, L., Chen, Y., Hu, Y., . . . Karin, M. (1999). 
JNK2 and IKKbeta are required for activating the innate response to viral 
infection. Immunity, 11(6), 721-731. 
 
Chua, B. H., Phuektes, P., Sanders, S. A., Nicholls, P. K., & McMinn, P. C. (2008). The 
molecular basis of mouse adaptation by human enterovirus 71. J Gen Virol, 
89(7), 1622-1632. 
 
Chua, K. B., Chua, B. H., Lee, C. S., Chem, Y. K., Ismail, N., Kiyu, A., & Kumarasamy, 
V. (2007). Genetic diversity of enterovirus 71 isolated from cases of hand, foot 
and mouth disease in the 1997, 2000 and 2005 outbreaks, Peninsular Malaysia. 
Malays J Pathol, 29(2), 69-78. 
 
Chung, C. Y., Chen, C. Y., Lin, S. Y., Chung, Y. C., Chiu, H. Y., Chi, W. K., . . . Hu, Y. 
C. (2010). Enterovirus 71 virus-like particle vaccine: improved production 
conditions for enhanced yield. Vaccine, 28(43), 6951-6957. 
 
Collins, F. M. (1974). Vaccines and cell-mediated immunity. Bacteriol Rev, 38(4), 371-
402. 
 
Conn, P. Michael, & SpringerLink. (2008). Neuroscience in medicine (3rd ed.). Totowa, 
NJ: Humana Press. 
 
de Vries, H. E., Kuiper, J., de Boer, A. G., Van Berkel, T. J., & Breimer, D. D. (1997). 
The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev, 49(2), 
143-155. 
 
Deng, Y. Q., Ma, J., Xu, L. J., Li, Y. X., Zhao, H., Han, J. F., . . . Qin, C. F. (2015). 
Generation and characterization of a protective mouse monoclonal antibody 
against human enterovirus 71. Appl Microbiol Biotechnol, 99(18), 7663-7671. 
 
Dong, C., Liu, L., Zhao, H., Wang, J., Liao, Y., Zhang, X., . . . Li, Q. (2011). 
Immunoprotection elicited by an enterovirus type 71 experimental inactivated 
vaccine in mice and rhesus monkeys. Vaccine, 29(37), 6269-6275. 
 
Dotzauer, A., & Kraemer, L. (2012). Innate and adaptive immune responses against 
picornaviruses and their counteractions: An overview. World J Virol, 1(3), 91-
107. 
 
Elgert, K.D. (2009). Immunology: Understanding The Immune System. New York: 
Wiley. 
 
Fan, P., Li, X., Sun, S., Su, W., An, D., Gao, F., . . . Jiang, C. (2015). Identification of a 
common epitope between enterovirus 71 and human MED25 proteins which 
may explain virus-associated neurological disease. Viruses, 7(4), 1558-1577. 
 
Fields, B.N., Knipe, D.M., & Howley, P.M. (2013). Fields Virology (6th ed.): United 
kingdon: Wolters Kluwer Health. 
 
Foo, D. G., Alonso, S., Chow, V. T., & Poh, C. L. (2007). Passive protection against 
lethal enterovirus 71 infection in newborn mice by neutralizing antibodies 
elicited by a synthetic peptide. Microbes Infect, 9(11), 1299-1306. 
144 
 
Fu, Y. C., Chi, C. S., Chiu, Y. T., Hsu, S. L., Hwang, B., Jan, S. L., . . . Chang, Y. 
(2004). Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child, 
89(4), 368-373. 
 
Fu, Y. C., Chi, C. S., Lin, N. N., Cheng, C. C., Jan, S. L., Hwang, B., . . . Chiu, Y. T. 
(2006). Comparison of heart failure in children with enterovirus 71 
rhombencephalitis and cats with norepinephrine cardiotoxicity. Pediatr Cardiol, 
27(5), 577-584. 
 
Fujii, K., Nagata, N., Sato, Y., Ong, K. C., Wong, K. T., Yamayoshi, S., . . . Koike, S. 
(2013). Transgenic mouse model for the study of enterovirus 71 
neuropathogenesis. Proc Natl Acad Sci U S A, 110(36), 14753-14758. 
 
Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R. A., . . . Colonna, 
M. (2006). Essential role of mda-5 in type I IFN responses to 
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. 
Proc Natl Acad Sci U S A, 103(22), 8459-8464. 
 
Gong, X., Zhou, J., Zhu, W., Liu, N., Li, J., Li, L., . . . Duan, Z. (2012). Excessive 
proinflammatory cytokine and chemokine responses of human monocyte-
derived macrophages to enterovirus 71 infection. BMC Infect Dis, 12, 224. 
 
Gorson, K. C., & Ropper, A. H. (2001). Nonpoliovirus poliomyelitis simulating 
Guillain-Barre syndrome. Arch Neurol, 58(9), 1460-1464. 
 
Gromeier, M., & Wimmer, E. (1998). Mechanism of injury-provoked poliomyelitis. J 
Virol, 72(6), 5056-5060. 
 
Han, J. F., Cao, R. Y., Deng, Y. Q., Tian, X., Jiang, T., Qin, E. D., & Qin, C. F. (2011). 
Antibody dependent enhancement infection of enterovirus 71 in vitro and in 
vivo. Virol J, 8, 106. 
 
He, D. L., Xia, N. S., Xu, F. H., Cheng, T., Weng, Z. X., Ge, S. X., . . . Chen, Z. M. . 
(2012). Enterovirus 71 neutralized epitope polypeptide and application thereof: 
Google Patents. 
 
He, Y., Ong, K. C., Gao, Z., Zhao, X., Anderson, V. M., McNutt, M. A., . . . Lu, M. 
(2014). Tonsillar crypt epithelium is an important extra-central nervous system 
site for viral replication in EV71 encephalomyelitis. Am J Pathol, 184(3), 714-
720. 
 
Heimer, Lennart. (1995). The human brain and spinal cord : functional neuroanatomy 
and dissection guide (2nd ed.). New York ; London: Springer. 
 
Hemming, V. G. (2001). Use of intravenous immunoglobulins for prophylaxis or 
treatment of infectious diseases. Clin Diagn Lab Immunol, 8(5), 859-863. 
 
Hinson, V. K., & Tyor, W. R. (2001). Update on viral encephalitis. Curr Opin Neurol, 
14(3), 369-374. 
 
Ho, M. (2000). Enterovirus 71: the virus, its infections and outbreaks. J Microbiol 
Immunol Infect, 33(4), 205-216. 
145 
 
Hoff, J. T., Nishimura, M., Garcia-Uria, J., & Miranda, S. (1981). Experimental 
neurogenic pulmonary edema. Part 1: The role of systemic hypertension. J 
Neurosurg, 54(5), 627-631. 
 
Huang, C. C. (2001). Neurologic complications of enterovirus 71 infection in children: 
lessons from this Taiwan epidemic. Acta Paediatr Taiwan, 42(1), 5-7. 
 
Huang, C. C., Liu, C. C., Chang, Y. C., Chen, C. Y., Wang, S. T., & Yeh, T. F. (1999). 
Neurologic complications in children with enterovirus 71 infection. N Engl J 
Med, 341(13), 936-942. 
 
Huang, H. I., Lin, J. Y., Chen, H. H., Yeh, S. B., Kuo, R. L., Weng, K. F., & Shih, S. R. 
(2014). Enterovirus 71 infects brain-derived neural progenitor cells. Virology, 
468-470, 592-600. 
 
Jackson, Alan C. (2013). Viral infections of the human nervous system Birkhäuser 
advances in infectious diseases (pp. 1 online resource). Retrieved from 
http://eproxy.lib.hku.hk/login?url=http://link.springer.com/openurl?genre=book
&isbn=978-3-0348-0424-0  
 
Jarvis, D. L. (2009). Baculovirus-insect cell expression systems. Methods Enzymol, 463, 
191-222. 
 
Jiao, X. Y., Guo, L., Huang, D. Y., Chang, X. L., & Qiu, Q. C. (2014). Distribution of 
EV71 receptors SCARB2 and PSGL-1 in human tissues. Virus Res, 190, 40-52. 
 
John, T. J., & Vashishtha, V. M. (2013). Eradicating poliomyelitis: India's journey from 
hyperendemic to polio-free status. Indian J Med Res, 137(5), 881-894. 
 
Jolles, S., Sewell, W. A., & Misbah, S. A. (2005). Clinical uses of intravenous 
immunoglobulin. Clin Exp Immunol, 142(1), 1-11. 
 
Kao, S. J., Yang, F. L., Hsu, Y. H., & Chen, H. I. (2004). Mechanism of fulminant 
pulmonary edema caused by enterovirus 71. Clin Infect Dis, 38(12), 1784-1788. 
 
Kapitein, L. C., & Hoogenraad, C. C. (2011). Which way to go? Cytoskeletal 
organization and polarized transport in neurons. Mol Cell Neurosci, 46(1), 9-20. 
 
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., . . . Akira, 
S. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of 
RNA viruses. Nature, 441(7089), 101-105. 
 
Kemball, C. C., Alirezaei, M., & Whitton, J. L. (2010). Type B coxsackieviruses and 
their interactions with the innate and adaptive immune systems. Future 
Microbiol, 5(9), 1329-1347. 
 
Khong, W. X., Yan, B., Yeo, H., Tan, E. L., Lee, J. J., Ng, J. K., . . . Alonso, S. (2012). 
A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, 
causing neurological manifestations in a novel mouse model of EV71 infection. 
J Virol, 86(4), 2121-2131. 
146 
 
Kiener, T. K., Jia, Q., Meng, T., Chow, V. T., & Kwang, J. (2014). A novel universal 
neutralizing monoclonal antibody against enterovirus 71 that targets the highly 
conserved "knob" region of VP3 protein. PLoS Negl Trop Dis, 8(5), e2895. 
 
Kim, Y. I., Song, J. H., Kwon, B. E., Kim, H. N., Seo, M. D., Park, K., . . . Chang, S. Y. 
(2015). Pros and cons of VP1-specific maternal IgG for the protection of 
Enterovirus 71 infection. Vaccine, 33(48), 6604-6610. 
 
Koyuncu, O. O., Hogue, I. B., & Enquist, L. W. (2013). Virus infections in the nervous 
system. Cell Host Microbe, 13(4), 379-393. 
 
Ku, Z., Ye, X., Huang, X., Cai, Y., Liu, Q., Li, Y., . . . Huang, Z. (2013). Neutralizing 
antibodies induced by recombinant virus-like particles of enterovirus 71 
genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One, 8(2), 
e57601. 
 
Lancaster, K. Z., & Pfeiffer, J. K. (2010). Limited trafficking of a neurotropic virus 
through inefficient retrograde axonal transport and the type I interferon response. 
PLoS Pathog, 6(3), e1000791. 
 
Lee, H., Cifuente, J. O., Ashley, R. E., Conway, J. F., Makhov, A. M., Tano, Y., . . . 
Hafenstein, S. (2013). A strain-specific epitope of enterovirus 71 identified by 
cryo-electron microscopy of the complex with fab from neutralizing antibody. J 
Virol, 87(21), 11363-11370. 
 
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., . . . Jones, 
A. R. (2007). Genome-wide atlas of gene expression in the adult mouse brain. 
Allen Mouse Brain Atlas. Retrieved from http://mouse.brain-
map.org/experiment/show/72081482 
 
Leong, W. F., & Chow, V. T. (2006). Transcriptomic and proteomic analyses of 
rhabdomyosarcoma cells reveal differential cellular gene expression in response 
to enterovirus 71 infection. Cell Microbiol, 8(4), 565-580. 
 
Levinson, W., & Jawetz, E. (1992). Medical Microbiology & Immunology: Examination 
and Board Review. Boston: Appleton & Lange. 
 
Li, M. L., Hsu, T. A., Chen, T. C., Chang, S. C., Lee, J. C., Chen, C. C., . . . Shih, S. R. 
(2002). The 3C protease activity of enterovirus 71 induces human neural cell 
apoptosis. Virology, 293(2), 386-395. 
 
Li, Y. X., Zhao, H., Cao, R. Y., Deng, Y. Q., Han, J. F., Zhu, S. Y., . . . Qin, C. F. 
(2014). Recombinant tandem multi-linear neutralizing epitopes of human 
enterovirus 71 elicited protective immunity in mice. Virol J, 11, 79. 
 
Li, Z., Xu, L., He, D., Yang, L., Liu, C., Chen, Y., . . . Xia, N. (2014). In Vivo Time-
Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody 
against Lethal Enterovirus 71 Infection in a Mouse Model. PLoS One, 9(10), 
e109391. 
 
147 
 
Liang, C. C., Sun, M. J., Lei, H. Y., Chen, S. H., Yu, C. K., Liu, C. C., . . . Yeh, T. M. 
(2004). Human endothelial cell activation and apoptosis induced by enterovirus 
71 infection. J Med Virol, 74(4), 597-603. 
 
Liang, Z., & Wang, J. (2014). EV71 vaccine, an invaluable gift for children. Clin Transl 
Immunology, 3(10), e28. 
 
Lim, X. F., Jia, Q., Khong, W. X., Yan, B., Premanand, B., Alonso, S., . . . Kwang, J. 
(2012). Characterization of an isotype-dependent monoclonal antibody against 
linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. 
PLoS One, 7(1), e29751. 
 
Lin, S. Y., Yeh, C. T., Li, W. H., Yu, C. P., Lin, W. C., Yang, J. Y., . . . Hu, Y. C. 
(2015). Enhanced enterovirus 71 virus-like particle yield from a new baculovirus 
design. Biotechnol Bioeng, 112(10), 2005-2015. 
 
Lin, T. Y., Chang, L. Y., Hsia, S. H., Huang, Y. C., Chiu, C. H., Hsueh, C., . . . Wu, M. 
H. (2002). The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and 
management. Clin Infect Dis, 34 Suppl 2, S52-57. 
 
Lin, T. Y., Chang, L. Y., Huang, Y. C., Hsu, K. H., Chiu, C. H., & Yang, K. D. (2002). 
Different proinflammatory reactions in fatal and non-fatal enterovirus 71 
infections: implications for early recognition and therapy. Acta Paediatr, 91(6), 
632-635. 
 
Lin, T. Y., Hsia, S. H., Huang, Y. C., Wu, C. T., & Chang, L. Y. (2003). 
Proinflammatory cytokine reactions in enterovirus 71 infections of the central 
nervous system. Clin Infect Dis, 36(3), 269-274. 
 
Lin, Y. W., Wang, S. W., Tung, Y. Y., & Chen, S. H. (2009). Enterovirus 71 infection 
of human dendritic cells. Exp Biol Med (Maywood), 234(10), 1166-1173. 
 
Lin, Y. W., Yu, S. L., Shao, H. Y., Lin, H. Y., Liu, C. C., Hsiao, K. N., . . . Chow, Y. H. 
(2013). Human SCARB2 transgenic mice as an infectious animal model for 
enterovirus 71. PLoS One, 8(2), e57591. 
 
Liou, J. F., Chang, C. W., Tailiu, J. J., Yu, C. K., Lei, H. Y., Chen, L. R., & Tai, C. 
(2010). Passive protection effect of chicken egg yolk immunoglobulins on 
enterovirus 71 infected mice. Vaccine, 28(51), 8189-8196. 
 
Liu, C. C., Chou, A. H., Lien, S. P., Lin, H. Y., Liu, S. J., Chang, J. Y., . . . Chong, P. 
(2011). Identification and characterization of a cross-neutralization epitope of 
Enterovirus 71. Vaccine, 29(26), 4362-4372. 
 
Liu, J., Dong, W., Quan, X., Ma, C., Qin, C., & Zhang, L. (2012). Transgenic 
expression of human P-selectin glycoprotein ligand-1 is not sufficient for 
enterovirus 71 infection in mice. Arch Virol, 157(3), 539-543. 
 
Liu, L., Mo, Z., Liang, Z., Zhang, Y., Li, R., Ong, K. C., . . . Li, Q. (2015). Immunity 
and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese 
children: a report of further observations. BMC Med, 13(1), 226. 
148 
 
Lu, M., Meng, G., He, Y. X., Zheng, J., Liao, S. L., Zhong, Y. F., . . . Gao, Z. F. (2009). 
[Pathology of enterovirus 71 infection: an autopsy study of 5 cases]. Zhonghua 
Bing Li Xue Za Zhi, 38(2), 81-85. 
 
Lum, L. C., Wong, K. T., Lam, S. K., Chua, K. B., & Goh, A. Y. (1998). Neurogenic 
pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet, 352(9137), 
1391. 
 
Luo, S. T., Chiang, P. S., Chao, A. S., Liou, G. Y., Lin, R., Lin, T. Y., & Lee, M. S. 
(2009). Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis, 
15(4), 581-584. 
 
Mao, Q. Y., Wang, Y., Bian, L., Xu, M., & Liang, Z. (2016). EV71 vaccine, a new tool 
to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev 
Vaccines, 15(5), 599-606. 
 
Mawdsley, S. E. (2014). Polio provocation: solving a mystery with the help of history. 
Lancet, 384(9940), 300-301. 
 
McMinn, P. C. (2002). An overview of the evolution of enterovirus 71 and its clinical 
and public health significance. FEMS Microbiol Rev, 26(1), 91-107. 
 
McMinn, P., Stratov, I., Nagarajan, L., & Davis, S. (2001). Neurological manifestations 
of enterovirus 71 infection in children during an outbreak of hand, foot, and 
mouth disease in Western Australia. Clin Infect Dis, 32(2), 236-242. 
 
Meng, T., Kolpe, A. B., Kiener, T. K., Chow, V. T., & Kwang, J. (2011). Display of 
VP1 on the surface of baculovirus and its immunogenicity against heterologous 
human enterovirus 71 strains in mice. PLoS One, 6(7), e21757. 
 
Nathanson, N., & Langmuir, A. D. (1995). The Cutter incident. Poliomyelitis following 
formaldehyde-inactivated poliovirus vaccination in the United States during the 
Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J 
Epidemiol, 142(2), 109-140. 
 
Ng, Q., He, F., & Kwang, J. (2015). Recent Progress towards Novel EV71 Anti-
Therapeutics and Vaccines. Viruses, 7(12), 6441-6457. 
 
Offit, P. A. (2005). The Cutter incident, 50 years later. N Engl J Med, 352(14), 1411-
1412. 
 
Ohka, S., Matsuda, N., Tohyama, K., Oda, T., Morikawa, M., Kuge, S., & Nomoto, A. 
(2004). Receptor (CD155)-dependent endocytosis of poliovirus and retrograde 
axonal transport of the endosome. J Virol, 78(13), 7186-7198. 
 
Ohka, S., Sakai, M., Bohnert, S., Igarashi, H., Deinhardt, K., Schiavo, G., & Nomoto, A. 
(2009). Receptor-dependent and -independent axonal retrograde transport of 
poliovirus in motor neurons. J Virol, 83(10), 4995-5004. 
 
Ohka, S., Yang, W. X., Terada, E., Iwasaki, K., & Nomoto, A. (1998). Retrograde 
transport of intact poliovirus through the axon via the fast transport system. 
Virology, 250(1), 67-75. 
149 
 
Ong, K. C., Badmanathan, M., Devi, S., Leong, K. L., Cardosa, M. J., & Wong, K. T. 
(2008). Pathologic characterization of a murine model of human enterovirus 71 
encephalomyelitis. J Neuropathol Exp Neurol, 67(6), 532-542. 
 
Ong, K. C., Devi, S., Cardosa, M. J., & Wong, K. T. (2010). Formaldehyde-inactivated 
whole-virus vaccine protects a murine model of enterovirus 71 
encephalomyelitis against disease. J Virol, 84(1), 661-665. 
 
Ong, K. C., & Wong, K. T. (2015). Understanding Enterovirus 71 neuropathogenesis 
and its impact on other neurotropic Enteroviruses. Brain Pathol, 25(5), 614-624. 
 
Ooi, E. E., Phoon, M. C., Ishak, B., & Chan, S. H. (2002). Seroepidemiology of human 
enterovirus 71, Singapore. Emerg Infect Dis, 8(9), 995-997. 
 
Ooi, M. H., Solomon, T., Podin, Y., Mohan, A., Akin, W., Yusuf, M. A., . . . Cardosa, J. 
(2007). Evaluation of different clinical sample types in diagnosis of human 
enterovirus 71-associated hand-foot-and-mouth disease. J Clin Microbiol, 45(6), 
1858-1866. 
 
Ooi, M. H., Wong, S. C., Lewthwaite, P., Cardosa, M. J., & Solomon, T. (2010). 
Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol, 
9(11), 1097-1105. 
 
Ooi, M. H., Wong, S. C., Mohan, A., Podin, Y., Perera, D., Clear, D., . . . Solomon, T. 
(2009). Identification and validation of clinical predictors for the risk of 
neurological involvement in children with hand, foot, and mouth disease in 
Sarawak. BMC Infect Dis, 9, 3. 
 
Ooi, M. H., Wong, S. C., Podin, Y., Akin, W., del Sel, S., Mohan, A., . . . Solomon, T. 
(2007). Human enterovirus 71 disease in Sarawak, Malaysia: a prospective 
clinical, virological, and molecular epidemiological study. Clin Infect Dis, 44(5), 
646-656. 
 
Orbach, H., Katz, U., Sherer, Y., & Shoenfeld, Y. (2005). Intravenous immunoglobulin: 
adverse effects and safe administration. Clin Rev Allergy Immunol, 29(3), 173-
184. 
 
Oshiumi, H., Okamoto, M., Fujii, K., Kawanishi, T., Matsumoto, M., Koike, S., & Seya, 
T. (2011). The TLR3/TICAM-1 pathway is mandatory for innate immune 
responses to poliovirus infection. J Immunol, 187(10), 5320-5327. 
 
Pathinayake, P. S., Hsu, A. C., & Wark, P. A. (2015). Innate immunity and immune 
evasion by Enterovirus 71. Viruses, 7(12), 6613-6630. 
 
Paust, S., Senman, B., & von Andrian, U. H. (2010). Adaptive immune responses 
mediated by natural killer cells. Immunol Rev, 235(1), 286-296. 
 
Phyu, W. K., Ong, K. C., & Wong, K. T. (2016). A Consistent Orally-infected hamster 
model for Enterovirus A71 encephalomyelitis demonstrates squamous lesions in 
the paws, skin and oral cavity reminiscent of hand-foot-and-mouth disease. 
PLoS One, 11(1), e0147463. 
150 
 
Plevka, P., Perera, R., Cardosa, J., Kuhn, R. J., & Rossmann, M. G. (2012). Crystal 
structure of human enterovirus 71. Science, 336(6086), 1274. 
 
Premanand, B., Kiener, T. K., Meng, T., Tan, Y. R., Jia, Q., Chow, V. T., & Kwang, J. 
(2012). Induction of protective immune responses against EV71 in mice by 
baculovirus encoding a novel expression cassette for capsid protein VP1. 
Antiviral Res, 95(3), 311-315. 
 
Roberts, G. B., & Boyd, J. F. (1987). The histopathology of enterovirus infections of 
new-born mice. J Infect, 15(1), 45-56. 
 
Saunders, N. R., Liddelow, S. A., & Dziegielewska, K. M. (2012). Barrier mechanisms 
in the developing brain. Front Pharmacol, 3, 46. 
 
Schmidt, N. J., Lennette, E. H., & Ho, H. H. (1974). An apparently new enterovirus 
isolated from patients with disease of the central nervous system. J Infect Dis, 
129(3), 304-309. 
 
Schulze, C., & Firth, J. A. (1992). Interendothelial junctions during blood-brain barrier 
development in the rat: morphological changes at the level of individual tight 
junctional contacts. Brain Res Dev Brain Res, 69(1), 85-95. 
 
Seder, R. A., & Hill, A. V. (2000). Vaccines against intracellular infections requiring 
cellular immunity. Nature, 406(6797), 793-798. 
 
Solomon, T., Lewthwaite, P., Perera, D., Cardosa, M. J., McMinn, P., & Ooi, M. H. 
(2010). Virology, epidemiology, pathogenesis, and control of enterovirus 71. 
Lancet Infect Dis, 10(11), 778-790. 
 
Strebel, P. M., Ion-Nedelcu, N., Baughman, A. L., Sutter, R. W., & Cochi, S. L. (1995). 
Intramuscular injections within 30 days of immunization with oral poliovirus 
vaccine--a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J 
Med, 332(8), 500-506. 
 
Takeuchi, O., & Akira, S. (2008). MDA5/RIG-I and virus recognition. Curr Opin 
Immunol, 20(1), 17-22. 
 
Tan, S. H., Ong, K. C., & Wong, K. T. (2014). Enterovirus 71 can directly infect the 
brainstem via cranial nerves and infection can be ameliorated by passive 
immunization. J Neuropathol Exp Neurol, 73(11), 999-1008. 
 
Tian, X., Su, X., Li, X., Li, H., Li, T., Zhou, Z., . . . Zhou, R. (2012). Protection against 
enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 
hexon. PLoS One, 7(7), e41381. 
 
Tirado, S. M., & Yoon, K. J. (2003). Antibody-dependent enhancement of virus 
infection and disease. Viral Immunol, 16(1), 69-86. 
 
Tung, W. H., Sun, C. C., Hsieh, H. L., Wang, S. W., Horng, J. T., & Yang, C. M. 
(2007). EV71 induces VCAM-1 expression via PDGF receptor, PI3-K/Akt, p38 
MAPK, JNK and NF-kappaB in vascular smooth muscle cells. Cell Signal, 
19(10), 2127-2137. 
151 
 
Tyler, K. L. (2009). Emerging viral infections of the central nervous system: Part 1. 
Archives of Neurology, 66(8), 939-948. 
 
Volle, R., Archimbaud, C., Couraud, P. O., Romero, I. A., Weksler, B., Mirand, A., . . . 
Bailly, J. L. (2015). Differential permissivity of human cerebrovascular 
endothelial cells to enterovirus infection and specificities of serotype EV-A71 in 
crossing an in vitro model of the human blood-brain barrier. J Gen Virol, 96(7), 
1682-1695. 
 
Wang, S. M., Chen, I. C., Su, L. Y., Huang, K. J., Lei, H. Y., & Liu, C. C. (2010). 
Enterovirus 71 infection of monocytes with antibody-dependent enhancement. 
Clin Vaccine Immunol, 17(10), 1517-1523. 
 
Wang, S. M., Lei, H. Y., Huang, K. J., Wu, J. M., Wang, J. R., Yu, C. K., . . . Liu, C. C. 
(2003). Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric 
patients: roles of cytokines and cellular immune activation in patients with 
pulmonary edema. J Infect Dis, 188(4), 564-570. 
 
Wang, S. M., Lei, H. Y., Huang, M. C., Su, L. Y., Lin, H. C., Yu, C. K., . . . Liu, C. C. 
(2006). Modulation of cytokine production by intravenous immunoglobulin in 
patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol, 
37(1), 47-52. 
 
Wang, S. M., Lei, H. Y., & Liu, C. C. (2012). Cytokine immunopathogenesis of 
enterovirus 71 brain stem encephalitis. Clin Dev Immunol, 2012, 876241. 
 
Wang, S. M., Liu, C. C., Tseng, H. W., Wang, J. R., Huang, C. C., Chen, Y. J., . . . Yeh, 
T. F. (1999). Clinical spectrum of enterovirus 71 infection in children in 
southern Taiwan, with an emphasis on neurological complications. Clin Infect 
Dis, 29(1), 184-190. 
 
Wang, W., Duo, J., Liu, J., Ma, C., Zhang, L., Wei, Q., & Qin, C. (2011). A mouse 
muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes 
Infect, 13(10), 862-870. 
 
Wang, Y. F., Chou, C. T., Lei, H. Y., Liu, C. C., Wang, S. M., Yan, J. J., . . . Yu, C. K. 
(2004). A mouse-adapted enterovirus 71 strain causes neurological disease in 
mice after oral infection. J Virol, 78(15), 7916-7924. 
 
Wang, Y. F., & Yu, C. K. (2014). Animal models of enterovirus 71 infection: 
applications and limitations. J Biomed Sci, 21(1), 31. 
 
Warren, H. S., & Smyth, M. J. (1999). NK cells and apoptosis. Immunol Cell Biol, 77(1), 
64-75. 
 
Wei, D., Li, K. X., & Chen, E. (2010). [Autopsy report of two cases with enterovirus 
type 71 infection brainstem encephalitis and literature review]. Zhonghua Er Ke 
Za Zhi, 48(3), 220-223. 
 
Weng, K. F., Chen, L. L., Huang, P. N., & Shih, S. R. (2010). Neural pathogenesis of 
enterovirus 71 infection. Microbes Infect, 12(7), 505-510. 
152 
 
Weng, K. F., Li, M. L., Hung, C. T., & Shih, S. R. (2009). Enterovirus 71 3C protease 
cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS 
Pathog, 5(9), e1000593. 
 
Wilson-Pauwels, L., Akesson, E.J., & Stewart, P.A. (2002). Cranial nerves : in health 
and disease (2nd ed.). Hamilton, Ont. London: BC Decker. 
 
Wilton, T., Dunn, G., Eastwood, D., Minor, P. D., & Martin, J. (2014). Effect of 
formaldehyde inactivation on poliovirus. J Virol, 88(20), 11955-11964. 
 
Wong, K. T., Munisamy, B., Ong, K. C., Kojima, H., Noriyo, N., Chua, K. B., . . . 
Nagashima, K. (2008). The distribution of inflammation and virus in human 
enterovirus 71 encephalomyelitis suggests possible viral spread by neural 
pathways. J Neuropathol Exp Neurol, 67(2), 162-169. 
 
Wong, K. T., Ng, K. Y., Ong, K. C., Ng, W. F., Shankar, S. K., Mahadevan, A., . . . 
Takasaki, T. (2012). Enterovirus 71 encephalomyelitis and Japanese encephalitis 
can be distinguished by topographic distribution of inflammation and specific 
intraneuronal detection of viral antigen and RNA. Neuropathol Appl Neurobiol, 
38(5), 443-453. 
 
Wong, S. S., Yip, C. C., Lau, S. K., & Yuen, K. Y. (2010). Human enterovirus 71 and 
hand, foot and mouth disease. Epidemiol Infect, 138(8), 1071-1089. 
 
World Health Organization. (2011). A guide to clinical management and public health 
response for hand, foot and mouth disease (HFMD). Retrieved from 
http://www.wpro.who.int/emerging_diseases/documents/HFMDGuidance/en/ 
 
Xu, L., He, D., Li, Z., Zheng, J., Yang, L., Yu, M., . . . Xia, N. (2014). Protection 
against lethal enterovirus 71 challenge in mice by a recombinant vaccine 
candidate containing a broadly cross-neutralizing epitope within the VP2 EF 
loop. Theranostics, 4(5), 498-513. 
 
Yamamoto, K. R., Alberts, B. M., Benzinger, R., Lawhorne, L., & Treiber, G. (1970). 
Rapid bacteriophage sedimentation in the presence of polyethylene glycol and 
its application to large-scale virus purification. Virology, 40(3), 734-744. 
 
Yamayoshi, S., Fujii, K., & Koike, S. (2014). Receptors for enterovirus 71. Emerg 
Microbes Infect, 3(7), e53. 
 
Yamayoshi, S., Yamashita, Y., Li, J., Hanagata, N., Minowa, T., Takemura, T., & 
Koike, S. (2009). Scavenger receptor B2 is a cellular receptor for enterovirus 71. 
Nat Med, 15(7), 798-801. 
 
Yan, J. J., Wang, J. R., Liu, C. C., Yang, H. B., & Su, I. J. (2000). An outbreak of 
enterovirus 71 infection in Taiwan 1998: a comprehensive pathological, 
virological, and molecular study on a case of fulminant encephalitis. J Clin Virol, 
17(1), 13-22. 
 
 
 
153 
 
Yang, Y., Wang, H., Gong, E., Du, J., Zhao, X., McNutt, M. A., . . . Zheng, J. (2009). 
Neuropathology in 2 cases of fatal enterovirus type 71 infection from a recent 
epidemic in the People's Republic of China: a histopathologic, 
immunohistochemical, and reverse transcription polymerase chain reaction 
study. Hum Pathol, 40(9), 1288-1295. 
 
Yao, P. P., Qian, L., Xia, Y., Xu, F., Yang, Z. N., Xie, R. H., . . . Zhu, H. P. (2012). 
Enterovirus 71-induced neurological disorders in young gerbils, Meriones 
unguiculatus: development and application of a neurological disease model. 
PLoS One, 7(12), e51996. 
 
Yap, M. S., Tang, Y. Q., Yeo, Y., Lim, W. L., Lim, L. W., Tan, K. O., . . . Heng, B. C. 
(2016). Pluripotent human embryonic stem cell derived neural lineages for in 
vitro modelling of enterovirus 71 infection and therapy. Virol J, 13(1), 5. 
 
Yu, P., Gao, Z., Zong, Y., Bao, L., Xu, L., Deng, W., . . . Qin, C. (2014). 
Histopathological features and distribution of EV71 antigens and SCARB2 in 
human fatal cases and a mouse model of enterovirus 71 infection. Virus Res, 189, 
121-132. 
 
Zeng, H., Wen, F., Gan, Y., & Huang, W. (2012). MRI and associated clinical 
characteristics of EV71-induced brainstem encephalitis in children with hand-
foot-mouth disease. Neuroradiology, 54(6), 623-630. 
 
Zhang, Y., Cui, W., Liu, L., Wang, J., Zhao, H., Liao, Y., . . . Li, Q. (2011). 
Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest, 
91(9), 1337-1350. 
 
Zhao, M., Bai, Y., Liu, W., Xiao, X., Huang, Y., Cen, S., . . . Zeng, Y. (2013). 
Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective 
antibody responses. BMC Microbiol, 13, 287. 
 
Zhu, F. C., Meng, F. Y., Li, J. X., Li, X. L., Mao, Q. Y., Tao, H., . . . Shen, X. L. (2013). 
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 
71 vaccine in children in China: a multicentre, randomised, double-blind, 
placebo-controlled, phase 3 trial. Lancet, 381(9882), 2024-2032. 
 
Zhu, Fengcai, Xu, Wenbo, Xia, Jielai, Liang, Zhenglun, Liu, Yan, Zhang, Xuefeng, . . . 
Wang, Nan. (2014). Efficacy, Safety, and Immunogenicity of an Enterovirus 71 
Vaccine in China. N Engl J Med, 370(9), 818-828. 
 
154 
 
List of publications and papers presented 
 
 
 
1. Tan, S. H., Ong, K. C., & Wong, K. T. (2014). Enterovirus 71 Can Directly 
Infect the Brainstem via Cranial Nerves and Infection Can Be Ameliorated by 
Passive Immunization. J Neuropathol Exp Neurol, 73(11), 999-1008. 
2. Liu, L., Mo, Z., Liang, Z., Zhang, Y., Li, R., Ong, K. C., . . . Li, Q. (2015). 
Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in 
healthy Chinese children: a report of further observations. BMC Med, 13(1), 226. 
 
3. Tan, S. H., Ong, K. C., David, P., & Wong, K. T. (2016). A monoclonal 
antibody to ameliorate central nervous system infection and improve survival in 
a murine model of human Enterovirus-A71 encephalomyelitis. Antivir Res. In 
press. 
 
 
155 
 
Appendix A 
Solution for IHC 
1. Citrate buffer (pH 6.0) 
Sodium citrate   1.26 g 
Citric acid   0.252 g 
Distilled water (dH2O) 900 ml 
Sodium citrate and citrate acid were dissolved in 900 ml of dH2O and pH was 
adjusted to 6.0 by adding hydrochloric acid (HCl) or Sodium hydroxide (NaOH) 
before topped up with dH2O to 1 litre. 
 
2. Tris-buffered Saline (TBS), pH 7.6 
Tris base   6.05 g 
Sodium chloride (NaCl) 80.00 g 
1 N HCl   38.00 ml 
dH2O    9.00 litres 
Tris base and NaCl were dissolved in 9 litres of dH2O and 38 ml of HCl. pH was 
adjusted to 7.6 by adding HCl before topped up with dH2O to 10 litres. 
 
3. Hydrogen peroxidase (3%) 
30% hydrogen peroxide 5 ml 
Methanol   45 ml 
3% of hydrogen peroxide was prepared fresh for each staining procedure. 
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Appendix B 
Solution for ISH 
1 Stock solutions 
1.1 NaCl, 5M 
NaCl    146.1 g 
dH2O to a final volume of 500 ml 
NaCl was dissolved in dH2O and sterilised via autoclaving. 
 
1.2 Disodium Ethylenediaminetetra acetate (EDTA) solution, 0.5M (pH 8.0) 
EDTA    18.61 g 
dH2O    90.00 ml 
EDTA was dissolved in dH2O and pH was adjusted to 8.0 by adding NaOH. The 
volume was topped up to 100 ml with dH2O and sterilised via autoclaving. 
 
1.3 Saline sodium citrate (SSC), 20x 
NaCl    175.3 g 
Sodium citrate   88.2 g 
dH2O    900.0 ml 
NaCl and sodium citrate were dissolved in dH2O and pH was adjusted to 7.0 by 
adding NaOH. The volume was topped up to 1 litre with dH2O and sterilised via 
autoclaving. 
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1.4 Glysine, 10% 
Glysine    0.5 g 
dH2O to a final volume of  5.0 ml 
 
1.5 Sodium dodecylsulfate (SDS), 10% 
SDS      10 g 
dH2O     90 ml 
SDS was dissolved in 90 ml of dH2O by heating and stirring at 68°C. pH was 
adjusted to 7.2 by adding HCl and topped up to a final volume of 100 ml with 
dH2O. 
 
1.6 Tris, 1M (pH 7.5) 
Tris base    121.1 g 
dH2O     900.0 ml 
Tris base was dissolved in 900 ml of dH2O and pH was adjusted to 7.5 by adding 
HCl. The solution was topped up to a final volume of 1 litre with dH2O and 
sterilised via autoclaving. 
 
1.7 Tris, 1M (pH 9.5) 
Tris base    121.1 g 
dH2O     900.0 ml 
Tris base was dissolved in 900 ml of dH2O and pH was adjusted to 9.5 by adding 
HCl. The solution was topped up to a final volume of 1 litre with dH2O and 
sterilised via autoclaving. 
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1.8 HCl, 10 M 
Concentrated HCl   82.8 ml 
dH2O     17.2 ml 
Both solutions were mixed inside fume hood and allowed to cool to room 
temperature before used. 
 
1.9 Dextran sulphate 10% 
Dextran sulphate   0.5 g 
Formamide to a final volume of  5.0 ml 
Dextran sulphate was dissolved by gentle stirring and stored at -20°C. 
 
1.10 Dendhart solution, 50x 
Ficoll     0.1 g 
Polyvinylpyrolidone   0.1 g 
dH2O to a final volume of   10.0 ml 
Solution was store at -20°C. 
  
1.11 Blocking solution 10% 
Blocking reagent    2 g 
Tris/NaCl buffer to a final volume of  20 ml 
Blocking reagent was dissolved in Tris/NaCl buffer (pH 7.5) by stirring and 
heating. The solution was stored at 4°C. 
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2 Working solutions 
2.1 Phosphate buffered saline (PBS) 
NaCl     8.00 g 
KCl     0.20 g 
KH2PO4    0.24 g 
Na2HPO4    1.44 g 
dH2O     900.00 ml 
All chemicals were dissolved in 900 ml of dH2O and pH was adjusted to 7.4 by 
adding HCl. The solution was topped up to a final volume of 1 litre with dH2O 
and sterilised via autoclaving. 
 
2.2 HCl, 0.2 N 
HCl 10N    4 ml 
dH2O     96 ml 
Both solutions were mixed inside fume hood and allowed to cool to room 
temperature before used. 
 
2.3 Glycine, 0.2% 
10% Glycine    1 ml 
PBS     49 ml 
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2.4 Digestion buffer 
Tris, 1M    0.1 ml 
EDTA, 0.5 M    0.1 ml 
dH2O     90.0 ml 
All solutions were mixed with 90 ml of dH2O and pH was adjusted to 7.8 by 
adding HCl and/or NaOH. 500 µL of 10% SDS was added and topped up to a 
final volume of 100 ml with dH2O. 
 
2.5 Digestion buffer with 100 µg/ml proteinase K 
Digestion buffer (pH 7.8)  1.99 ml 
Proteinase K, 20 mg/ml  0.10 ml 
 
2.6 Tris-HCl / EDTA buffer 
Tris, 1M (pH 9.5)   10 ml 
EDTA     5 ml 
dH2O     400 ml 
The mixture was adjusted to pH 9.5 by adding HCl and topped up to a final 
volume of 500 ml with dH2O. Solution was sterilised with autoclaving. 
 
 
 
 
 
161 
 
2.7 Tris-HCl / NaCl buffer 
Tris, 1M (pH 7.5)   100 ml 
NaCl     30 ml 
dH2O     900 ml 
The mixture was adjusted to pH 7.5 by adding HCl and topped up to a final 
volume of 1 liter with dH2O. Solution was sterilised with autoclaving. 
 
2.8 Hybridisation solution 
20 x SSC    0.30 ml 
50 x Denhardts solution  0.10 ml 
Denatured Salmon sperm DNA 0.01 ml 
dH2O     0.09 ml 
10% Dextran sulphate   0.50 ml 
The solutions were mixed well before DIG-labelled DNA probe was added to a 
final concentration of 2 µg/ml. 
 
2.9 Tris-HCl / NaCl / MgCl buffer 
Tris, 1 M (pH 9.5)   50.0 ml 
NaCl, 5 M    10.0 ml  
MgCl, 1M    2.5 ml 
dH2O     400 ml 
The mixture was adjusted to pH 9.5 by adding HCl or NaOH. The solution was 
topped up to a final volume of 500 ml with dH2O and sterilised via autoclaving. 
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Appendix C 
Primers and probe for qPCR 
 
EV-A71 primers and probe for qPCR were designed using the “Primer Blast” software 
(NCBI website). 
 
Sense Primer 
GCACAACTCACCATTGGA 
 
Antisense primer 
GCTGTAGCATCGTCATCA 
 
Probe 
5’FAM-CACCATTACTACACAGGAGGCGGC-3’TAMRA 
 
